US11958865B1 - Leucine-rich repeat kinase 2 (LRRK2) inhibitors - Google Patents

Leucine-rich repeat kinase 2 (LRRK2) inhibitors Download PDF

Info

Publication number
US11958865B1
US11958865B1 US18/467,162 US202318467162A US11958865B1 US 11958865 B1 US11958865 B1 US 11958865B1 US 202318467162 A US202318467162 A US 202318467162A US 11958865 B1 US11958865 B1 US 11958865B1
Authority
US
United States
Prior art keywords
mmol
methyl
compound
mixture
nitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US18/467,162
Inventor
Thomas Jensen
Thomas Andersen
Mikkel Jessing
Jacob Nielsen
Henrik Daver
Christopher Richard Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Assigned to H. LUNDBECK A/S reassignment H. LUNDBECK A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JONES, CHRISTOPHER RICHARD, ANDERSEN, THOMAS, DAVER, Henrik, JENSEN, THOMAS, JESSING, Mikkel, NIELSEN, JACOB
Assigned to VERNALIS (R&D) LIMITED reassignment VERNALIS (R&D) LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: H. LUNDBECK A/S
Priority to US18/583,002 priority Critical patent/US20240343741A1/en
Application granted granted Critical
Publication of US11958865B1 publication Critical patent/US11958865B1/en
Assigned to H. LUNDBECK A/S reassignment H. LUNDBECK A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VERNALIS (R&D) LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • the present invention relates to compounds which are LRRK2 inhibitors and to pharmaceutical composition comprising said compounds. Further the invention relates to methods of treating diseases using said compounds or pharmaceutical compositions.
  • Parkinson's disease is a neurodegenerative disease. It is the second most common neurodegenerative disease after Alzheimer's disease and affects more than 1% of the general population above the age of 65. Parkinson's disease is clinically characterized by resting tremor, bradykinesia, muscular rigidity, and postural instability. In addition to motor symptoms, other symptoms such as neuropsychiatric symptoms are also present in many patients, and in late stages of the disease, Parkinson's disease dementia commonly develops. Pathologically, the disease is characterized by loss of dopaminergic neurons with consequent decrease in dopamine levels in the brain and by aggregation of the protein ⁇ -synuclein in the dopaminergic neurons. These aggregations, called Lewy bodies, are composed of various elements, but insoluble ⁇ -synuclein phosphorylated at serine-129 and ubiquitin are both abundantly found in Lewy bodies.
  • Parkinson's disease therapeutic intervention strategies aim at increasing the dopamine levels by administration of levodopa or monoamine oxidase B inhibitors.
  • dopamine agonists are administered to stimulate dopaminergic receptors, an effect similar to that obtained by increasing the dopamine levels.
  • these therapies provide significant symptomatic benefit to the patient, they are also associated with adverse side effects and often become ineffective after prolonged treatment and progression of the underlying disease.
  • none of the existing therapies addresses the underlying and disease-causing problem, i.e. the progressive loss of dopaminergic neurons.
  • Leucine-rich repeat kinase 2 (LRRK2) is a 2527 amino acid protein involved in catalyzing protein phosphorylation. Evidence is mounting for a relationship between LRRK2 and the pathogenesis of Parkinson's disease. Single nucleotide polymorphisms that alter amino acids in functional domains of LRRK2 have been shown to cause familiar and sporadic Parkinson's disease.
  • LRRK2 Parkinsonism Several such pathogenic variants have been identified including G2019S, 12020T, N1437H, R1441C, R1441G, R1441H and Y1699C (Shu et al., A Comprehensive Analysis of Population Differences in LRRK2 Variant Distribution in Parkinson's Disease, Front Aging Neurosci., 11:13, 2019; Chittoor-Vinod et al., Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism, Int. J. Mol. Sci., 2021, 22, 1045).
  • the most common pathogenic form of LRRK2-associated Parkinson's disease is the amino acid substitution G2019S in the kinase domain of the LRRK2 protein.
  • G2019S Parkinson's disease is inherited in an autosomal dominant fashion suggesting a gain-of-function mutation of the LRRK2 protein.
  • biochemical studies have shown that both G2019S and other pathogenic LRRK2 variants lead to an increased kinase activity of LRRK2 (West et al, Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity, Proc. Nat. Acad. Sci, 102, 16842-16847, 2005; Chittoor-Vinod et al., Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism, Int. J. Mol. Sci., 2021, 22, 1045).
  • Parkinson's disease associated with LRRK2 mutations are very similar to those of idiopathic Parkinson's disease (Trinh et al., A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism, Neurobiol. Aging., 35(5), 1125-31, 2014). This strongly suggests a causal involvement of overactive LRRK2 in the pathogenesis of Parkinson's disease in patients with such activating mutations in LRRK2 and that inhibitors of LRRK2 could be used as disease modifying treatment in familiar Parkinson's disease.
  • LRRK2 variants with lower but significant association with Parkinson's disease showing that LRRK2 also contributes to idiopathic Parkinson's disease.
  • LRRK2 also contributes to idiopathic Parkinson's disease.
  • These include very common single-nucleotide polymorphisms in the LRRK2 gene promotor region, where the Parkinson's disease associated variants appear to be associated with increased LRRK2 expression at least in some cell types (Nalls et al., Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies, Lancet Neurol, 2019, 18, 1091-1102; Sun et al., Genetic Variants Associated With Neurodegenerative Diseases Regulate Gene Expression in Immune Cell CD14+ Monocytes, Front Genet., 2018, 18, 9:666; Langston et al., Association of a Common Genetic Variant with Parkinson's Disease is Propagated through MicrogIia, bioRxiv, 2021
  • LRRK2 Parkinson's disease risk variants including the A419V and G2385R that are common in the Asian population (Shu et al., A Comprehensive Analysis of Population Differences in LRRK2 Variant Distribution in Parkinson's Disease, Front Aging Neurosci., 11:13, 2019).
  • LRRK2 LRRK2 N551K R1398H variant
  • Wang et al. Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10, Scientific Reports, 2021, 11:12900
  • LRRK2 inhibition in idiopathic Parkinson's disease by showing that wild-type LRRK2 activity is not optimal in a Parkinson's disease context.
  • LRRK2 affects trafficking of lysosomes and other vesicles through phosphorylation of RAB GTPases, and PD-associated genes are enriched for genes involved in lysosomal function and autophagy (Chang et al., A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci, Nat Genet., 2017, 49(10): 1511-1516).
  • LRRK2 inhibitors for treatment of Parkinson's disease
  • LRRK2 is highly expressed in white blood cells and spleen suggesting a potential for LRRK2 inhibitors for treatment of aberrant immune responses. This is further supported by genetic association of LRRK2 with such diseases particularly inflammatory bowel diseases including Crohn's disease and leprosy (Liu et al., Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations, Nat Genet., 2015, 47(9):979-986; Rastegar et al., Leucine Rich Repeat Kinase 2 and Innate Immunity, Front Neurosci., 2020, 10; 14:193). Thus, LRRK2 inhibitors may have potential for treatment of these diseases.
  • LRRK2 inhibitors The historic development of LRRK2 inhibitors is well described in the literature (Delgado et al., N-bridged 5,6-bicyclic pyridines: Recent applications in central nervous system disorders, European Journal of Medicinal Chemistry 97 (2015) 719-731); Xiao Ding & Feng Ren (2020) Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present), Expert Opinion on Therapeutic Patents, 30:4, 275-286).
  • the invention provides a compound of formula IIa, or a pharmaceutically acceptable salt thereof, wherein:
  • the invention provides a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein:
  • X is CH or CR 1 and Y is CH or CR 1 .
  • X is CH and Y is CH.
  • X is CR 1 and Y is CR 1 .
  • X is CH and Y is CR 1 .
  • X is CR 1 and Y is CH.
  • X is CH or CR 1 and Y is N.
  • X is N and Y is CH or CR 1 .
  • X is N and Y is CR 1 .
  • X is N and Y is CH.
  • X is CH and Y is N.
  • X is CR 1 and Y is N.
  • R 1 is a C 1 -C 3 alkyl.
  • R 1 is —CH 3 .
  • R 1 is —CH 2 CH 3 .
  • R 1 is a halogen
  • R 1 is fluoro
  • R 2 is selected from the group consisting of —CH 3 , —CH 2 CH 3 , and —CD 3 .
  • R 2 is —CH 3 .
  • R 2 is —CH 2 CH 3 .
  • R 2 is —CD 3 .
  • R 3 is a halogen
  • R 3 is chloro
  • R 4 is selected from the group consisting of —CH 3 , —CH 2 CH 3 , —OCH 3 , —OCH 2 CH 3 , —CHF 2 , —CF 3 , —O—C 3 cycloalkyl, O-cyclopropane, —OCH 2 F, —OCHF 2 , —OCF 3 , and —OCD 3 .
  • R 4 is —CH 3 .
  • R 4 is —CH 2 CH 3 .
  • R 4 is —OCH 3 .
  • R 4 is —OCH 2 CH 3 .
  • R 4 is —CHF 2 .
  • R 4 is —CF 3 .
  • R 4 is —CF 2 CH 3 .
  • R 4 is —O—C 3 cycloalkyl.
  • R 4 is O-cyclopropane.
  • R 4 is —OCH 2 F.
  • R 4 is —OCHF 2 .
  • R 4 is —OCF 3 .
  • R 4 is —OCD 3 .
  • n is 2.
  • n 1
  • n 0.
  • the compound of the invention is selected from the list consisting of:
  • the compound of the invention is selected from the list consisting of:
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.
  • the invention provides compounds of formula I, formula Iia or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in therapy.
  • the invention provides compounds of formula I, formula Iia or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in the treatment of a synucleinopathy.
  • the invention provides use of compounds of formula I, formula Ia or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof in the treatment of a synucleinopathy.
  • the invention relates to the use of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a synucleinopathy.
  • the invention relates to a method for the treatment of a disease associated with LRRK2 such as synucleinopathies, the method comprising the administration of a therapeutically effective amount of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • the invention provides compounds of formula I, formula IIa or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in the treatment of a disease associated with LRRK2, such as Parkinson's disease.
  • the invention provides compounds of formula I, formula IIa or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in the treatment of Lewy body dementia, multiple system atrophy, or Parkinson's disease.
  • the invention relates to the use of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a disease associated with LRRK2 such as Parkinson's disease.
  • the invention relates to a method for the treatment of a disease associated with LRRK2 such as Parkinson disease, the method comprising the administration of a therapeutically effective amount of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • LRRK2 inhibitors The inventors of the present disclosure have identified new compounds that are LRRK2 inhibitors. These compounds are listed in table 1. As can be seen from the examples I-V of the present disclosure, these compounds were demonstrated to possess a both low clearance and a high brain penetrance, while maintaining a high potency and selectivity for LRRK2, as well as displaying a good pharmacokinetic profile. As has been demonstrated in the historic literature of LRRK2 inhibitors, as presented above, the provision of compounds which are LRRK2 inhibitors, and which also display characteristics mentioned above is a highly complex and unpredictable.
  • alkyl is intended to indicate a straight or branched saturated hydrocarbon.
  • C 1 -C 3 -alkyl is intended to indicate such hydrocarbon having 1, 2 or 3 carbon atoms in the longest continuous carbon chain.
  • Typical alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl and the like.
  • isotopically labelled C 1 -C 3 -alkyl means that either one or more of the carbon or one or more of the hydrogen atom(s) in the alkyl group is replaced with a corresponding isotope such as 13 C and/or 14 C for carbon atom(s), or deuterium or tritium for hydrogen atom(s).
  • at least one 13 C atom is replaced with a 14 C atom.
  • at least one 12 C atom is replaced with a 14 C atom.
  • at least one 12 C atom is replaced with a 13 C atom.
  • at least one hydrogen atom is replaced with deuterium.
  • the hydrogen atoms are all replaced by deuterium.
  • Representative examples of isotopically labelled alkyl include but are not limited to —CD 3 , —CD 2 CD 3 .
  • the isotopically labelled C 1 -C 3 -alkyl is —CD 3 .
  • the term “isotopically labelled O—C 1 -C 3 -alkyl” means that either one or more of the carbon or one or more of the hydrogen atom(s) in the alkyl group is replaced with a corresponding isotope such as 13 C and/or 14 C for carbon atom(s), or deuterium or tritium for hydrogen atom(s).
  • at least one 13 C atom is replaced with a 14 C atom.
  • at least one 12 C atom is replaced with a 14 C atom.
  • at least one 12 C atom is replaced with a 13 C atom.
  • at least one hydrogen atom is replaced with deuterium.
  • the hydrogen atoms are all replaced by deuterium.
  • isotopically labelled alkoxy include but are not limited to —O-CD 3 , —O-CD 2 CD 3 .
  • the isotopically labelled O—C 1 -C 3 -alkyl is —O-CD 3 .
  • alkoxy refers to a group of formula —O-alkyl, wherein alkyl is defined as above.
  • C 1 -C 3 -alkoxy is intended to indicate an alkoxy-group having 1, 2 or 3 hydrocarbon atoms in the longest continuous carbon chain.
  • alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, isobutoxy, t-butoxy and the like.
  • haloalkyl or “haloalkoxy” is intended to refer to an alkyl or alkoxy group as defined hereinabove with 1, 2 or 3 hydrogens replaced by a halogen. Representative examples include but are not limited to CH 2 F, CHF 2 , CF 3 , OCF 3 , OCH 2 F, and OCHF 2 , Similarly, the term “fluoroalkyl” is intended to refer to an alkyl group as defined hereinabove, with 1, 2, or 3 hydrogens replaced by fluorine. Representative examples include but are not limited to CH 2 F, CHF 2 , and —CF 3 .
  • halogen is intended to indicate members of the 7 th main group of the periodic table of the elements, such as bromine, fluorine, and chlorine.
  • heteroatom is intended to mean sulfur, oxygen, or nitrogen.
  • cyano as used herein, means at least one —CN group is appended to the parent molecular moiety.
  • cyanoalkyl as used herein is intended to indicate an alkyl group as defined herein, wherein at least one —CN group is appended to the parent molecular moiety.
  • cyclic refers to any cyclic structure, including heterocyclic, aromatic and heteroaromatic non-fused ring systems.
  • membered is meant to denote the number of skeletal atoms that constitute the ring.
  • pyridyl, pyranyl, and pyrimidinyl are six-membered rings and pyrrolyl, and tetrahydrofuranyl are five-membered rings.
  • cycloalkyl refers to a carbocyclic ring system containing three to ten carbon atoms, zero heteroatoms and zero double bonds.
  • the cycloalkyl may be monocyclic or bicyclic, wherein the bicyclic ring is joined bridged, fused, or spirocyclic.
  • heterocycle refers to saturated or unsaturated nonaromatic rings containing from 4 to 7 ring atoms where one or more of the ring atoms are heteroatoms.
  • the heterocycle may be monocyclic or bicyclic, wherein the bicyclic ring is joined bridged, fused, or spirocyclic.
  • the term “therapeutically effective amount” of a compound is intended to indicate an amount sufficient to alleviate or partially arrest the clinical manifesta-tions of a given disease and its complications in a therapeutic intervention comprising the administration of said compound.
  • An amount adequate to accomplish this is defined as “therapeutically effective amount”.
  • Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, e.g. by con-structing a matrix of values and testing different points in the matrix, which is all within the ordinary skills of a trained physician.
  • treatment means the management and care of a patient for the purpose of combating a disease.
  • the term is intended to include the full spectrum of treatments for a given disease from which the patient is suffering, such as administration of the active compound to alleviate the symptoms or complications, to delay the progression of the disease, to alleviate or relief the symptoms and complications, and/or to cure or eliminate the disease.
  • the patient to be treated is preferably a mammal, in particular a human being.
  • “disease” can be used synonymous with disorder, condition, mal-function, dysfunction, and the like.
  • the invention provides a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein:
  • X is CH or CR 1 and Y is CH or CR 1 .
  • X is CH and Y is CH.
  • X is CR 1 and Y is CR 1 .
  • X is CH and Y is CR 1 .
  • X is CR 1 and Y is CH.
  • X is CH or CR 1 and Y is N.
  • X is N and Y is CH or CR 1 .
  • X is N and Y is CR 1 .
  • X is N and Y is CH.
  • X is CH and Y is N.
  • X is CR 1 and Y is N.
  • R 1 is a C 1 -C 3 alkyl.
  • R 1 is —CH 3 .
  • R 1 is —CH 2 CH 3 .
  • R 1 is a halogen
  • R 1 is fluoro
  • R 2 is selected from the group consisting of —CH 3 , —CH 2 CH 3 , and —CD 3 .
  • R 2 is —CH 3 .
  • R 2 is —CH 2 CH 3 .
  • R 2 is —CD 3 .
  • R 3 is a halogen
  • R 3 is chloro
  • R 4 is selected from the group consisting of —CH 3 , —CH 2 CH 3 , —OCH 3 , —OCH 2 CH 3 , —CHF 2 , —CF 3 , —O—C 3 cycloalkyl, O-cyclopropane, —OCH 2 F, —OCHF 2 , —OCF 3 , and —OCD 3 .
  • R 4 is —CH 3 .
  • R 4 is —CH 2 CH 3 .
  • R 4 is —OCH 3 .
  • R 4 is —OCH 2 CH 3 .
  • R 4 is —CHF 2 .
  • R 4 is —CF 3 .
  • R 4 is —CF 2 CH 3 .
  • R 4 is —O—C 3 cycloalkyl.
  • R 4 is O-cyclopropane.
  • R 4 is —OCH 2 F.
  • R 4 is —OCHF 2 .
  • R 4 is —OCF 3 .
  • R 4 is —OCD 3 .
  • n is 2.
  • n 1
  • n 0.
  • the compound of the invention is selected from the list consisting of:
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compounds of the present invention may have one or more asymmetric centres and it is intended that any optical isomers (i.e. enantiomers or diastereomers) as separated, pure or partially purified optical isomers and any mixtures thereof including racemic mixtures, i.e. a mixture of stereoisomers, are included within the scope of the invention.
  • any optical isomers i.e. enantiomers or diastereomers
  • pure or partially purified optical isomers i.e. a mixture of stereoisomers
  • one embodiment of the invention relates to a compound of the invention having an enantiomeric excess (ee) of at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 96%, preferably at least 98%.
  • Racemic forms can be resolved into the optical antipodes by known methods, for example by separation of diastereomeric salts thereof with an optically active acid and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optically active matrix.
  • the compounds of the present invention may also be resolved by the formation of diastereomeric derivatives. Additional methods for the resolution of optical isomers, known to those skilled in the art, may be used. Such methods include those discussed by J. Jaques, A. Collet and S. Wilen in “Enantiomers, Racemates, and Resolutions”, John Wiley and Sons, New York (1981).
  • Optically active compounds can also be prepared from optically active starting materials. Abso-lute stereochemistry may be determined by methods known to the skilled person, such as vi-brational circular dichroism (VCD) Spectroscopic analysis.
  • VCD vi-brational circular dichroism
  • geometric isomers may be formed. It is intended that any geometric isomers as separated, pure or partially purified geometric isomers or mixtures thereof are included within the scope of the invention. Likewise, molecules having a bond with restricted rotation may form geometric isomers. These are also intended to be included within the scope of the present invention.
  • a compound of formula I, formula IIa or formula Ia is isotopically labelled at the R 2 position.
  • one or more of the hydrogen atoms of the compound of formula I, formula IIa or formula Ia are represented by deuterium.
  • one or more of the hydrogen atoms at the R 2 position of the compound of formula I, formula IIa or formula Ia are represented by deuterium.
  • all hydrogen atoms at the R 2 position of the compound of formula I, formula IIa or formula Ia are represented by deuterium. It is recognized that elements are present in natural isotopic abundances in most synthetic compounds and result in inherent incorporation of deuterium.
  • the natural isotopic abundance of hydrogen isotopes such as deuterium is immaterial (about 0.015%) relative to the degree of stable isotopic substitution of compounds indicated herein.
  • designation of an atom as deuterium at a position indicates that the abundance of deuterium is significantly greater than the natural abundance of deuterium.
  • Any atom not designated as a particular isotope is intended to represent any stable isotope of that atom, as will be apparent to the ordi-narily skilled artisan.
  • designation of a position as “D” in a compound has a minimum deuterium incorporation of greater than about 60% at that position such as greater than about 70% at that position such as greater than about 80% at that position such as greater than about 85% at that position. In a further embodiment, designation of a position as “D” in a compound has a minimum deuterium incorporation of greater than about 90% at that position such as greater than about 95% at that position such as greater than about 97% at that position such as greater than about 99% at that position.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.
  • the invention provides compounds of formula I, formula IIa or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in therapy.
  • the invention provides compounds of formula I, formula IIa or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in the treatment of a synucleinopathy.
  • the invention provides compounds of formula I, formula IIa or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in the treatment of Lewy body dementia, multiple system atrophy, or Parkinson's disease.
  • the invention provides compounds of formula I, formula Ia or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in the treatment of Parkinson's disease.
  • the invention provides compounds of formula I, formula Ia or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in the treatment of a disease associated with LRRK2 such as Parkinson's disease.
  • the invention provides use of compounds of formula I, formula Ia or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof in the treatment of a synucleinopathy.
  • the invention provides use of compounds of formula I, formula IIa or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof in the treatment of Lewy body dementia, multiple system atrophy, or Parkinson's disease.
  • the invention provides use of compounds of formula I, formula IIa or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof in the treatment of Parkinson's disease.
  • the invention provides use of compounds of formula I, formula IIa or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof in the treatment of a disease associated with LRRK2 such as Parkinson's disease.
  • the invention relates to the use of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a synucleinopathy.
  • the invention relates to the use of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of Lewy body dementia, multiple system atrophy, or Parkinson's disease.
  • the invention relates to the use of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of Parkinson's disease.
  • the invention relates to the use of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a disease associated with LRRK2 such as Parkinson's disease.
  • the invention relates to a method for the treatment of a disease associated with LRRK2 such as synucleinopathies, the method comprising the administration of a therapeutically effective amount of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • the invention relates to a method for the treatment of a disease associated with LRRK2, wherein the disease is Lewy body dementia, multiple system atrophy, or Parkinson's disease; the method comprising the administration of a therapeutically effective amount of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • the invention relates to a method for the treatment of Parkinson's disease, the method comprising the administration of a therapeutically effective amount of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • the invention relates to a method for the treatment of a disease associated with LRRK2 such as Parkinson disease, the method comprising the administration of a therapeutically effective amount of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • the compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof.
  • a compound of formula I, formula IIa or formula Ia contains a free base
  • such salts may be prepared in a conventional manner by treating a solution or suspension of a free base of formula I, formula IIa or formula Ia with a molar equivalent of a pharmaceutically acceptable acid.
  • suitable organic and inorganic acids are described below.
  • Pharmaceutically acceptable salts in the present context are intended to indicate non-toxic, i.e. physiologically acceptable salts.
  • the term pharmaceutically acceptable salts includes salts formed with inorganic and/or organic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitrous acid, sulphuric acid, benzoic acid, citric acid, gluconic acid, lactic acid, maleic acid, succinic acid, tartaric acid, acetic acid, propionic acid, oxalic acid, maleic acid, fumaric acid, glutamic acid, pyroglutamic acid, salicylic acid and sulfonic acids, such as methanesul-fonic acid, ethanesulfonic acid, toluenesulfonic acid and benzene-sulfonic acid.
  • di- or tri-acids i.e. acids containing two or three acidic hydrogens, such as phosphoric acid, sulphuric acid, fumaric acid and maleic acid.
  • Di- and tri-acids may form 1:1, 1:2 or 1:3 (tri-acids) salts, i.e. a salt formed between two or three molecules of the compound of the present invention and one molecule of the acid.
  • pharmaceutically acceptable salts include salts formed with inorganic and/or organic bases, such as alkali metal bases, such as sodium hydroxide, lithium hydroxide, potassium hydroxide, alkaline earth bases, such as calcium hydroxide and magnesium hydroxide, and organic bases, such as trimethylamine.
  • alkali metal bases such as sodium hydroxide, lithium hydroxide, potassium hydroxide
  • alkaline earth bases such as calcium hydroxide and magnesium hydroxide
  • organic bases such as trimethylamine.
  • Some of the bases listed above are di- or tri-bases, i.e. bases able to receive two or three acidic hydrogens, such as calcium hydroxide and magnesium hydroxide.
  • Di- and tri-bases may form 1:1 or 1:2 salts, i.e. a salt formed between two molecules of the compound of the present invention and one molecule of the base.
  • the above-mentioned compounds or pharmaceutically acceptable salts may be in a composition as the sole active pharmaceutical ingredient or in combination with other pharmaceutically active ingredients. Additionally, one or more pharmaceutically acceptable carriers or diluents may be in the composition.
  • compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sub-lingual), transdermal, intracisternal, intraperitoneal, vaginal, and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous, and intradermal) route, the oral route being preferred. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.
  • compositions for oral administration include solid dosage forms such as capsules, tablets, dragées, pills, lozenges, powders, and granules. Where appropriate, they can be prepared with coatings.
  • Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups, and elixirs.
  • compositions for parenteral administration include sterile aqueous and nonaqueous injectable solutions, dispersions, suspensions, or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use.
  • Suitable administration forms include suppositories, sprays, ointments, creams, gels, inhalants, dermal patches, implants, etc.
  • the compounds of the invention are administered in a unit dosage form containing said compounds in an amount of about 0.1 to 500 mg, such as 10 mg, 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg of a compound of the present invention.
  • solutions of the compound of the invention in sterile aqueous solution aqueous propylene glycol, aqueous vitamin E or sesame or peanut oil may be employed.
  • aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • the aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration.
  • the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
  • Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions, and various organic solvents.
  • solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid, and lower alkyl ethers of cellulose.
  • liquid carriers are syrup, peanut oil, olive oil, phosphor lipids, fatty acids, fatty acid amines, polyoxyethylene and water.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient.
  • the orally available formulations may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion.
  • the preparation may be tablet, e.g. placed in a hard gelatine capsule in powder or pellet form or in the form of a troche or lozenge.
  • the amount of solid carrier may vary but will usually be from about 25 mg to about 1 g.
  • the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
  • Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents followed by compression of the mixture in a conventional tabletting machine.
  • adjuvants or diluents comprise corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compati-ble with the active ingredients.
  • LRRK2 inhibitors may be used in the treatment of Parkinson's disease and particular mention is made of Parkinson's disease associated with mutations in LRRK2, such as Gly2019Ser. Moreover, LRRK2 inhibitors are also expected to be useful in the treatment of other diseases which are associated with LRRK2. LRRK2 has been identified as a core compo-nent in Lewy body formation and is thus expected to be useful in the treatment of synucleinopathies such as Lewy body dementia [Neuropathol. Appl. Neurobiol., 34, 272-283, 2008].
  • LRRK2 mRNA is highly enriched in brain, lungs, kidney, spleen, and blood suggesting that functional impact of increased LRRK2 activity is likely to be most relevant in pathogenic and pathologic conditions associated with those regions. Support for that notion can be found in studies showing an increased risk of non-skin cancer in LRRK2 Gly2019Ser mutation carriers and especially for renal and lung cancer [Mov. Disorder, 25, 2536-2541, 2010]. Over-expression of LRRK2 by chromosomal amplification has also been identified in papillary renal and thyroid car-cinomas. Also, genetic association of LRRK2 has been reported for diseases where aberrant responses of the immune system are involved.
  • a compound, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition according to the invention for use in the treatment of a disease in the central nervous system, such as a synucleinopthy selected from Lewy body dementia, multiple system atrophy, and Parkinson's disease.
  • a synucleinopthy selected from Lewy body dementia, multiple system atrophy, and Parkinson's disease.
  • the disease in the central nervous system is Parkinson's disease.
  • the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying a G2019S mutation in LRRK2.
  • the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying one or more genetic mutations, which result in the expression of the G2019S variant of the LRRK2 protein.
  • the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying one or more genetic mutations, which result in the expression of one or more of the G2019S, 12020T, G2385R, A419V, R1441G, R1441H, R1441C, R1628P and Y1699C variants of the LRRK2 protein.
  • the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying one or more genetic mutations, which result in the expression of one or more of the M1646T, S1647T, Y2189C, N1437H, M1646T and N2081D variants of the LRRK2 protein.
  • the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients who do not carry one or more genetic mutations, which result in the expression of one or more of the N551K, R1398H and K1423K variants of the LRRK2 protein.
  • the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying one or more LRRK2 genetic non-coding variants selected from rs76904798-T and Rs1491942-G.
  • the Parkinson's disease is idiopathic Parkinson's disease.
  • the Parkinson's disease is sporadic Parkinson's disease.
  • the Parkinson's disease is in patients carrying a G2019S mutation in LRRK2.
  • the Parkinson's disease is in patients carrying one or more genetic mutations, which result in the expression of the G2019S variant of the LRRK2 protein.
  • the Parkinson's disease is in patients carrying one or more genetic mutations, which result in the expression of one or more of the G2019S, 12020T, G2385R, A419V, R1441G, R1441H, R1441C, R1628P and Y1699C variants of the LRRK2 protein.
  • the Parkinson's disease is in patients carrying one or more genetic mutations, which result in the expression of one or more of the M1646T, S1647T, Y2189C, N1437H, M1646T and N2081D variants of the LRRK2 protein.
  • the Parkinson's disease is in patients who does not carry one or more genetic mutations, which result in the expression of one or more of the N551K, R1398H and K1423K variants of the LRRK2 protein.
  • the Parkinson's disease is in patients carrying one or more LRRK2 genetic non-coding variants selected from rs76904798-T and Rs1491942-G.
  • the Parkinson's disease is in patients carrying one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G.
  • the Parkinson's disease is in patients carrying one or more mutated forms of LRRK2 selected from G2019S, 12020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, and Y2189C.
  • LRRK2 selected from G2019S, 12020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, and Y2189C.
  • the compound of the present invention is administered in an amount from about 0.001 mg/kg body weight to about 100 mg/kg body weight per day.
  • daily dosages may be in the range of 0.01 mg/kg body weight to about 50 mg/kg body weight per day. The exact dosages will depend upon the frequency and mode of administration, the sex, the age, the weight, and the general condition of the subject to be treated, the nature and the severity of the condition to be treated, any concomitant diseases to be treated, the desired effect of the treatment and other factors known to those skilled in the art.
  • a typical oral dosage for adults will be in the range of 1-1000 mg/day of a compound, or pharmaceutically acceptable salt thereof of the present invention, such as 1-500 mg/day.
  • the compounds, or pharmaceutically acceptable salt thereof of the present invention may be administered alone as a pure compound or in a pharmaceutical composition comprising the compound or a pharmaceutical salt thereof and one or more pharmaceutically acceptable carriers or excipients, in either single or multiple doses.
  • the pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 22 nd Edition, Pharmaceutical Press, 2012.
  • excipient”, “carrier”, “diluent”, “adjuvant” and the like are used synonymously and are intended to mean the same.
  • the compounds of the invention may be administered as a monotherapy or as part of an adjunctive treatment regimen.
  • the compounds of the invention may be administered as monotherapy in the treatment of a synucleinopathy, such as Lewy body dementia, multiple system atrophy or Parkinson's disease.
  • a synucleinopathy such as Lewy body dementia, multiple system atrophy or Parkinson's disease.
  • Such monotherapy indicates that the compound of the invention is the only active ingredient administered to the patient to treat this specific disease, however such monotherapy does not exclude that the patient may be treated with other drugs to treat other conditions.
  • the compounds of the invention may be administered as part of an adjunctive treatment regimen targeting the synucleinopathy such as Lewy body dementia, multiple system atrophy or Parkinson's disease.
  • an adjunctive treatment indicates that the compound of the invention is administered adjunctive to an already existing treatment regimen targeting the synucleinopathy or the associated symptoms.
  • the adjunctive treatment may also indicate that the compound of the invention is the first drug to be administered to treat the synucleinopathy and then subsequently another drug is added to the treatment regimen, which additional drug is also targeting the synucleinopathy or the associated symptoms.
  • the compound of the invention is administered in combination with an additional compound for the combined treatment of a synucleinopathy such as Lewy body dementia, multiple system atrophy or Parkinson's disease.
  • a synucleinopathy such as Lewy body dementia, multiple system atrophy or Parkinson's disease.
  • such additional compound may be selected from caspase inhibitors, calpain inhibitors, LRRK2 inhibitors, BACE1 inhibitors, antibodies against any form of A ⁇ peptides, inflammation inhibitors, LAG-3 antibodies, molecules inhibiting alphasynuclein aggregation, nicotine, caffeine, Monoamine oxidase B inhibitor, Levodopa/carbidopa, Dopamine agonists, COMT inhibitors, A 2 A antagonists, anti-alphasynuclein antibodies, Mitogen-activated protein kinase 14 inhibitors, USP30 inhibitors, Beta adrenoreceptor agonists, dopamine D1 PAMs, Toll-like receptor 2 antagonists, Carnitine palmitoyl transferase 1 inhibitors, Glutamate 5 receptor antagonists, Muscarinic M2 receptor antagonists, Muscarinic M3 receptor antagonists, Muscarinic M4 receptor antagonists, 5 Hydroxy tryptamine 1A receptor agonists, 5 Hydr
  • the additional compound is selected from the list consisting of trihexyphenidyl, biperiden, metixene, procyclidine, profenamine, dexetimide, phenglutarimide, mazaticol, bornaprine, tropatepine, etanautine, orphenadrine, benzatropine, etybenzatropine, dopamine, levodopa, carbidopa, levodopa/carbidopa, melevodopa, etilevodopa, foslevodopa, amantadine, bromocriptine, pergolide, dihydroergocryptine mesylate, ropinirole, pramipexole, cabergoline, apomorphine, piribedil, rotigotine, selegiline, rasagiline, safinamide, tolcapone, entacapone, budipine, opicapone,
  • the compounds of the invention may be prepared by methods described in the experimental section, together with synthetic methods known in the art of organic chemistry, or modifications that are familiar to those of ordinary skill in the art.
  • the invention provides compounds which are useful as intermediate compounds in a manufacturing process for compounds of the invention.
  • such intermediate compounds are compounds of formula XVI, or a salt thereof, wherein:
  • such intermediate compounds are compounds of formula II, or a salt thereof, wherein:
  • X is CH or CR 1 and Y is CH or CR 1 .
  • X is CH and Y is CH.
  • X is CR 1 and Y is CR 1 .
  • X is CH and Y is CR 1 .
  • X is CR 1 and Y is CH.
  • X is CH or CR 1 and Y is N.
  • X is N and Y is CH or CR 1 .
  • X is N and Y is CR 1 .
  • X is N and Y is CH.
  • X is CH and Y is N.
  • X is CR 1 and Y is N.
  • R 1 is a C 1 -C 3 alkyl.
  • R 1 is —CH 3 .
  • R 1 is —CH 2 CH 3 .
  • R 1 is a halogen
  • R 1 is fluoro
  • R 2 is selected from the group consisting of —CH 3 , —CH 2 CH 3 , and —CD 3 .
  • R 2 is —CH 3 .
  • R 2 is —CH 2 CH 3 .
  • R 2 is —CD 3 .
  • R 3 is a halogen
  • R 3 is chloro
  • R 4 is selected from the group consisting of —CH 3 , —CH 2 CH 3 , —OCH 3 , —OCH 2 CH 3 , —CHF 2 , —CF 3 , —O—C 3 cycloalkyl, O-cyclopropane, —OCH 2 F, —OCHF 2 , —OCF 3 , and —OCD 3 .
  • R 4 is —CH 3 .
  • R 4 is —CH 2 CH 3 .
  • R 4 is —OCH 3 .
  • R 4 is —OCH 2 CH 3 .
  • R 4 is —CHF 2 .
  • R 4 is —CF 3 .
  • R 4 is —CF 2 CH 3 .
  • R 4 is —O—C 3 cycloalkyl.
  • R 4 is O-cyclopropane.
  • R 4 is —OCH 2 F.
  • R 4 is —OCHF 2 .
  • R 4 is —OCF 3 .
  • R 4 is —OCD 3 .
  • n is 2.
  • n 1
  • n 0.
  • the invention provides a process for manufacturing a compound of the invention or a pharmaceutically acceptable salt thereof, which process comprises reducing an intermediate compound of type XVI with iron and ammonium chloride in a suitable solvent e.g. a mixture of ethanol and water.
  • a suitable solvent e.g. a mixture of ethanol and water.
  • the invention provides a process for manufacturing a compound of the invention or a pharmaceutically acceptable salt thereof, which process comprises reducing an intermediate compound of type XVI with iron and ammonium chloride in a suitable solvent e.g. a mixture of ethanol and water followed by a cyclization step.
  • a suitable solvent e.g. a mixture of ethanol and water followed by a cyclization step.
  • the invention provides a process for manufacturing a compound of the invention or a pharmaceutically acceptable salt thereof, which process comprises reducing an intermediate of type II with iron and ammonium chloride in a suitable solvent e.g. a mixture of ethanol and water.
  • a suitable solvent e.g. a mixture of ethanol and water.
  • the invention provides a process for manufacturing a compound of the invention or a pharmaceutically acceptable salt thereof, which process comprises reducing an intermediate of type II with iron and ammonium chloride in a suitable solvent e.g. a mixture of ethanol and water followed by a cyclization step.
  • a suitable solvent e.g. a mixture of ethanol and water followed by a cyclization step.
  • the first embodiment is denoted E1
  • the second embodiment is denoted E2 and so forth.
  • E12 The compound according to any one of embodiments E1-E11, or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from the group consisting of —CH 3 , —CH 2 CH 3 , —OCH 3 , and —OCH 2 CH 3 .
  • a pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to any one of the previous embodiments E1 to E23 and one or more pharmaceutically acceptable carriers or diluents.
  • E26 The compound according to any one of embodiments E1 to E23, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or disorder in the central nervous system, such as a synucleinopathy selected from Lewy body dementia, multiple system atrophy, and Parkinson's disease.
  • a synucleinopathy selected from Lewy body dementia, multiple system atrophy, and Parkinson's disease.
  • Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease, Parkinson's disease in patients carrying a G2019S mutation in LRRK2, or Parkinson's disease in patients carrying one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G.
  • Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying one or more mutated forms of LRRK2 selected from G2019S, 12020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, and Y2189C.
  • LRRK2 selected from G2019S, 12020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, and Y2189C.
  • Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying a G2019S mutation in LRRK2.
  • Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G.
  • E31 The compound according to any one of embodiments E1 to E23, or a pharmaceutically acceptable salt thereof, for use in a method for the treatment of a disease or disorder characterized by increased LRRK2 kinase activity or by expression of one or more mutated forms of LRRK2 selected from G2019S, 12020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, and Y2189C or a LRRK2 non-coding variant alone or in combination selected from rs76904798-T and Rs1491942-G.
  • a method for the treatment of a disease or disorder in the central nervous system selected from Lewy body dementia, multiple system atrophy or Parkinson's disease comprising the administration of a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, according to any one of embodiments E1 to E23 to a patient in need thereof.
  • E35 The compound, use or method according to any of the preceding embodiments, wherein the patient to be treated carries one or more genetic mutations, which result in the expression of one or more of the G2019S, 12020T, G2385R, A419V, R1441G, R1441H, R1441C, R1628P and Y1699C variants of the LRRK2 protein.
  • E36 The compound, use or method according to any of the preceding embodiments, wherein the patient to be treated carries one or more genetic mutations, which result in the expression of one or more of the M1646T, S1647T, Y2189C, N1437H, M1646T and N2081D variants of the LRRK2 protein.
  • the first further embodiment is denoted EE1
  • the second embodiment is denoted EE2 and so forth.
  • EE7 The compound of any of embodiments EE1-EE6 or a pharmaceutically acceptable salt thereof, wherein R 1 is a C 1 -C 3 alkyl.
  • EE12 The compound of any of embodiments EE1-EE11 or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from the group consisting of —CH 3 , —CH 2 CH 3 , and —CD 3 .
  • EE14 The compound of any of embodiments EE1-EE12 or a pharmaceutically acceptable salt thereof, wherein R 2 is —CH 2 CH 3 .
  • EE15 The compound of any of embodiments EE1-EE12 or a pharmaceutically acceptable salt thereof, wherein R 2 is —CD 3 .
  • EE16 The compound of any of embodiments EE1-EE15 or a pharmaceutically acceptable salt thereof, wherein R 3 is a halogen.
  • EE18 The compound of any of embodiments EE1-EE17 or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from the group consisting of —CH 3 , —CH 2 CH 3 , —OCH 3 , —OCH 2 CH 3 , —CHF 2 , —CF 3 , —CF 2 CH 3 , —O—C 3 cycloalkyl, O-cyclopropane, —OCH 2 F, —OCHF 2 , —OCF 3 , and —OCD 3 .
  • EE20 The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R 4 is —CH 2 CH 3 .
  • EE26 The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R 4 is —O—C 3 cycloalkyl.
  • EE28 The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R 4 is —OCH 2 F.
  • EE30 The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R 4 is —OCF 3 .
  • EE31 The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R 4 is —OCD 3 .
  • EE32 The compound of any of embodiments EE1-EE31 or a pharmaceutically acceptable salt thereof, wherein n is 2.
  • EE33 The compound of any of embodiments EE1-EE31 or a pharmaceutically acceptable salt thereof, wherein n is 1.
  • EE34 The compound of any of embodiments EE1-EE31 or a pharmaceutically acceptable salt thereof, wherein n is 0.
  • EE35 The compound of any of embodiments EE1-EE34 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the list consisting of:
  • EE36 The compound of any of embodiments EE1-EE34 or a pharmaceutically salt thereof, wherein the compound is selected from the list consisting of:
  • EE37 The compound of embodiments EE1-EE36 or a pharmaceutically acceptable salt thereof for use in therapy.
  • a pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof of the previous embodiments EE1-EE36 and one or more pharmaceutically acceptable carriers or diluents.
  • EE39 The compound according to any one of embodiments EE1-EE36, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or disorder in the central nervous system selected from Lewy body dementia, multiple system atrophy, and Parkinson's disease.
  • Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease, Parkinson's disease in patients carrying a G2019S mutation in LRRK2, or Parkinson's disease in patients carrying one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G.
  • EE41 The compound according to embodiment EE39, or a pharmaceutically acceptable salt thereof, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying one or more mutated forms of LRRK2 selected from G2019S, 12020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, and Y2189C.
  • LRRK2 mutated forms of LRRK2 selected from G2019S, 12020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, and Y2189C.
  • EE42 The compound according to embodiment EE39, or a pharmaceutically acceptable salt thereof, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying a G2019S mutation in LRRK2.
  • Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G.
  • EE44 The compound according to any one of embodiments EE1-EE36, or a pharmaceutically acceptable salt thereof, for use in a method for the treatment of a disease or disorder characterized by increased LRRK2 kinase activity or by expression of one or more mutated forms of LRRK2 selected from G2019S, 12020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, and Y2189C or a LRRK2 non-coding variant alone or in combination selected from rs76904798-T and Rs1491942-G.
  • EE45 Use of a compound according to any one of embodiments EE1-EE36, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or disorder in the central nervous system selected from Lewy body dementia, multiple system atrophy or Parkinson's disease.
  • EE46 Use of a compound according to any one of embodiments EE1-EE36, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of Parkinson's disease.
  • a method for the treatment of a disease or disorder in the central nervous system selected from Lewy body dementia, multiple system atrophy or Parkinson's disease comprising the administration of a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, according to any one of embodiments EE1-EE36 to a patient in need thereof.
  • EE47 The compound according to any one of embodiments EE1-EE36 or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or disorder characterized by increased LRRK2 kinase activity or by expression of one or more mutated forms of LRRK2 selected from G2019S, 12020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, and Y2189C or a LRRK2 non-coding variant alone or in combination selected from rs76904798-T and Rs1491942-G.
  • the first additional embodiment is denoted I1
  • the second embodiment is denoted I2 and so forth.
  • a pharmaceutical composition comprising a compound according to any one of the previous embodiments I1 to II11 and one or more pharmaceutically acceptable carriers.
  • a disease in the central nervous system such as synucleinopathy selected from Lewy body dementia, multiple system atrophy, or Parkinson's disease.
  • Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying a G2019S mutation in LRRK2.
  • I17 Use of a compound according to any one of embodiments I1 to I11, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or disorder in the central nervous system, such as synucleinopathy selected from Lewy body dementia, multiple system atrophy, or Parkinson's disease.
  • a disease or disorder in the central nervous system such as synucleinopathy selected from Lewy body dementia, multiple system atrophy, or Parkinson's disease.
  • Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying a G2019S mutation in LRRK2, or Parkinson's disease in patients carrying one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G.
  • a method for the treatment of a disease or disorder in the central nervous system selected from Lewy body dementia, multiple system atrophy or Parkinson's disease comprising the administration of a therapeutically effective amount of the compound according to any one of embodiments I1 to I11, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
  • Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease, Parkinson's disease in patients carrying a G2019S mutation in LRRK2, or Parkinson's disease in patients carrying one or more LRRK2 non-coding variants alone selected from rs76904798-T and Rs1491942-G.
  • the compounds of formula I, formula IIa or formula Ia may be prepared by methods described below, together with synthetic methods known in the art of organic chemistry, or modifications that are familiar to those of ordinary skill in the art.
  • the methods describe the use of selective protecting groups during the synthesis of the compounds of the invention.
  • One skilled in the art would be able to select the appropriate protecting group for a particular reaction. Methods for protection and deprotection of such groups are well known in the art and may be found in Watts and Green et al., Protective Groups in Organic Synthesis, 2006, 4 th Edition, Wiley Interscience, New York.
  • the starting materials used herein are available commercially or may be prepared by routine methods known in the art, such as those method described in standard reference books such as “Compendium of Organic Synthetic Methods, Vol. I-XII” (published by Wiley Interscience). Preferred methods include, but are not limited to, those described below.
  • the schemes are representative of methods useful in synthesizing the compounds of the present invention. They are not to constrain the scope of the invention in any way.
  • compounds of formula I can be prepared according to scheme 1.
  • the compounds of formula I can for example be prepared through a one pot reduction-cyclization procedure by reducing an intermediate of type II with iron and ammonium chloride in a suitable solvent e.g. a mixture of ethanol and water followed by cyclization as described for Example 2.
  • a suitable solvent e.g. a mixture of ethanol and water followed by cyclization as described for Example 2.
  • a nitropyrazole intermediate of type II can be prepared according to scheme 2 starting from an alcohol such as IV.
  • An intermediate of type IV can be reacted with a pyrazolopyrimidine such as III under Mitsunobu-type conditions employing for example diisopropyl azodicarboxylate and triphenylphosphine in a solvent such as tetrahydrofuran to afford an intermediate of type II.
  • Intermediates of type V (wherein Pg 1 is for example TBS) can be converted into an alchohol intermediate of type IV using for example a fluoride source such as tetrabutylammonium fluoride in an appropriate solvent for example tetrahydrofuran.
  • a pyrazole intermediate of type V can be prepared through the coupling of an intermediate of type VII with a pyridine intermediate of type VI (wherein M is for example B(OH) 2 .
  • the coupling is exemplified by a Chan-Lam type coupling.
  • the reaction can be performed by reacting an intermediate of type VII with a boronic acid intermediate VI in which M ⁇ B(OH) 2 in the presence of a copper salt such as copper(II) acetate, a base for example pyridine, a drying agent such as 4 ⁇ molecular sieves under an oxygen atmosphere and a suitable solvent such as 1,2-dichloroethane.
  • An intermediate of type VII (wherein Pg 1 is for example TBS) can be prepared according to scheme 3.
  • Intermediates of type VII (wherein Pg 1 is for example TBS) can be prepared from an alcohol intermediate of type VIII using for example tert-butyldimethylsilyl chloride in the presence of a base such as imidazole and a catalyst such as 4-dimethylaminopyridine in an appropriate solvent such as dichloromethane.
  • An alcohol intermediate such as VIII can be prepared from a nitropyazole such as IX (wherein Pg 2 is for example, 2-tetrahydropyranyl) by treatment with an acid such as aqueous hydrochloric acid in a suitable solvent for example methanol.
  • Alcohol intermediates of type IX can be prepared by reacting a chloro intermediate XI with propane-1,3-diol X in the presence of a base for example cesium fluoride in a solvent such as N,N-dimethylacetamide.
  • Chloro intermediates such as XI (wherein Pg 2 is for example, 2-tetrahydropyranyl) can be prepared from a nitropyrazole intermediate XII (wherein Pg 2 is for example, 2-tetrahydropyranyl) using a strong base for example lithium bis(trimethylsilyl)amide, and an electrophile for example hexachloroethane in a suitable solvent such as tetrahydrofuran.
  • a nitropyrazole intermediate of type XII (wherein Pg 2 is for example, 2-tetrahydropyranyl) can be prepared from a pyrazole such as XIII employing 3,4-dihydro-2H-pyran in the presence of an acid for example para-toluenesulfonic acid monohydrate in an appropriate solvent for example tetrahydrofuran.
  • compounds of formula I can be prepared from a compound of formula XIV according to scheme 4.
  • the compounds of formula I can be prepared by employing e.g. a copper-mediated coupling between an intermediate of type XIV and an intermediate of type VI (wherein M is for example B(OH) 2 ).
  • the coupling is exemplified by but not limited to a Chan-Lam type coupling.
  • the reaction can be performed by reacting an intermediate of type XIV with a boronic acid intermediate VI in which M ⁇ B(OH) 2 in the presence of a copper salt such as copper(II) acetate, a base for example pyridine, a drying agent such as 4 ⁇ molecular sieves under an oxygen atmosphere and a suitable solvent such as 1,2-dichloroethane as described for Example 1.
  • a copper salt such as copper(II) acetate
  • a base for example pyridine
  • a drying agent such as 4 ⁇ molecular sieves under an oxygen atmosphere
  • a suitable solvent such as 1,2-dichloroethane as described for Example 1.
  • An intermediate such as XIV can be prepared according to scheme 5.
  • the intermediates of type XIV can for example be prepared through a one pot procedure by reducing an intermediate of type XV (wherein Pg 2 is for example, 2-tetrahydropyranyl) with iron and ammonium chloride in a suitable solvent e.g. a mixture of ethanol and water.
  • a suitable solvent e.g. a mixture of ethanol and water.
  • Nitropyrazole intermediates like XV can be prepared by reaction a pyrazolopyrimidine like III with an alcohol such as IX (wherein Pg 2 is for example, 2-tetrahydropyranyl) employing Mitsunobu-like reaction conditions for example diisopropyl azodicarboxylate and triphenylphosphine in a solvent such as tetrahydrofuran.
  • an alcohol such as IX (wherein Pg 2 is for example, 2-tetrahydropyranyl) employing Mitsunobu-like reaction conditions for example diisopropyl azodicarboxylate and triphenylphosphine in a solvent such as tetrahydrofuran.
  • Compounds of formula IIa can be prepared according to scheme 6.
  • the compounds of formula IIa can for example be prepared through a one pot reduction-cyclization procedure by reducing an intermediate of type XVI with iron and ammonium chloride in a suitable solvent e.g. a mixture of ethanol and water followed by cyclization as described for in Example 21.
  • a suitable solvent e.g. a mixture of ethanol and water followed by cyclization as described for in Example 21.
  • a nitropyrazole intermediate of type XVI can be prepared through a 3-step sequence according to scheme 7 starting from a nitropyrazole such as VII.
  • a pyrazole intermediate of type XVIII (wherein Pg 1 is for example TBS) can be prepared through the coupling of an intermediate of type VII (wherein Pg 1 is for example TBS) with an intermediate of type XIX (wherein M is for example B(OH) 2 .
  • the coupling is exemplified by a Chan-Lam type coupling.
  • the reaction can be performed by reacting an intermediate of type VII (wherein Pg 1 is for example TBS) with a boronic acid intermediate XIX in which M ⁇ B(OH) 2 in the presence of a copper salt such as copper(II) triflate, a base for example N,N,N′,N′-tetramethylethylenediamine under an oxygen atmosphere and a suitable solvent such as acetonitrile and dichloromethane.
  • a pyrazole intermediate of type VII can be reacted with an intermediate of type XX (wherein Hal is e.g., CI) to afford an intermediate such as XVIII in the presence of a base e.g., potassium carbonate and an appropriate solvent like acetonitrile.
  • An alcohol of intermediate such as XVII can be reacted with a pyrazolopyrimidine such as III under Mitsunobu-type conditions employing for example diisopropyl azodicarboxylate and triphenylphosphine in a solvent such as tetrahydrofuran to afford an intermediate of type XVI.
  • compounds of formula IIa can be prepared according to scheme 7 through a 4-step sequence starting from a nitropyrazole intermediate of type XXV.
  • Nitropyrazole intermediates such as XXIV can for example be synthesized through reaction of a pyrazolopyrimidine such as IV and an alcohol like XXV employing Mitsunobu-like reaction conditions.
  • the Mitsunobu-like coupling can for example be conducted using e.g., triphenylphosphine and diisopropyl azodicarboxylate in a suitable solvent like tetrahydrofuran.
  • Intermediates of type XXIII can be synthesized from a nitropyrazole intermediate such as XXIV employing a one-pot reduction and cyclization procedure.
  • the reduction and subsequent cyclization can be performed using for example iron in the presence of ammonium chloride in a suitable solvent such as a mixture of ethanol and water.
  • a bromo intermediate such as XXI can be prepared from a pyrazole like XXIII using a brominating agent for example 2,4,4,6-tetrabromocyclohexa-2,5-dien-1-one in a suitable solvent such as tetrahydrofuran.
  • a brominating agent for example 2,4,4,6-tetrabromocyclohexa-2,5-dien-1-one in a suitable solvent such as tetrahydrofuran.
  • a bromo intermediate of type XXI can be reacted with an organometallic species such as XXII (wherein M is for example Bpin, B(OH) 2 , Sn(n-Bu) 3 or SnMe 3 , Zn, ZnBr or ZnCI).
  • M is for example Bpin, B(OH) 2 , Sn(n-Bu) 3 or SnMe 3 , Zn, ZnBr or ZnCI).
  • the coupling is exemplified by but not limited to a Negishi-type cross-coupling.
  • the reaction can be performed by reacting an intermediate of type XXI with an organozinc species such as (CD 3 ) 2 Zn in the presence of a catalyst like bis[tris(tert-butyl)phosphine]palladium, a base such as lithium bis(trimethylsilyl)amide in an appropriate solvent such as tetrahydrofuran to provide a compounds of formula IIa (wherein R 2 ⁇ CD 3 ) as described for Example 25.
  • organozinc species such as (CD 3 ) 2 Zn
  • a catalyst like bis[tris(tert-butyl)phosphine]palladium
  • a base such as lithium bis(trimethylsilyl)amide
  • an appropriate solvent such as tetrahydrofuran
  • a method to prepare an intermediate of type XXV is depicted in scheme 9.
  • a nitropyrazole intermediate of type XXXI (wherein Pg 3 is for example, 2-tetrahydropyranyl) can be prepared from a pyrazole of type XXXII using e.g., 3,4-dihydro-2H-pyran in the presence of an acid for example para-toluenesulfonic acid monohydrate in an appropriate solvent such as tetrahydrofuran.
  • Chloro intermediates such as XXX (wherein Pg 3 is for example, 2-tetrahydropyranyl) can be prepared from a nitropyrazole intermediate XXXI (wherein Pg 3 is for example, 2-tetrahydropyranyl) using a strong base for example lithium bis(trimethylsilyl)amide, and an electrophile for example hexachloroethane in a suitable solvent such as tetrahydrofuran.
  • Alcohol intermediates of type XXIX (wherein Pg 3 is for example, 2-tetrahydropyranyl) can be prepared by reacting a chloro intermediate XXX with a diol of type X in the presence of a base for example cesium fluoride in a solvent such as N,N-dimethylacetamide.
  • An intermediate of type XXIX (wherein Pg 3 is for example, 2-tetrahydropyranyl) can be converted into a pyrazole such as XXVIII by treatment with an acid such as aqueous hydrochloric acid in a suitable solvent for example methanol.
  • Nitropyrazole intermediates of type XXVI (wherein Pg 3 is e.g., TBS) can synthesized from pyrazole intermediates such as XXVII and an intermediate of type XIX (wherein M is for example B(OH) 2 ).
  • the coupling is exemplified by a Chan-Lam type coupling.
  • the reaction can be performed by reacting an intermediate of type XXVII (wherein Pg 2 is for example TBS) with a boronic acid intermediate XIX in which M ⁇ B(OH) 2 in the presence of a copper salt such as copper(II) acetate, a base for example pyridine, and a drying agent such as 4 ⁇ molecular sieves under an oxygen atmosphere in a suitable solvent such 1,2-dichloroethane.
  • a copper salt such as copper(II) acetate
  • a base for example pyridine
  • a drying agent such as 4 ⁇ molecular sieves
  • alcohol intermediates of type XXV can be prepared from a nitro pyrazole intermediate of type XXVI (wherein Pg 2 is e.g., TBS) using tetra-n-butyl ammonium fluoride in a suitable solvent such as tetrahydrofuran.
  • Pg 2 is e.g., TBS
  • tetra-n-butyl ammonium fluoride in a suitable solvent such as tetrahydrofuran.
  • the synthetic schemes 8 and 9 is for example detailed in the synthesis of 3-bromo-8-chloro-2-(2,6-dimethylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine.
  • Boc tert-butyloxycarbonyl
  • Bpin pinacol boronate
  • BRIJ-35 polyoxyethylene (23) lauryl ether
  • C Celsius
  • CPME cyclopentyl methyl ether
  • c-Pr cyclopropyl
  • DBAD di-tert-butyl azodicarboxylate
  • DCM dichloromethane
  • DIAD diisopropyl azodicarboxylate
  • DIPEA N,N-diisopropylethylamine
  • DMA N,N-dimethylacetamide
  • DMF N,N-dimethylformamide
  • DMSO dimethylsulfoxide
  • DTBPF 1,1-bis(di-tert-butylphosphino)ferrocene
  • DTT dithiothreitol
  • EGTA ethylene glycol-bis( ⁇ -aminoethyl ether)-N,N,N,N′-tetraace
  • Tetra-n-butylammonium fluoride TEA: triethylamine
  • THF tetrahydrofuran
  • THP tetrahydropyran
  • TMEDA N,N,N′,N′-tetramethylethylenediamine
  • TMS trimethylsilyl
  • Tris trisaminomethane
  • Ts toluenesulfonyl.
  • Method A LC-MS were run on Agilent Prime-6125B UPLC-MS consisting of Agilent Prime including column manager, binary solvent manager, sample organizer, PDA detector (operating at 254 nm), ELS detector, and 6125B equipped with APPI-source operating in positive ion mode.
  • LC-conditions The column was Agilent Poroshell 120 EC-C18 1.9 ⁇ m; 3.0 ⁇ 30 mm operating at 50° C. with 1.5 mL/min of a binary gradient consisting of water+0.037% trifluoroacetic acid (A) and acetonitrile+0.018% trifluoroacetic acid(B).
  • the retention times (t R ) are expressed in minutes based on UV-trace at 254 nm.
  • Method B LC-MS were run on Agilent LC1200-MS6150 UPLC-MS consisting of Agilent LC1200 including column manager, binary solvent manager, sample organizer, PDA detector (operating at 220&254 nm), ELS detector, and MS6150 equipped with APPI-source operating in positive ion mode.
  • LC-conditions The column was MERCK, RP-18 e 25 ⁇ 3.0 mm operating at 50° C. with 1.5 mL/min of a binary gradient consisting of water+0.037% trifluoroacetic acid (A) and acetonitrile+0.018% trifluoroacetic acid(B). The retention times (t R ) are expressed in minutes based on UV-trace at 220&254 nm.
  • Method C LC-MS were run on Agilent LC1200-MS6110 UPLC-MS consisting of Agilent LC1200 including column manager, binary solvent manager, sample organizer, PDA detector (operating at 220&254 nm), ELS detector, and MS6110 equipped with APPI-source operating in positive ion mode.
  • LC-conditions The column was Xbridge Shield, RP-18 e 50 ⁇ 2.1 mm operating at 30° C. with 1 mL/min of a binary gradient consisting of water(4 L)+NH 3 —H 2 O(0.8 mL) (A) and acetonitrile (B). The retention times (t R ) are expressed in minutes based on UV-trace at 220&254 nm.
  • Method D LC-MS were run on Waters Aquity UPLC-MS consisting of Waters Aquity including column manager, binary solvent manager, sample organizer, PDA detector (operating at 254 nm), ELS detector, and TQD-MS equipped with ESI-source operating in positive ion mode.
  • LC-conditions The column was Acquity UPLC BEH C18 1.7 ⁇ m; 2.1 ⁇ 50 mm operating at 60° C. with 1.2 ml/min of a binary gradient consisting of water+0.05% trifluoroacetic acid (A) and acetonitrile+5% water+0.03% trifluoroacetic acid.
  • the retention times (t R ) are expressed in minutes based on UV-trace at 254 nm.
  • Method E LC-MS were run on Waters Aquity UPLC-MS consisting of Waters Aquity including column manager, binary solvent manager, sample organizer, PDA detector (operating at 254 nm), ELS detector, and TQD-MS equipped with ESI-source operating in positive ion mode.
  • LC-conditions The column was Acquity UPLC HSS T3 1.8 ⁇ m; 2.1 ⁇ 50 mm operating at 60° C. with 1.2 ml/min of a binary gradient consisting of water+0.05% trifluoroacetic acid (A) and acetonitrile+5% water+0.035% trifluoroacetic acid.
  • the retention times (t R ) are expressed in minutes based on UV-trace at 254 nm.
  • Method F LC-MS were run on Agilent Prime-6125B UPLC-MS consisting of Agilent Prime including column manager, binary solvent manager, sample organizer, PDA detector (operating at 254 nm), ELS detector, and MS6125B equipped with APPI-source operating in positive ion mode.
  • LC-conditions The column was Agilent Poroshell 120 HPH-C18 1.9 ⁇ m 3.0 ⁇ 30 mm operating at 30° C. with 1.5 mL/min of a binary gradient consisting of water+0.05% NH 3 —H 2 O (A) and acetonitrile (B). The retention times (t R ) are expressed in minutes based on UV-trace at 254 nm.
  • (Methyl-d 3 )boronic acid can be prepared in the following manner:
  • n-BuLi 13 mL, 33 mmol, 2.5 M in hexane
  • 3-bromo-2,5-dimethyl-pyridine 3 g, 16 mmol
  • triisopropyl borate 6.07 g, 32.3 mmol
  • THF 50 mL
  • the mixture was stirred at ⁇ 78° C. for 3 h.
  • the mixture was quenched with aqueous NH 4 Cl (20 mL) and then extracted with EtOAc (20 mL ⁇ 4).
  • the combined organic layers were concentrated under reduced pressure to afford (2,5-dimethyl-3-pyridyl)boronic acid (2 g) of sufficient purity for the subsequent step.
  • 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (16.3 g, 129 mmol) was added to a stirred suspension of 2,6-dibromo-5-fluoropyridin-3-amine (13.0 g, 51.8 mmol), K 3 PO 4 (22.0 g, 104 mmol), and XPhos Pd G 3 (4.38 g, 5.18 mmol) in 1,4-dioxane (450 mL). The mixture was stirred at 95° C. for 12 h. The reaction mixture was concentrated under reduced pressure.
  • n-BuLi (8.61 mL, 22 mmol, 2.5 M in hexane) was slowly added to a solution of 3-bromo-5-fluoro-2-(trideuteriomethoxy)pyridine (3.0 g, 14 mmol) and triisopropyl borate (6.82 g, 36.3 mmol) in THF (30 mL) at ⁇ 65° C.
  • the mixture was stirred at ⁇ 65° C. for 2 h and then allowed to warm to 25° C. and stirred for 14 h.
  • the mixture was adjusted to pH 6 with aqueous HCl (1 M) and concentrated under reduced pressure.
  • reaction mixture was concentrated under reduced pressure.
  • the residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0 ⁇ 0:100) and triturated with MeOH (20 mL) to afford 8-chloro-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (1.5 g) of sufficient purity for the subsequent step.
  • NBS 150 mg, 0.843 mmol
  • CHCl 3 20 mL
  • NBS 50 mg, 0.28 mmol
  • the mixture was washed with water (30 mL ⁇ 2) and concentrated under reduced pressure.
  • the compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((5-methyl-1-(2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (188 mg, 0.41 mmol), Fe (113 mg, 2.03 mmol), and NH 4 Cl (109 mg, 2.03 mmol) in EtOH (20 mL) and H 2 O (5 mL) at 80° C.
  • the compound was prepared in a manner similar to Example 2 using of 3,6-dichloro-1-(3-((1-(2-ethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (40 mg, 0.84 mmol), Fe (23 mg, 0.42 mmol), and NH 4 Cl (22 mg, 0.41 mmol) in EtOH (8 mL) and H 2 O (2 mL) at 80° C.
  • the compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((5-ethyl-1-(2-methoxypyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (240 mg, 0.48 mmol), Fe (144 mg, 2.58 mmol), and NH 4 Cl (144 mg, 2.69 mmol) in EtOH (20 mL) and H 2 O (5 mL) at 80° C.
  • the compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(5-fluoro-2-methoxypyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (580 mg, 1.17 mmol), Fe (348 mg, 6.23 mmol), and NH 4 Cl (348 mg, 6.51 mmol) in EtOH (30 mL) and H 2 O (3 mL) at 80° C.
  • the compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(2-methoxy-4-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (240 mg, 0.49 mmol), Fe (136 mg, 2.43 mmol), and NH 4 Cl (130 mg, 2.43 mmol) in EtOH (10 mL) and H 2 O (1.5 mL) at 80° C.
  • Example 8 8-Chloro-3-ethyl-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
  • the compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((5-ethyl-1-(2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (680 mg, 1.42 mmol), Fe (408 mg, 7.31 mmol), and NH 4 Cl (408 mg, 7.63 mmol) in EtOH (40 mL) and H 2 O (4 mL) at 80° C. for 15 h.
  • the compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(2,6-dimethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (220 mg, 0.46 mmol), Fe (129 mg, 2.30 mmol), and NH 4 Cl (123 mg, 2.30 mmol) in EtOH (10 mL) and H 2 O (1.5 mL) at 80° C.
  • the compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(5-fluoro-2-methyl pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[[3,4-d]pyrimidine (180 mg, 0.37 mmol), Fe (104 mg, 1.87 mmol), and NH 4 Cl (100 mg, 1.87 mmol) in EtOH (18 mL) and H 2 O (1.8 mL) at 80° C.
  • the compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(2,5-dimethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-[3,4-d]pyrimidine (500 m, 1.05 mg mm ol), Fe (300, 5.37 mmol), and NH 4 Cl (300 mg, 5.61 mmol) in EtOH (50 mL) and H 2 O (5 mL) at 80° C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is directed to compounds of formula IIa
Figure US11958865-20240416-C00001
These compounds are considered useful for the treatment of diseases associated with leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease. Furthermore, the invention relates to pharmaceutical compositions comprising said compounds.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to European Application No. EP22195861.4, filed Sep. 15, 2022, and European Application No. EP23168862.3, filed Apr. 20, 2023, the entire contents of the aforementioned applications are hereby incorporated herein by reference.
FIELD OF THE INVENTION
The present invention relates to compounds which are LRRK2 inhibitors and to pharmaceutical composition comprising said compounds. Further the invention relates to methods of treating diseases using said compounds or pharmaceutical compositions.
BACKGROUND OF THE INVENTION
Parkinson's disease (PD) is a neurodegenerative disease. It is the second most common neurodegenerative disease after Alzheimer's disease and affects more than 1% of the general population above the age of 65. Parkinson's disease is clinically characterized by resting tremor, bradykinesia, muscular rigidity, and postural instability. In addition to motor symptoms, other symptoms such as neuropsychiatric symptoms are also present in many patients, and in late stages of the disease, Parkinson's disease dementia commonly develops. Pathologically, the disease is characterized by loss of dopaminergic neurons with consequent decrease in dopamine levels in the brain and by aggregation of the protein α-synuclein in the dopaminergic neurons. These aggregations, called Lewy bodies, are composed of various elements, but insoluble α-synuclein phosphorylated at serine-129 and ubiquitin are both abundantly found in Lewy bodies.
Current Parkinson's disease therapeutic intervention strategies aim at increasing the dopamine levels by administration of levodopa or monoamine oxidase B inhibitors. As an alternative, dopamine agonists are administered to stimulate dopaminergic receptors, an effect similar to that obtained by increasing the dopamine levels. Although these therapies provide significant symptomatic benefit to the patient, they are also associated with adverse side effects and often become ineffective after prolonged treatment and progression of the underlying disease. Importantly, none of the existing therapies addresses the underlying and disease-causing problem, i.e. the progressive loss of dopaminergic neurons.
Leucine-rich repeat kinase 2 (LRRK2) is a 2527 amino acid protein involved in catalyzing protein phosphorylation. Evidence is mounting for a relationship between LRRK2 and the pathogenesis of Parkinson's disease. Single nucleotide polymorphisms that alter amino acids in functional domains of LRRK2 have been shown to cause familiar and sporadic Parkinson's disease. Several such pathogenic variants have been identified including G2019S, 12020T, N1437H, R1441C, R1441G, R1441H and Y1699C (Shu et al., A Comprehensive Analysis of Population Differences in LRRK2 Variant Distribution in Parkinson's Disease, Front Aging Neurosci., 11:13, 2019; Chittoor-Vinod et al., Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism, Int. J. Mol. Sci., 2021, 22, 1045). The most common pathogenic form of LRRK2-associated Parkinson's disease is the amino acid substitution G2019S in the kinase domain of the LRRK2 protein. G2019S Parkinson's disease is inherited in an autosomal dominant fashion suggesting a gain-of-function mutation of the LRRK2 protein. In support of this notion, biochemical studies have shown that both G2019S and other pathogenic LRRK2 variants lead to an increased kinase activity of LRRK2 (West et al, Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity, Proc. Nat. Acad. Sci, 102, 16842-16847, 2005; Chittoor-Vinod et al., Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism, Int. J. Mol. Sci., 2021, 22, 1045). The clinical and pathological features of Parkinson's disease associated with LRRK2 mutations are very similar to those of idiopathic Parkinson's disease (Trinh et al., A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism, Neurobiol. Aging., 35(5), 1125-31, 2014). This strongly suggests a causal involvement of overactive LRRK2 in the pathogenesis of Parkinson's disease in patients with such activating mutations in LRRK2 and that inhibitors of LRRK2 could be used as disease modifying treatment in familiar Parkinson's disease.
In addition to the rare high-penetrance exonic LRRK2 variants mentioned above, there are also common LRRK2 variants with lower but significant association with Parkinson's disease showing that LRRK2 also contributes to idiopathic Parkinson's disease. These include very common single-nucleotide polymorphisms in the LRRK2 gene promotor region, where the Parkinson's disease associated variants appear to be associated with increased LRRK2 expression at least in some cell types (Nalls et al., Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies, Lancet Neurol, 2019, 18, 1091-1102; Sun et al., Genetic Variants Associated With Neurodegenerative Diseases Regulate Gene Expression in Immune Cell CD14+ Monocytes, Front Genet., 2018, 18, 9:666; Langston et al., Association of a Common Genetic Variant with Parkinson's Disease is Propagated through MicrogIia, bioRxiv, 2021) suggesting that LRRK2 inhibition might be relevant. Further, investigations of common exonic polymorphic variants have highlighted several LRRK2 Parkinson's disease risk variants including the A419V and G2385R that are common in the Asian population (Shu et al., A Comprehensive Analysis of Population Differences in LRRK2 Variant Distribution in Parkinson's Disease, Front Aging Neurosci., 11:13, 2019). There is also a protective variant of LRRK2 with reduced kinase activity such as the LRRK2 N551K R1398H variant (Wang et al., Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10, Scientific Reports, 2021, 11:12900), which lends further support to the potential of LRRK2 inhibition in idiopathic Parkinson's disease by showing that wild-type LRRK2 activity is not optimal in a Parkinson's disease context. Functionally, LRRK2 affects trafficking of lysosomes and other vesicles through phosphorylation of RAB GTPases, and PD-associated genes are enriched for genes involved in lysosomal function and autophagy (Chang et al., A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci, Nat Genet., 2017, 49(10): 1511-1516). Two genes associated with Parkinson's disease, VPS35 and RAB29, have been shown to directly interact with LRRK2 biology as they increase LRRK2 activity (Taylor et al., Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease, Curr Opin Cell Biol., 2020, 63:102-113), and as mentioned above, LRRK2 associated Parkinson's disease is very similar to idiopathic PD. Together this strongly supports the relevance of LRRK2 inhibition in treatment of idiopathic PD.
Several lines of evidence suggest that LRRK2 activity may impact α-synuclein pathology development after seeding with α-synuclein (O'Hara et al., LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson's Disease?, Front Neurosci., 2020, 17; 14:577).
In addition to strengthening the case for potential of LRRK2 inhibitors for treatment of Parkinson's disease, this indicates potential of LRRK2 inhibitors for treatment of other synucleinopathies including Lewy body dementia and multiple system atrophy.
LRRK2 is highly expressed in white blood cells and spleen suggesting a potential for LRRK2 inhibitors for treatment of aberrant immune responses. This is further supported by genetic association of LRRK2 with such diseases particularly inflammatory bowel diseases including Crohn's disease and leprosy (Liu et al., Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations, Nat Genet., 2015, 47(9):979-986; Rastegar et al., Leucine Rich Repeat Kinase 2 and Innate Immunity, Front Neurosci., 2020, 10; 14:193). Thus, LRRK2 inhibitors may have potential for treatment of these diseases.
Both from the pharmaceutical industry and academic labs there has been a high interest in developing potent selective LRRK2 inhibitors due to their great promise in treating Parkinson's disease and other synucleinopathies.
The historic development of LRRK2 inhibitors is well described in the literature (Delgado et al., N-bridged 5,6-bicyclic pyridines: Recent applications in central nervous system disorders, European Journal of Medicinal Chemistry 97 (2015) 719-731); Xiao Ding & Feng Ren (2020) Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present), Expert Opinion on Therapeutic Patents, 30:4, 275-286). Even though a lot of focus has been on designing new LRRK2 inhibitors by the pharmaceutical industry and academic labs, the task of designing a brain penetrant, potent, selective LRRK2 inhibitor remains a challenge for the medicinal chemistry community (Delgado et al., N-bridged 5,6-bicyclic pyridines: Recent applications in central nervous system disorders, European Journal of Medicinal Chemistry 97 (2015) 719-731).
Despite the tremendous efforts from pharmaceutical industry and academic labs only two molecules (DNL201 and DNL151) from Denali Therapeutics have reached clinical phase (Xiao Ding & Feng Ren (2020) Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present), Expert Opinion on Therapeutic Patents, 30:4, 275-286).
Against this background there is still a high unmet need to provide LRRK2 inhibitors with good pharmacokinetic properties, whilst maintaining high potency and good selectivity.
SUMMARY OF THE INVENTION
The present inventors have surprisingly found that certain 2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine compounds are LRRK2 inhibitors.
In a first aspect, the invention provides a compound of formula IIa, or a pharmaceutically acceptable salt thereof, wherein:
Figure US11958865-20240416-C00002
    • X is CH, CR1 or N;
    • Y is CH, CR1 or N;
    • R1 is independently selected from the group consisting of a C1-C3 alkyl, a C1-C3 haloalkyl, and halogen;
    • R2 is selected from a C1-C3 alkyl or an isotopically labelled C1-C3 alkyl;
    • R3 is selected from the group consisting of a halogen, a cyano, and a C1-C3 haloalkyl;
    • R4 is selected from the group consisting of a C1-C3 alkyl, an isotopically labelled C1-C3 alkyl, a C1-C3 haloalkyl, a O—C1-C3 alkyl, an isotopically labelled O—C1-C3 alkyl, a O—C1-C3 haloalkyl,
    • and a O—C3-C6 cycloalkyl;
      • n is 0, 1 or 2.
In an embodiment, the invention provides a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein:
Figure US11958865-20240416-C00003
    • R1 is independently selected from the group consisting of a C1-C3 alkyl, a C1-C3 haloalkyl, and a halogen;
    • R2 is selected from a C1-C3 alkyl or an isotopically labelled C1-C3 alkyl;
    • R3 is selected from the group consisting of a halogen, a cyano, and a C1-C3 haloalkyl;
    • R4 is selected from the group consisting of a C1-C3 alkyl, a O—C1-C3 haloalkyl, a O—C1-C3 alkyl,
    • and a C1-C3 haloalkyl;
      • n is 0, 1 or 2.
In a further embodiment, is provided a compound of formula Ia, or a pharmaceutically acceptable salt thereof wherein:
Figure US11958865-20240416-C00004
    • R1 is selected from the group consisting of a C1-C3 alkyl, a C1-C3 haloalkyl, and a halogen;
    • R2 is selected from a C1-C3 alkyl or an isotopically labelled C1-C3 alkyl;
    • R3 is halogen;
    • R4 is selected from the group consisting of a C1-C3 alkyl, a O—C1-C3 haloalkyl, a O—C1-C3 alkyl,
    • and a C1-C3 haloalkyl;
      • n is 0 or 1.
In an embodiment X is CH or CR1 and Y is CH or CR1.
In an embodiment X is CH and Y is CH.
In an embodiment X is CR1 and Y is CR1.
In an embodiment X is CH and Y is CR1.
In an embodiment X is CR1 and Y is CH.
In an embodiment X is CH or CR1 and Y is N.
In an embodiment X is N and Y is CH or CR1.
In an embodiment X is N and Y is CR1.
In an embodiment X is N and Y is CH.
In an embodiment X is CH and Y is N.
In an embodiment X is CR1 and Y is N.
In an embodiment, R1 is a C1-C3 alkyl.
In an embodiment, R1 is —CH3.
In an embodiment, R1 is —CH2CH3.
In an embodiment, R1 is a halogen.
In an embodiment, R1 is fluoro.
In an embodiment, R2 is selected from the group consisting of —CH3, —CH2CH3, and —CD3.
In an embodiment, R2 is —CH3.
In an embodiment, R2 is —CH2CH3.
In an embodiment, R2 is —CD3.
In an embodiment, R3 is a halogen.
In an embodiment, R3 is chloro.
In an embodiment, R4 is selected from the group consisting of —CH3, —CH2CH3, —OCH3, —OCH2CH3, —CHF2, —CF3, —O—C3 cycloalkyl, O-cyclopropane, —OCH2F, —OCHF2, —OCF3, and —OCD3.
In an embodiment, R4 is —CH3.
In an embodiment, R4 is —CH2CH3.
In an embodiment, R4 is —OCH3.
In an embodiment, R4 is —OCH2CH3.
In an embodiment, R4 is —CHF2.
In an embodiment, R4 is —CF3.
In an embodiment, R4 is —CF2CH3.
In an embodiment, R4 is —O—C3 cycloalkyl.
In an embodiment, R4 is O-cyclopropane.
In an embodiment, R4 is —OCH2F.
In an embodiment, R4 is —OCHF2.
In an embodiment, R4 is —OCF3.
In an embodiment, R4 is —OCD3.
In an embodiment, n is 2.
In an embodiment, n is 1.
In an embodiment, n is 0.
In an embodiment, the compound of the invention is selected from the list consisting of:
Figure US11958865-20240416-C00005
Figure US11958865-20240416-C00006
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound of the invention is selected from the list consisting of:
Figure US11958865-20240416-C00007
Figure US11958865-20240416-C00008
Figure US11958865-20240416-C00009
Figure US11958865-20240416-C00010
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00011
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00012
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00013
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00014
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00015
or a pharmaceutically acceptable salt thereof.
In a further aspect, the invention provides a pharmaceutical composition comprising a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.
In a further aspect, the invention provides compounds of formula I, formula Iia or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in therapy.
In a further aspect, the invention provides compounds of formula I, formula Iia or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in the treatment of a synucleinopathy.
In a further aspect, the invention provides use of compounds of formula I, formula Ia or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof in the treatment of a synucleinopathy.
In a further aspect, the invention relates to the use of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a synucleinopathy.
In a further aspect, the invention relates to a method for the treatment of a disease associated with LRRK2 such as synucleinopathies, the method comprising the administration of a therapeutically effective amount of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof to a patient in need thereof.
In a further aspect, the invention provides compounds of formula I, formula IIa or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in the treatment of a disease associated with LRRK2, such as Parkinson's disease.
In a further aspect, the invention provides compounds of formula I, formula IIa or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in the treatment of Lewy body dementia, multiple system atrophy, or Parkinson's disease. In a further aspect, the invention relates to the use of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a disease associated with LRRK2 such as Parkinson's disease.
In a further aspect, the invention relates to a method for the treatment of a disease associated with LRRK2 such as Parkinson disease, the method comprising the administration of a therapeutically effective amount of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof to a patient in need thereof.
DETAILED DESCRIPTION OF THE INVENTION
The inventors of the present disclosure have identified new compounds that are LRRK2 inhibitors. These compounds are listed in table 1. As can be seen from the examples I-V of the present disclosure, these compounds were demonstrated to possess a both low clearance and a high brain penetrance, while maintaining a high potency and selectivity for LRRK2, as well as displaying a good pharmacokinetic profile. As has been demonstrated in the historic literature of LRRK2 inhibitors, as presented above, the provision of compounds which are LRRK2 inhibitors, and which also display characteristics mentioned above is a highly complex and unpredictable.
TABLE 1
Compounds of the invention
Compound
number Name Structure
 1 8-Chloro-2-(2-methoxypyridin-3-yl)- 3-methyl-2,4,12,13-tetrahydro-11H- 5,7-(azenometheno)dipyrazolo[3,4- b:5′,1′-g][1]oxa[4,6,8] triazacycloundecine
Figure US11958865-20240416-C00016
 2 8-Chloro-2-(2-ethoxypyridin-3-yl)-3- methyl-2,4,12,13-tetrahydro-11H- 5,7-(azenometheno)dipyrazolo[3,4- b:5′,1′-g][1]oxa[4,6,8] triazacycloundecine
Figure US11958865-20240416-C00017
 3 8-Chloro-3-methyl-2-(2-methylpyridin- 3-yl)-2,4,12,13-tetrahydro-11H- 5,7-(azenometheno)dipyrazolo[3,4- b:5′,1′-g][1]oxa[4,6,8] triazacycloundecine
Figure US11958865-20240416-C00018
 4 8-Chloro-2-(2-ethylpyridin-3-yl)-3- methyl-2,4,12,13-tetrahydro-11H- 5,7-(azenometheno)dipyrazolo[3,4- b:5′,1′-g][1]oxa[4,6,8] triazacycloundecine
Figure US11958865-20240416-C00019
 5 8-Chloro-3-ethyl-2-(2-methoxypyridin- 3-yl)-2,4,12,13-tetrahydro-11H- 5,7-(azenometheno)dipyrazolo[3,4- b:5′,1′-g][1]oxa[4,6,8] triazacycloundecine
Figure US11958865-20240416-C00020
 6 8-Chloro-2-(5-fluoro-2-methoxypyridin- 3-yl)-3-methyl-2,4,12,13-tetra- hydro-11H-5,7-(azenometheno) dipyrazolo[3,4-b:5′,1′- g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00021
 7 8-Chloro-2-(2-methoxy-4- methylpyridin-3-yl)-3-methyl- 2,4,12,13-tetrahydro-11H-5,7- (azenometheno)dipyrazolo[3,4- b:5′,1′-g][1]oxa[4,6,8] triazacycloundecine
Figure US11958865-20240416-C00022
 8 8-Chloro-3-ethyl-2-(2-methylpyridin- 3-yl)-2,4,12,13-tetrahydro-11H- 5,7-(azenometheno)dipyrazolo[3,4- b:5′,1′-g][1]oxa[4,6,8] triazacycloundecine
Figure US11958865-20240416-C00023
 9 8-Chloro-2-(2,6-dimethylpyridin-3- yl)-3-methyl-2,4,12,13-tetrahydro- 11H-5,7-(azenometheno) dipyrazolo[3,4-b:5′,1′- g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00024
10 8-Chloro-2-(5-fluoro-2-methylpyridin- 3-yl)-3-methyl-2,4,12,13- tetrahydro-11H-5,7-(azenometheno)- dipyrazolo[3,4-b:5′,1′- g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00025
11 8-Chloro-2-(2,5-dimethylpyridin-3- yl)-3-methyl-2,4,12,13-tetrahydro- 11H-5,7-(azenometheno)dipyrazolo [3,4-b:5′,1′- g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00026
12 8-Chloro-2-(2-methoxy-5- methylpyridin-3-yl)-3-methyl- 2,4,12,13-tetrahydro-11H-5,7- (azenometheno)dipyrazolo[3,4- b:5′,1′-g][1]oxa[4,6,8] triazacycloundecine
Figure US11958865-20240416-C00027
13 8-Chloro-2-(2-methoxy-6- methylpyridin-3-yl)-3-methyl- 2,4,12,13-tetrahydro-11H-5,7- (azenometheno)dipyrazolo[3,4- b:5′,1′-g][1]oxa[4,6,8] triazacycloundecine
Figure US11958865-20240416-C00028
14 8-Chloro-2-(2-(1,1-difluoro- ethyl)pyridin-3-yl)-3-methyl- 2,4,12,13-tetrahydro-11H-5,7- (azenometheno)dipyrazolo[3,4- b:5′,1′-g][1]oxa[4,6,8] triazacycloundecine
Figure US11958865-20240416-C00029
15 8-Chloro-2-(5-fluoro-2,6-dime- thylpyridin-3-yl)-3-methyl- 2,4,12,13-tetrahydro-11H-5,7- (azenometheno)dipyrazolo[3,4- b:5′,1′-g][1]oxa[4,6,8] triazacycloundecine
Figure US11958865-20240416-C00030
16 8-Chloro-2-(2-cyclopropoxypyridin- 3-yl)-3-methyl-2,4,12,13-tetrahydro- 11H-5,7-(azenometheno) dipyrazolo[3,4-b:5′,1′- g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00031
17 8-Chloro-3-methyl-2-(2-(trifluoro- methyl)pyridin-3-yl)-2,4,12,13- tetrahydro-11H-5,7-(azenometheno) dipyrazolo[3,4-b:5′,1′- g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00032
18 8-Chloro-2-(2-(fluoromethoxy) pyridin-3-yl)-3-methyl-2,4,12,13- tetrahydro-11H-5,7-(azenometheno) dipyrazolo [3,4-b:5′,1′- g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00033
19 8-Chloro-2-(2-(difluorometh- oxy)pyridin-3-yl)-3-methyl- 2,4,12,13-tetrahydro-11H-5,7- (azenometheno)dipyrazolo[3,4- b:5′,1′-g][1]oxa[4,6,8] triazacycloundecine
Figure US11958865-20240416-C00034
20 8-Chloro-3-methyl-2-(2-(trifluoro- methoxy)pyridin-3-yl)-2,4,12,13- tetrahydro-11H-5,7-(azenome- theno)dipyrazolo[3,4-b:5′,1′- g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00035
21 8-Chloro-2-(3-methoxypyridazin-4- yl)-3-methyl-2,4,12,13-tetrahydro- 11H-5,7-(azenometheno)dipyrazolo [3,4-b:5′,1′- g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00036
22 8-Chloro-2-(4-methoxy-2- methylpyrimidin-5-yl)-3-methyl- 2,4,12,13-tetrahydro-11H-5,7- (azenometheno)dipyrazolo[3,4-b:5′,1′- g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00037
23 8-Chloro-2-(5-fluoro-2-(methoxy- d3)pyridin-3-yl)-3-methyl-2,4,12,13- tetrahydro-11H-5,7-(azenometheno) dipyrazolo[3,4-b:5′,1′- g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00038
24 8-Chloro-2-(2-(methoxy-d3)pyridin- 3-yl)-3-methyl-2,4,12,13-tetrahydro- 11H-5,7-(azenometheno)dipyrazolo [3,4-b:5′,1′- g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00039
25 8-Chloro-2-(2,6-dimethylpyridin-3- yl)-3-(methyl-d3)-2,4,12,13-tetrahydro- 11H-5,7-(azenometheno) dipyrazolo[3,4-b:5′,1′- gl[1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00040
26 8-Chloro-3-(methyl-d3)-2-(2- methylpyridin-3-yl)-2,4,12,13- tetrahydro-11H-5,7-(azenometheno) dipyrazolo[3,4-b:5′,1′- g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00041
27 8-Chloro-2-(2,5-dimethylpyridin-3- yl)-3-(methyl-d3)-2,4,12,13- tetrahydro-11H-5,7-(azenometheno) dipyrazolo[3,4-b:5′,1′- g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00042
28 8-Chloro-2-(2-methoxypyridin-3-yl)- 3-(methyl-d3)-2,4,12,13-tetrahydro- 11H-5,7-(azenometheno)dipyrazolo [3,4-b:5′,1′- g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00043
29 8-Chloro-2-(5-fluoro-2-methoxypyridin- 3-yl)-3-(methyl-d3)-2,4,12,13- tetrahydro-11H-5,7-(azenometheno) dipyrazolo[3,4-b:5′,1′- g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00044
30 8-Chloro-2-(5-fluoro-2-methylpyridin- 3-yl)-3-(methyl-d3)-2,4,12,13- tetrahydro-11H-5,7-(azenometheno) dipyrazolo[3,4-b:5′,1′- g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00045
Definitions
In the present context, “alkyl” is intended to indicate a straight or branched saturated hydrocarbon. In particular, C1-C3-alkyl is intended to indicate such hydrocarbon having 1, 2 or 3 carbon atoms in the longest continuous carbon chain. Typical alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl and the like.
As used herein, the term “isotopically labelled C1-C3-alkyl” means that either one or more of the carbon or one or more of the hydrogen atom(s) in the alkyl group is replaced with a corresponding isotope such as 13C and/or 14C for carbon atom(s), or deuterium or tritium for hydrogen atom(s). In one embodiment at least one 13C atom is replaced with a 14C atom. In one embodiment at least one 12C atom is replaced with a 14C atom. In one embodiment at least one 12C atom is replaced with a 13C atom. In a further embodiment at least one hydrogen atom is replaced with deuterium. In an embodiment of the invention the hydrogen atoms are all replaced by deuterium. Representative examples of isotopically labelled alkyl include but are not limited to —CD3, —CD2CD3. In a preferred embodiment, the isotopically labelled C1-C3-alkyl is —CD3.
As used herein, the term “isotopically labelled O—C1-C3-alkyl” means that either one or more of the carbon or one or more of the hydrogen atom(s) in the alkyl group is replaced with a corresponding isotope such as 13C and/or 14C for carbon atom(s), or deuterium or tritium for hydrogen atom(s). In one embodiment at least one 13C atom is replaced with a 14C atom. In one embodiment at least one 12C atom is replaced with a 14C atom. In one embodiment at least one 12C atom is replaced with a 13C atom. In another embodiment at least one hydrogen atom is replaced with deuterium. In an embodiment of the invention the hydrogen atoms are all replaced by deuterium. Representative examples of isotopically labelled alkoxy include but are not limited to —O-CD3, —O-CD2CD3. In a preferred embodiment, the isotopically labelled O—C1-C3-alkyl is —O-CD3.
The term “alkoxy” as used herein refers to a group of formula —O-alkyl, wherein alkyl is defined as above. In particular, C1-C3-alkoxy is intended to indicate an alkoxy-group having 1, 2 or 3 hydrocarbon atoms in the longest continuous carbon chain. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, isobutoxy, t-butoxy and the like.
The term “haloalkyl” or “haloalkoxy” is intended to refer to an alkyl or alkoxy group as defined hereinabove with 1, 2 or 3 hydrogens replaced by a halogen. Representative examples include but are not limited to CH2F, CHF2, CF3, OCF3, OCH2F, and OCHF2, Similarly, the term “fluoroalkyl” is intended to refer to an alkyl group as defined hereinabove, with 1, 2, or 3 hydrogens replaced by fluorine. Representative examples include but are not limited to CH2F, CHF2, and —CF3.
In the present context, “halogen” is intended to indicate members of the 7th main group of the periodic table of the elements, such as bromine, fluorine, and chlorine.
The term “heteroatom” is intended to mean sulfur, oxygen, or nitrogen.
The term “cyano” as used herein, means at least one —CN group is appended to the parent molecular moiety.
The term “cyanoalkyl” as used herein is intended to indicate an alkyl group as defined herein, wherein at least one —CN group is appended to the parent molecular moiety.
The term “cyclic” as used herein refers to any cyclic structure, including heterocyclic, aromatic and heteroaromatic non-fused ring systems. The term “membered” is meant to denote the number of skeletal atoms that constitute the ring. Thus, for example, pyridyl, pyranyl, and pyrimidinyl are six-membered rings and pyrrolyl, and tetrahydrofuranyl are five-membered rings.
The term “cycloalkyl,” as used herein, refers to a carbocyclic ring system containing three to ten carbon atoms, zero heteroatoms and zero double bonds. The cycloalkyl may be monocyclic or bicyclic, wherein the bicyclic ring is joined bridged, fused, or spirocyclic.
The terms “heterocycle”, “heterocyclic” and “heterocyclyl” as used herein, alone or in combination, refers to saturated or unsaturated nonaromatic rings containing from 4 to 7 ring atoms where one or more of the ring atoms are heteroatoms. The heterocycle may be monocyclic or bicyclic, wherein the bicyclic ring is joined bridged, fused, or spirocyclic.
In the present context, the term “therapeutically effective amount” of a compound is intended to indicate an amount sufficient to alleviate or partially arrest the clinical manifesta-tions of a given disease and its complications in a therapeutic intervention comprising the administration of said compound. An amount adequate to accomplish this is defined as “therapeutically effective amount”. Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, e.g. by con-structing a matrix of values and testing different points in the matrix, which is all within the ordinary skills of a trained physician.
In the present context, the term “treatment” and “treating” means the management and care of a patient for the purpose of combating a disease. The term is intended to include the full spectrum of treatments for a given disease from which the patient is suffering, such as administration of the active compound to alleviate the symptoms or complications, to delay the progression of the disease, to alleviate or relief the symptoms and complications, and/or to cure or eliminate the disease. The patient to be treated is preferably a mammal, in particular a human being. In the present context, “disease” can be used synonymous with disorder, condition, mal-function, dysfunction, and the like.
The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. For example, the phrase “the compound” is to be understood as referring to various “compounds” of the invention or particular described aspect, unless otherwise indicated.
The description herein of any aspect or aspect of the invention using terms such as “comprising”, “having,” “including,” or “containing” with reference to an element or elements is intended to provide support for a similar aspect or aspect of the invention that “consists of”, “consists essentially of”, or “substantially comprises” that particular element or elements, unless otherwise stated or clearly contradicted by context (e.g., a composition described herein as comprising a particular element should be understood as also describing a composition consisting of that element, unless otherwise stated or clearly contradicted by context).
Embodiments of the Invention
In the following, embodiments of the invention are disclosed.
In a first aspect of the invention is provided a compound of formula IIa, or a pharmaceutically acceptable salt thereof, wherein:
Figure US11958865-20240416-C00046
    • X is CH, CR1 or N;
    • Y is CH, CR1 or N;
    • R1 is independently selected from the group consisting of a C1-C3 alkyl, a C1-C3 haloalkyl, and halogen;
    • R2 is selected from a C1-C3 alkyl or an isotopically labelled C1-C3 alkyl;
    • R3 is selected from the group consisting of a halogen, a cyano, and a C1-C3 haloalkyl;
    • R4 is selected from the group consisting of a C1-C3 alkyl, an isotopically labelled C1-C3 alkyl, a C1-C3 haloalkyl, a O—C1-C3 alkyl, an isotopically labelled O—C1-C3 alkyl, a O—C1-C3 haloalkyl,
    • and a O—C3-C6 cycloalkyl;
    • n is 0,1 or 2.
In an embodiment, the invention provides a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein:
Figure US11958865-20240416-C00047
    • R1 is independently selected from the group consisting of a C1-C3 alkyl, a C1-C3 haloalkyl, and a halogen;
    • R2 is selected from a C1-C3 alkyl or an isotopically labelled C1-C3 alkyl;
    • R3 is selected from the group consisting of a halogen, a cyano, and a C1-C3 haloalkyl;
    • R4 is selected from the group consisting of a C1-C3 alkyl, a O—C1-C3 haloalkyl, a O—C1-C3 alkyl,
    • and a C1-C3 haloalkyl;
      • n is 0, 1 or 2.
In a further embodiment, is provided a compound of formula Ia, or a pharmaceutically acceptable salt thereof wherein:
Figure US11958865-20240416-C00048
    • R1 is selected from the group consisting of a C1-C3 alkyl, a C1-C3 haloalkyl, and a halogen;
    • R2 is selected from a C1-C3 alkyl or an isotopically labelled C1-C3 alkyl;
    • R3 is halogen;
    • R4 is selected from the group consisting of a C1-C3 alkyl, a O—C1-C3 haloalkyl, a O—C1-C3 alkyl,
    • and a C1-C3 haloalkyl;
    • n is 0 or 1.
In an embodiment X is CH or CR1 and Y is CH or CR1.
In an embodiment X is CH and Y is CH.
In an embodiment X is CR1 and Y is CR1.
In an embodiment X is CH and Y is CR1.
In an embodiment X is CR1 and Y is CH.
In an embodiment X is CH or CR1 and Y is N.
In an embodiment X is N and Y is CH or CR1.
In an embodiment X is N and Y is CR1.
In an embodiment X is N and Y is CH.
In an embodiment X is CH and Y is N.
In an embodiment X is CR1 and Y is N.
In an embodiment, R1 is a C1-C3 alkyl.
In an embodiment, R1 is —CH3.
In an embodiment, R1 is —CH2CH3.
In an embodiment, R1 is a halogen.
In an embodiment, R1 is fluoro.
In an embodiment, R2 is selected from the group consisting of —CH3, —CH2CH3, and —CD3.
In an embodiment, R2 is —CH3.
In an embodiment, R2 is —CH2CH3.
In an embodiment, R2 is —CD3.
In an embodiment, R3 is a halogen.
In an embodiment, R3 is chloro.
In an embodiment, R4 is selected from the group consisting of —CH3, —CH2CH3, —OCH3, —OCH2CH3, —CHF2, —CF3, —O—C3 cycloalkyl, O-cyclopropane, —OCH2F, —OCHF2, —OCF3, and —OCD3.
In an embodiment, R4 is —CH3.
In an embodiment, R4 is —CH2CH3.
In an embodiment, R4 is —OCH3.
In an embodiment, R4 is —OCH2CH3.
In an embodiment, R4 is —CHF2.
In an embodiment, R4 is —CF3.
In an embodiment, R4 is —CF2CH3.
In an embodiment, R4 is —O—C3 cycloalkyl.
In an embodiment, R4 is O-cyclopropane.
In an embodiment, R4 is —OCH2F.
In an embodiment, R4 is —OCHF2.
In an embodiment, R4 is —OCF3.
In an embodiment, R4 is —OCD3.
In an embodiment, n is 2.
In an embodiment, n is 1.
In an embodiment, n is 0.
In an embodiment, the compound of the invention is selected from the list consisting of:
Figure US11958865-20240416-C00049
Figure US11958865-20240416-C00050
Figure US11958865-20240416-C00051
Figure US11958865-20240416-C00052
Figure US11958865-20240416-C00053
Figure US11958865-20240416-C00054
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00055
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00056
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00057
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00058
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00059
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00060
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00061
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00062
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00063
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00064
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00065
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00066
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00067
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00068
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00069
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00070
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00071
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00072
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00073
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00074
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00075
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00076
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00077
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00078
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00079
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00080
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00081
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00082
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00083
or a pharmaceutically acceptable salt thereof.
In an embodiment, the compound is
Figure US11958865-20240416-C00084
or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is selected from the list consisting of:
8-Chloro-2-(2-methoxypyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenome-theno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-ethoxypyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenome-theno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-3-methyl-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenome-theno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-ethylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenome-theno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-3-ethyl-2-(2-methoxypyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenome-theno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(5-fluoro-2-methoxypyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-methoxy-4-methylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-3-ethyl-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenome-theno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2,6-dimethylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(5-fluoro-2-methylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2,5-dimethylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-methoxy-5-methylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-methoxy-6-methylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-(1,1-difluoroethyl)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(5-fluoro-2,6-dimethylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-cyclopropoxypyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-3-methyl-2-(2-(trifluoromethyl)pyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-(fluoromethoxy)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-(difluoromethoxy)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-3-methyl-2-(2-(trifluoromethoxy)pyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(3-methoxypyridazin-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(4-methoxy-2-methylpyrimidin-5-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(5-fluoro-2-(methoxy-d3)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-(methoxy-d3)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2,6-dimethylpyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-3-(methyl-d3)-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2,5-dimethylpyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-methoxypyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(5-fluoro-2-methoxypyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; and
8-Chloro-2-(5-fluoro-2-methylpyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(2-methoxypyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenome-theno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(2-ethoxypyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenome-theno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-3-methyl-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenome-theno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(2-ethylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenome-theno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-3-ethyl-2-(2-methoxypyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenome-theno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(5-fluoro-2-methoxypyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(2-methoxy-4-methylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-3-ethyl-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenome-theno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(2,6-dimethylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(5-fluoro-2-methylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(2,5-dimethylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(2-methoxy-5-methylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(2-methoxy-6-methylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(2-(1,1-difluoroethyl)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(5-fluoro-2,6-dimethylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(2-cyclopropoxypyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-3-methyl-2-(2-(trifluoromethyl)pyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(2-(fluoromethoxy)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(2-(difluoromethoxy)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-3-methyl-2-(2-(trifluoromethoxy)pyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(3-methoxypyridazin-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(4-methoxy-2-methylpyrimidin-5-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(5-fluoro-2-(methoxy-d3)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(2-(methoxy-d3)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenome-theno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(2,6-dimethylpyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-3-(methyl-d3)-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(2,5-dimethylpyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(2-methoxypyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(5-fluoro-2-methoxypyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
In an embodiment the compound of the invention is
8-Chloro-2-(5-fluoro-2-methylpyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
The compounds of the present invention may have one or more asymmetric centres and it is intended that any optical isomers (i.e. enantiomers or diastereomers) as separated, pure or partially purified optical isomers and any mixtures thereof including racemic mixtures, i.e. a mixture of stereoisomers, are included within the scope of the invention.
In this context is understood that when specifying the enantiomeric form, the compound is in enantiomeric excess, e.g. essentially in a pure form. Accordingly, one embodiment of the invention relates to a compound of the invention having an enantiomeric excess (ee) of at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 96%, preferably at least 98%.
Racemic forms can be resolved into the optical antipodes by known methods, for example by separation of diastereomeric salts thereof with an optically active acid and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optically active matrix. The compounds of the present invention may also be resolved by the formation of diastereomeric derivatives. Additional methods for the resolution of optical isomers, known to those skilled in the art, may be used. Such methods include those discussed by J. Jaques, A. Collet and S. Wilen in “Enantiomers, Racemates, and Resolutions”, John Wiley and Sons, New York (1981). Optically active compounds can also be prepared from optically active starting materials. Abso-lute stereochemistry may be determined by methods known to the skilled person, such as vi-brational circular dichroism (VCD) Spectroscopic analysis.
Furthermore, when a double bond or a fully or partially saturated ring system is present in the molecule geometric isomers may be formed. It is intended that any geometric isomers as separated, pure or partially purified geometric isomers or mixtures thereof are included within the scope of the invention. Likewise, molecules having a bond with restricted rotation may form geometric isomers. These are also intended to be included within the scope of the present invention.
Furthermore, some of the compounds of the present invention may exist in different tautomeric forms and it is intended that any tautomeric forms that the compounds are able to form are included within the scope of the present invention.
In one embodiment of the invention a compound of formula I, formula IIa or formula Ia is isotopically labelled at the R2 position. In a further embodiment of the invention, one or more of the hydrogen atoms of the compound of formula I, formula IIa or formula Ia are represented by deuterium. In a further embodiment of the invention, one or more of the hydrogen atoms at the R2 position of the compound of formula I, formula IIa or formula Ia are represented by deuterium. In a further embodiment of the invention, all hydrogen atoms at the R2 position of the compound of formula I, formula IIa or formula Ia are represented by deuterium. It is recognized that elements are present in natural isotopic abundances in most synthetic compounds and result in inherent incorporation of deuterium. However, the natural isotopic abundance of hydrogen isotopes such as deuterium is immaterial (about 0.015%) relative to the degree of stable isotopic substitution of compounds indicated herein. Thus, as used herein, designation of an atom as deuterium at a position indicates that the abundance of deuterium is significantly greater than the natural abundance of deuterium. Any atom not designated as a particular isotope is intended to represent any stable isotope of that atom, as will be apparent to the ordi-narily skilled artisan.
In one embodiment, designation of a position as “D” in a compound has a minimum deuterium incorporation of greater than about 60% at that position such as greater than about 70% at that position such as greater than about 80% at that position such as greater than about 85% at that position. In a further embodiment, designation of a position as “D” in a compound has a minimum deuterium incorporation of greater than about 90% at that position such as greater than about 95% at that position such as greater than about 97% at that position such as greater than about 99% at that position.
In a further aspect, the invention provides a pharmaceutical composition comprising a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.
In a further aspect, the invention provides compounds of formula I, formula IIa or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in therapy.
In a further aspect, the invention provides compounds of formula I, formula IIa or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in the treatment of a synucleinopathy.
In an embodiment, the invention provides compounds of formula I, formula IIa or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in the treatment of Lewy body dementia, multiple system atrophy, or Parkinson's disease.
In a further embodiment, the invention provides compounds of formula I, formula Ia or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in the treatment of Parkinson's disease.
In a further embodiment, the invention provides compounds of formula I, formula Ia or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof for use in the treatment of a disease associated with LRRK2 such as Parkinson's disease.
In a further aspect, the invention provides use of compounds of formula I, formula Ia or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof in the treatment of a synucleinopathy.
In an embodiment, the invention provides use of compounds of formula I, formula IIa or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof in the treatment of Lewy body dementia, multiple system atrophy, or Parkinson's disease.
In a further embodiment, the invention provides use of compounds of formula I, formula IIa or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof in the treatment of Parkinson's disease.
In a further embodiment, the invention provides use of compounds of formula I, formula IIa or formula Ia as disclosed herein or pharmaceutically acceptable salts thereof in the treatment of a disease associated with LRRK2 such as Parkinson's disease.
In a further aspect, the invention relates to the use of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a synucleinopathy.
In an embodiment, the invention relates to the use of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of Lewy body dementia, multiple system atrophy, or Parkinson's disease.
In a further embodiment, the invention relates to the use of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of Parkinson's disease.
In a further embodiment, the invention relates to the use of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a disease associated with LRRK2 such as Parkinson's disease.
In a further aspect, the invention relates to a method for the treatment of a disease associated with LRRK2 such as synucleinopathies, the method comprising the administration of a therapeutically effective amount of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof to a patient in need thereof.
In a further embodiment, the invention relates to a method for the treatment of a disease associated with LRRK2, wherein the disease is Lewy body dementia, multiple system atrophy, or Parkinson's disease; the method comprising the administration of a therapeutically effective amount of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof to a patient in need thereof.
In a further embodiment, the invention relates to a method for the treatment of Parkinson's disease, the method comprising the administration of a therapeutically effective amount of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof to a patient in need thereof.
In a further embodiment, the invention relates to a method for the treatment of a disease associated with LRRK2 such as Parkinson disease, the method comprising the administration of a therapeutically effective amount of a compound of formula I, formula IIa or formula Ia as disclosed herein or a pharmaceutically acceptable salt thereof to a patient in need thereof.
Pharmaceutically Acceptable Salts
The compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof. When a compound of formula I, formula IIa or formula Ia contains a free base, such salts may be prepared in a conventional manner by treating a solution or suspension of a free base of formula I, formula IIa or formula Ia with a molar equivalent of a pharmaceutically acceptable acid. Representative examples of suitable organic and inorganic acids are described below.
Pharmaceutically acceptable salts in the present context are intended to indicate non-toxic, i.e. physiologically acceptable salts. The term pharmaceutically acceptable salts includes salts formed with inorganic and/or organic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitrous acid, sulphuric acid, benzoic acid, citric acid, gluconic acid, lactic acid, maleic acid, succinic acid, tartaric acid, acetic acid, propionic acid, oxalic acid, maleic acid, fumaric acid, glutamic acid, pyroglutamic acid, salicylic acid and sulfonic acids, such as methanesul-fonic acid, ethanesulfonic acid, toluenesulfonic acid and benzene-sulfonic acid. Some of the acids listed above are di- or tri-acids, i.e. acids containing two or three acidic hydrogens, such as phosphoric acid, sulphuric acid, fumaric acid and maleic acid. Di- and tri-acids may form 1:1, 1:2 or 1:3 (tri-acids) salts, i.e. a salt formed between two or three molecules of the compound of the present invention and one molecule of the acid.
The term pharmaceutically acceptable salts include salts formed with inorganic and/or organic bases, such as alkali metal bases, such as sodium hydroxide, lithium hydroxide, potassium hydroxide, alkaline earth bases, such as calcium hydroxide and magnesium hydroxide, and organic bases, such as trimethylamine. Some of the bases listed above are di- or tri-bases, i.e. bases able to receive two or three acidic hydrogens, such as calcium hydroxide and magnesium hydroxide. Di- and tri-bases may form 1:1 or 1:2 salts, i.e. a salt formed between two molecules of the compound of the present invention and one molecule of the base.
Additional examples of useful acids and bases to form pharmaceutically acceptable salts can be found e.g. in Stahl and Wermuth (Eds.) “Handbook of Pharmaceutical salts. Properties, selection, and use”, Wiley-VCH, 2008.
Pharmaceutical Composition
The above-mentioned compounds or pharmaceutically acceptable salts may be in a composition as the sole active pharmaceutical ingredient or in combination with other pharmaceutically active ingredients. Additionally, one or more pharmaceutically acceptable carriers or diluents may be in the composition.
The pharmaceutical compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sub-lingual), transdermal, intracisternal, intraperitoneal, vaginal, and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous, and intradermal) route, the oral route being preferred. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.
Pharmaceutical compositions for oral administration include solid dosage forms such as capsules, tablets, dragées, pills, lozenges, powders, and granules. Where appropriate, they can be prepared with coatings.
Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups, and elixirs.
Pharmaceutical compositions for parenteral administration include sterile aqueous and nonaqueous injectable solutions, dispersions, suspensions, or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use.
Other suitable administration forms include suppositories, sprays, ointments, creams, gels, inhalants, dermal patches, implants, etc.
Conveniently, the compounds of the invention are administered in a unit dosage form containing said compounds in an amount of about 0.1 to 500 mg, such as 10 mg, 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg of a compound of the present invention.
For parenteral administration, solutions of the compound of the invention in sterile aqueous solution, aqueous propylene glycol, aqueous vitamin E or sesame or peanut oil may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions, and various organic solvents. Examples of solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid, and lower alkyl ethers of cellulose. Examples of liquid carriers are syrup, peanut oil, olive oil, phosphor lipids, fatty acids, fatty acid amines, polyoxyethylene and water. The pharmaceutical compositions formed by combining the compound of the invention and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient. Furthermore, the orally available formulations may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion.
If a solid carrier is used for oral administration, the preparation may be tablet, e.g. placed in a hard gelatine capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier may vary but will usually be from about 25 mg to about 1 g.
If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents followed by compression of the mixture in a conventional tabletting machine. Examples of adjuvants or diluents comprise corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compati-ble with the active ingredients.
Treating Diseases
As established above, LRRK2 inhibitors may be used in the treatment of Parkinson's disease and particular mention is made of Parkinson's disease associated with mutations in LRRK2, such as Gly2019Ser. Moreover, LRRK2 inhibitors are also expected to be useful in the treatment of other diseases which are associated with LRRK2. LRRK2 has been identified as a core compo-nent in Lewy body formation and is thus expected to be useful in the treatment of synucleinopathies such as Lewy body dementia [Neuropathol. Appl. Neurobiol., 34, 272-283, 2008]. Expression of LRRK2 mRNA is highly enriched in brain, lungs, kidney, spleen, and blood suggesting that functional impact of increased LRRK2 activity is likely to be most relevant in pathogenic and pathologic conditions associated with those regions. Support for that notion can be found in studies showing an increased risk of non-skin cancer in LRRK2 Gly2019Ser mutation carriers and especially for renal and lung cancer [Mov. Disorder, 25, 2536-2541, 2010]. Over-expression of LRRK2 by chromosomal amplification has also been identified in papillary renal and thyroid car-cinomas. Also, genetic association of LRRK2 has been reported for diseases where aberrant responses of the immune system are involved. This is the case for inflammatory bowel diseases such as Crohn's disease and ulcerative colitis as well as for leprosy [Nat. Genet. 42, 1118-1125, 2010; Inflamm. Bowel Dis. 16, 557-558, 2010; N. Engl. J. Med. 361, 2609-2618, 2009; Inflamm. Bowel Dis].
Thus, in an embodiment is provided a compound, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition according to the invention for use in the treatment of a disease in the central nervous system, such as a synucleinopthy selected from Lewy body dementia, multiple system atrophy, and Parkinson's disease.
In an embodiment, the disease in the central nervous system is Parkinson's disease.
In an embodiment, the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying a G2019S mutation in LRRK2.
In an embodiment, the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying one or more genetic mutations, which result in the expression of the G2019S variant of the LRRK2 protein.
In an embodiment, the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying one or more genetic mutations, which result in the expression of one or more of the G2019S, 12020T, G2385R, A419V, R1441G, R1441H, R1441C, R1628P and Y1699C variants of the LRRK2 protein.
In an embodiment, the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying one or more genetic mutations, which result in the expression of one or more of the M1646T, S1647T, Y2189C, N1437H, M1646T and N2081D variants of the LRRK2 protein.
In an embodiment, the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients who do not carry one or more genetic mutations, which result in the expression of one or more of the N551K, R1398H and K1423K variants of the LRRK2 protein.
In an embodiment, the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying one or more LRRK2 genetic non-coding variants selected from rs76904798-T and Rs1491942-G.
In an embodiment, the Parkinson's disease is idiopathic Parkinson's disease.
In an embodiment, the Parkinson's disease is sporadic Parkinson's disease.
In an embodiment, the Parkinson's disease is in patients carrying a G2019S mutation in LRRK2.
In an embodiment, the Parkinson's disease is in patients carrying one or more genetic mutations, which result in the expression of the G2019S variant of the LRRK2 protein.
In an embodiment, the Parkinson's disease is in patients carrying one or more genetic mutations, which result in the expression of one or more of the G2019S, 12020T, G2385R, A419V, R1441G, R1441H, R1441C, R1628P and Y1699C variants of the LRRK2 protein.
In an embodiment, the Parkinson's disease is in patients carrying one or more genetic mutations, which result in the expression of one or more of the M1646T, S1647T, Y2189C, N1437H, M1646T and N2081D variants of the LRRK2 protein.
In an embodiment, the Parkinson's disease is in patients who does not carry one or more genetic mutations, which result in the expression of one or more of the N551K, R1398H and K1423K variants of the LRRK2 protein.
In an embodiment, the Parkinson's disease is in patients carrying one or more LRRK2 genetic non-coding variants selected from rs76904798-T and Rs1491942-G.
In an embodiment, the Parkinson's disease is in patients carrying one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G.
In an embodiment, the Parkinson's disease is in patients carrying one or more mutated forms of LRRK2 selected from G2019S, 12020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, and Y2189C.
In one embodiment, the compound of the present invention is administered in an amount from about 0.001 mg/kg body weight to about 100 mg/kg body weight per day. In particular, daily dosages may be in the range of 0.01 mg/kg body weight to about 50 mg/kg body weight per day. The exact dosages will depend upon the frequency and mode of administration, the sex, the age, the weight, and the general condition of the subject to be treated, the nature and the severity of the condition to be treated, any concomitant diseases to be treated, the desired effect of the treatment and other factors known to those skilled in the art.
A typical oral dosage for adults will be in the range of 1-1000 mg/day of a compound, or pharmaceutically acceptable salt thereof of the present invention, such as 1-500 mg/day.
The compounds, or pharmaceutically acceptable salt thereof of the present invention may be administered alone as a pure compound or in a pharmaceutical composition comprising the compound or a pharmaceutical salt thereof and one or more pharmaceutically acceptable carriers or excipients, in either single or multiple doses. The pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 22nd Edition, Pharmaceutical Press, 2012. In the present context, “excipient”, “carrier”, “diluent”, “adjuvant” and the like are used synonymously and are intended to mean the same.
All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference in their entirety and to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law), regardless of any separately provided incorporation of particular documents made elsewhere herein.
Monotherapy, and Adjunctive Treatment
The compounds of the invention may be administered as a monotherapy or as part of an adjunctive treatment regimen.
In an embodiment, the compounds of the invention may be administered as monotherapy in the treatment of a synucleinopathy, such as Lewy body dementia, multiple system atrophy or Parkinson's disease. Such monotherapy indicates that the compound of the invention is the only active ingredient administered to the patient to treat this specific disease, however such monotherapy does not exclude that the patient may be treated with other drugs to treat other conditions.
In a further embodiment, the compounds of the invention may be administered as part of an adjunctive treatment regimen targeting the synucleinopathy such as Lewy body dementia, multiple system atrophy or Parkinson's disease. Such adjunctive treatment indicates that the compound of the invention is administered adjunctive to an already existing treatment regimen targeting the synucleinopathy or the associated symptoms. Alternatively, the adjunctive treatment may also indicate that the compound of the invention is the first drug to be administered to treat the synucleinopathy and then subsequently another drug is added to the treatment regimen, which additional drug is also targeting the synucleinopathy or the associated symptoms.
In an embodiment, the compound of the invention is administered in combination with an additional compound for the combined treatment of a synucleinopathy such as Lewy body dementia, multiple system atrophy or Parkinson's disease.
In a specific embodiment, such additional compound may be selected from caspase inhibitors, calpain inhibitors, LRRK2 inhibitors, BACE1 inhibitors, antibodies against any form of Aβ peptides, inflammation inhibitors, LAG-3 antibodies, molecules inhibiting alphasynuclein aggregation, nicotine, caffeine, Monoamine oxidase B inhibitor, Levodopa/carbidopa, Dopamine agonists, COMT inhibitors, A2A antagonists, anti-alphasynuclein antibodies, Mitogen-activated protein kinase 14 inhibitors, USP30 inhibitors, Beta adrenoreceptor agonists, dopamine D1 PAMs, Toll-like receptor 2 antagonists, Carnitine palmitoyl transferase 1 inhibitors, Glutamate 5 receptor antagonists, Muscarinic M2 receptor antagonists, Muscarinic M3 receptor antagonists, Muscarinic M4 receptor antagonists, 5 Hydroxy tryptamine 1A receptor agonists, 5 Hydroxy tryptamine 4 receptor agonists, 5 Hydroxy tryptamine 3 receptor agonists, 5 Hydroxy tryptamine 2A receptor antagonists, Alpha 1a adrenoreceptor antagonists, Sigma 1 receptor agonists, Sigma 2 receptor antagonists, Dopamine D1 receptor agonists, Dopamine D2 receptor agonists, Dopamine D3 receptor agonists, Dopamine D5 receptor antagonists, dopamine reuptake inhibitors, DOPA decarboxylase inhibitors, Insulin-like growth factor 1 antagonists, Insulin-like growth factor 2 antagonists, Tyrosine kinase inhibitors, Ras inhibitors, Leucotriene D4 antagonists, Leucotriene receptor antagonists, PDE1 inhibitors, T-type calcium channel antagonists, Peroxiredoxin inhibitors, GLP-1R agonists, NMDA receptor blockers, Lipoxygenase inhibitors, and Peroxisome proliferator-activated receptor gamma agonists.
In a further embodiment the additional compound is selected from the list consisting of trihexyphenidyl, biperiden, metixene, procyclidine, profenamine, dexetimide, phenglutarimide, mazaticol, bornaprine, tropatepine, etanautine, orphenadrine, benzatropine, etybenzatropine, dopamine, levodopa, carbidopa, levodopa/carbidopa, melevodopa, etilevodopa, foslevodopa, amantadine, bromocriptine, pergolide, dihydroergocryptine mesylate, ropinirole, pramipexole, cabergoline, apomorphine, piribedil, rotigotine, selegiline, rasagiline, safinamide, tolcapone, entacapone, budipine, opicapone, istradefylline, pralnacasan, bapineuzemab, solanezumab, gantenerumab, crenezumab, aducanumab, glunozumab, prasinezumab, miglustat, eliglustat, ropinerole, neflamapimod, bosutinib, oxafuramine, nadolol, nilotinib, vodobatinib, clenbuterol, mevidalen, emeramide, tomaralimab, mitometin, dipraglurant, ezeprogind, blarcamesine, buntanetap, renzapride, tavapadon, pramiprexole, salbutamol, Infudopa, alirinetide, antraquinolol, a rasagiline prodrug, apomorphine, pramiprexole, radotinib, talineuren, montelukast, lenrispodun, pirepemat, suvecaltamide, sonlicromanol, L-Demethyl phencynonate hydrochloride, mesocarb, roluperidone, exenatide, befiradol, ketamine, pridopidine, utroloxestat, aplindore, finamine, phenlarmide, (R)-troloxamide quinone, cannibigerol, and kenterin.
Compounds Useful in Manufacturing of Compounds of the Invention
The compounds of the invention may be prepared by methods described in the experimental section, together with synthetic methods known in the art of organic chemistry, or modifications that are familiar to those of ordinary skill in the art.
In an aspect the invention provides compounds which are useful as intermediate compounds in a manufacturing process for compounds of the invention.
In an embodiment, such intermediate compounds are compounds of formula XVI, or a salt thereof, wherein:
Figure US11958865-20240416-C00085
    • X is CH, CR1 or N;
    • Y is CH, CR1 or N;
    • R1 is independently selected from the group consisting of a C1-C3 alkyl, a C1-C3 haloalkyl, and halogen;
    • R2 is selected from a C1-C3 alkyl or an isotopically labelled C1-C3 alkyl;
    • R3 is selected from the group consisting of a halogen, a cyano, and a C1-C3 haloalkyl;
    • R4 is selected from the group consisting of a C1-C3 alkyl, an isotopically labelled C1-C3 alkyl, a C1-C3 haloalkyl, a O—C1-C3 alkyl, an isotopically labelled O—C1-C3 alkyl, a O—C1-C3 haloalkyl, and a O—C3-C6 cycloalkyl;
    • n is 0, 1 or 2.
In another embodiment, such intermediate compounds are compounds of formula II, or a salt thereof, wherein:
Figure US11958865-20240416-C00086
    • R1 is independently selected from the group consisting of a C1-C3 alkyl, a C1-C3 haloalkyl, and halogen;
    • R2 is selected from a C1-C3 alkyl or an isotopically labelled C1-C3 alkyl;
    • R3 is selected from the group consisting of a halogen, a cyano, and a C1-C3 haloalkyl;
    • R4 is selected from the group consisting of a C1-C3 alkyl, an isotopically labelled C1-C3 alkyl, a C1-C3 haloalkyl, a O—C1-C3 alkyl, an isotopically labelled O—C1-C3 alkyl, a O—C1-C3 haloalkyl, and a O—C3-C6 cycloalkyl;
    • n is 0, 1 or 2.
In an embodiment X is CH or CR1 and Y is CH or CR1.
In an embodiment X is CH and Y is CH.
In an embodiment X is CR1 and Y is CR1.
In an embodiment X is CH and Y is CR1.
In an embodiment X is CR1 and Y is CH.
In an embodiment X is CH or CR1 and Y is N.
In an embodiment X is N and Y is CH or CR1.
In an embodiment X is N and Y is CR1.
In an embodiment X is N and Y is CH.
In an embodiment X is CH and Y is N.
In an embodiment X is CR1 and Y is N.
In an embodiment, R1 is a C1-C3 alkyl.
In an embodiment, R1 is —CH3.
In an embodiment, R1 is —CH2CH3.
In an embodiment, R1 is a halogen.
In an embodiment, R1 is fluoro.
In an embodiment, R2 is selected from the group consisting of —CH3, —CH2CH3, and —CD3.
In an embodiment, R2 is —CH3.
In an embodiment, R2 is —CH2CH3.
In an embodiment, R2 is —CD3.
In an embodiment, R3 is a halogen.
In an embodiment, R3 is chloro.
In an embodiment, R4 is selected from the group consisting of —CH3, —CH2CH3, —OCH3, —OCH2CH3, —CHF2, —CF3, —O—C3 cycloalkyl, O-cyclopropane, —OCH2F, —OCHF2, —OCF3, and —OCD3.
In an embodiment, R4 is —CH3.
In an embodiment, R4 is —CH2CH3.
In an embodiment, R4 is —OCH3.
In an embodiment, R4 is —OCH2CH3.
In an embodiment, R4 is —CHF2.
In an embodiment, R4 is —CF3.
In an embodiment, R4 is —CF2CH3.
In an embodiment, R4 is —O—C3 cycloalkyl.
In an embodiment, R4 is O-cyclopropane.
In an embodiment, R4 is —OCH2F.
In an embodiment, R4 is —OCHF2.
In an embodiment, R4 is —OCF3.
In an embodiment, R4 is —OCD3.
In an embodiment, n is 2.
In an embodiment, n is 1.
In an embodiment, n is 0.
In an embodiment, the invention provides a process for manufacturing a compound of the invention or a pharmaceutically acceptable salt thereof, which process comprises reducing an intermediate compound of type XVI with iron and ammonium chloride in a suitable solvent e.g. a mixture of ethanol and water.
In an embodiment, the invention provides a process for manufacturing a compound of the invention or a pharmaceutically acceptable salt thereof, which process comprises reducing an intermediate compound of type XVI with iron and ammonium chloride in a suitable solvent e.g. a mixture of ethanol and water followed by a cyclization step.
In an embodiment, the invention provides a process for manufacturing a compound of the invention or a pharmaceutically acceptable salt thereof, which process comprises reducing an intermediate of type II with iron and ammonium chloride in a suitable solvent e.g. a mixture of ethanol and water.
In an embodiment, the invention provides a process for manufacturing a compound of the invention or a pharmaceutically acceptable salt thereof, which process comprises reducing an intermediate of type II with iron and ammonium chloride in a suitable solvent e.g. a mixture of ethanol and water followed by a cyclization step.
Specific intermediate compounds of the invention are further examplified in the experimental section.
SPECIFIC EMBODIMENTS OF THE INVENTION
In the following specific embodiments of the invention are disclosed.
The first embodiment is denoted E1, the second embodiment is denoted E2 and so forth.
E1. A compound of formula I, or a pharmaceutically acceptable salt thereof, wherein:
Figure US11958865-20240416-C00087
    • R1 is independently selected from the group consisting of C1-C3 alkyl, a C1-C3 haloalkyl, and a halogen;
    • R2 is selected from a C1-C3 alkyl or an isotopically labelled C1-C3 alkyl;
    • R3 is selected from the group consisting of a halogen, a cyano, and a C1-C3 haloalkyl;
    • R4 is selected from the group consisting of a C1-C3 alkyl, a O—C1-C3 haloalkyl, a O—C1-C3 alkyl,
    • and a C1-C3 haloalkyl;
    • n is 0, 1 or 2.
E2. The compound of embodiment E1, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula Ia, wherein:
Figure US11958865-20240416-C00088
    • R1 is selected from the group consisting of a C1-C3 alkyl, a C1-C3 haloalkyl, and a halogen;
    • R2 is selected from a C1-C3 alkyl or an isotopically labelled C1-C3 alkyl;
    • R3 is halogen;
    • R4 is selected from the group consisting of a C1-C3 alkyl, a O—C1-C3 haloalkyl, a O—C1-C3 alkyl,
    • and a C1-C3 haloalkyl;
    • n is 0 or 1.
E3. The compound according to any one of embodiments E1-E2, or a pharmaceutically acceptable salt thereof, wherein R1 is a C1-C3 alkyl.
E4. The compound according to any one of embodiments E1-E3, or a pharmaceutically acceptable salt thereof, wherein R1 is —CH3.
E5. The compound according to any one of embodiments E1-E3, or a pharmaceutically acceptable salt thereof, wherein R1 is —CH2CH3.
E6. The compound according to any one of embodiments E1-E3, or a pharmaceutically acceptable salt thereof, wherein R1 is fluoro.
E7. The compound according to any one of embodiments E1-E6, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from the group consisting of —CH3, —CH2CH3, and —CD3.
E8. The compound according to any one of embodiments E1-E6, or a pharmaceutically acceptable salt thereof, wherein R2 is —CH3.
E9. The compound according to any one of embodiments E1-E6, or a pharmaceutically acceptable salt thereof, wherein R2 is —CH2CH3.
E10. The compound according to any one of embodiments E1-E6, or a pharmaceutically acceptable salt thereof, wherein R2 is —CD3.
E11. The compound according to any one of embodiments E1-E10, or a pharmaceutically acceptable salt thereof, wherein R3 is chloro.
E12. The compound according to any one of embodiments E1-E11, or a pharmaceutically acceptable salt thereof, wherein R4 is selected from the group consisting of —CH3, —CH2CH3, —OCH3, and —OCH2CH3.
E13. The compound according to any one of embodiments E1-E11, or a pharmaceutically acceptable salt thereof, wherein R4 is —CH3.
E14. The compound according to any one of embodiments E1-E11, or a pharmaceutically acceptable salt thereof, wherein R4 is —CH2CH3.
E15. The compound according to any one of embodiments E1-E11, or a pharmaceutically acceptable salt thereof, wherein R4 is —OCH3.
E16. The compound according to any one of embodiments E1-E11, or a pharmaceutically acceptable salt thereof, wherein R4 is —OCH2CH3.
E17. The compound according to any one of embodiments E1-E11, or a pharmaceutically acceptable salt thereof, wherein n is 1.
E18. The compound according to any one of embodiments E1-E11, or a pharmaceutically acceptable salt thereof, wherein n is 0.
E19. The compound according to embodiment E1, wherein the compound is selected from the list consisting of:
Figure US11958865-20240416-C00089
Figure US11958865-20240416-C00090
or a pharmaceutically acceptable salt thereof.
E20. The compound according to embodiment E1, wherein the compound is
Figure US11958865-20240416-C00091
or a pharmaceutically acceptable salt thereof.
E21. The compound according to embodiment E1, wherein the compound is
Figure US11958865-20240416-C00092
or a pharmaceutically acceptable salt thereof.
E22. The compound according to embodiment E1, wherein the compound is
Figure US11958865-20240416-C00093
or a pharmaceutically acceptable salt thereof.
E23. The compound according to embodiment E1, wherein the compound is
Figure US11958865-20240416-C00094
or a pharmaceutically acceptable salt thereof.
E24. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to any one of the previous embodiments E1 to E23 and one or more pharmaceutically acceptable carriers or diluents.
E25. The compound according to any one of embodiments E1 to E23, or a pharmaceutically acceptable salt thereof for use in therapy.
E26. The compound according to any one of embodiments E1 to E23, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or disorder in the central nervous system, such as a synucleinopathy selected from Lewy body dementia, multiple system atrophy, and Parkinson's disease.
E27. The compound according to embodiment E26, or a pharmaceutically acceptable salt thereof, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease, Parkinson's disease in patients carrying a G2019S mutation in LRRK2, or Parkinson's disease in patients carrying one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G.
E28. The compound according to embodiment E26, or a pharmaceutically acceptable salt thereof, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying one or more mutated forms of LRRK2 selected from G2019S, 12020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, and Y2189C.
E29. The compound according to embodiment E26, or a pharmaceutically acceptable salt thereof, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying a G2019S mutation in LRRK2.
E30. The compound according to embodiment E26, or a pharmaceutically acceptable salt thereof, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G.
E31. The compound according to any one of embodiments E1 to E23, or a pharmaceutically acceptable salt thereof, for use in a method for the treatment of a disease or disorder characterized by increased LRRK2 kinase activity or by expression of one or more mutated forms of LRRK2 selected from G2019S, 12020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, and Y2189C or a LRRK2 non-coding variant alone or in combination selected from rs76904798-T and Rs1491942-G.
E32. Use of a compound according to any one of embodiments E1 to E23, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or disorder in the central nervous system selected from Lewy body dementia, multiple system atrophy or Parkinson's disease.
E33. A method for the treatment of a disease or disorder in the central nervous system selected from Lewy body dementia, multiple system atrophy or Parkinson's disease comprising the administration of a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, according to any one of embodiments E1 to E23 to a patient in need thereof.
E34. The compound, use or method according to any of the preceding embodiments, wherein the patient to be treated carries one or more genetic mutations, which result in the expression of the G2019S variant of the LRRK2 protein.
E35. The compound, use or method according to any of the preceding embodiments, wherein the patient to be treated carries one or more genetic mutations, which result in the expression of one or more of the G2019S, 12020T, G2385R, A419V, R1441G, R1441H, R1441C, R1628P and Y1699C variants of the LRRK2 protein.
E36. The compound, use or method according to any of the preceding embodiments, wherein the patient to be treated carries one or more genetic mutations, which result in the expression of one or more of the M1646T, S1647T, Y2189C, N1437H, M1646T and N2081D variants of the LRRK2 protein.
E37. The compound, use or method according to any of the preceding embodiments, wherein the patient to be treated does not carry one or more genetic mutations, which result in the expression of one or more of the N551K, R1398H and K1423K variants of the LRRK2 protein.
E38. The compound, use or method according to any of the preceding embodiments, wherein the patient to be treated carries one or more LRRK2 genetic non-coding variants selected from rs76904798-T and Rs1491942-G.
In the following further specific embodiments of the invention are disclosed.
The first further embodiment is denoted EE1, the second embodiment is denoted EE2 and so forth.
EE1. A compound of formula IIa, or a pharmaceutically acceptable salt thereof, wherein:
Figure US11958865-20240416-C00095
    • X is CH, CR1 or N;
    • Y is CH, CR1 or N;
    • R1 is independently selected from the group consisting of a C1-C3 alkyl, a C1-C3 haloalkyl, and halogen;
    • R2 is selected from a C1-C3 alkyl or an isotopically labelled C1-C3 alkyl;
    • R3 is selected from the group consisting of a halogen, a cyano, and a C1-C3 haloalkyl;
    • R4 is selected from the group consisting of a C1-C3 alkyl, an isotopically labelled C1-C3 alkyl, a C1-C3 haloalkyl, a O—C1-C3 alkyl, an isotopically labelled O—C1-C3 alkyl, a O—C1-C3 haloalkyl,
    • and a O—C3-C6 cycloalkyl;
    • n is 0, 1 or 2.
EE2. A compound of formula I, or a pharmaceutically acceptable salt thereof, wherein:
Figure US11958865-20240416-C00096
    • R1 is independently selected from the group consisting of a C1-C3 alkyl, a C1-C3 haloalkyl, and a halogen;
    • R2 is selected from a C1-C3 alkyl or an isotopically labelled C1-C3 alkyl;
    • R3 is selected from the group consisting of a halogen, a cyano, and a C1-C3 haloalkyl;
    • R4 is selected from the group consisting of a C1-C3 alkyl, a O—C1-C3 haloalkyl, a O—C1-C3 alkyl,
    • and a C1-C3 haloalkyl;
      • n is 0, 1 or 2.
EE3. A compound of formula Ia, or a pharmaceutically acceptable salt thereof wherein:
Figure US11958865-20240416-C00097
    • R1 is selected from the group consisting of a C1-C3 alkyl, a C1-C3 haloalkyl, and a halogen;
    • R2 is selected from a C1-C3 alkyl or an isotopically labelled C1-C3 alkyl;
    • R3 is halogen;
    • R4 is selected from the group consisting of a C1-C3 alkyl, a O—C1-C3 haloalkyl, a O—C1-C3 alkyl,
    • and a C1-C3 haloalkyl;
    • n is 0 or 1.
EE4. The compound of embodiment EE1 or a pharmaceutically acceptable salt thereof, wherein X is CH or CR1 and Y is CH or CR1.
EE5. The compound of embodiment EE1 or a pharmaceutically acceptable salt thereof, wherein X is CH or CR1 and Y is N.
EE6. The compound of embodiment EE1 or a pharmaceutically acceptable salt thereof, wherein X is N and Y is CH or CR1.
EE7. The compound of any of embodiments EE1-EE6 or a pharmaceutically acceptable salt thereof, wherein R1 is a C1-C3 alkyl.
EE8. The compound of any of embodiments EE1-EE7 or a pharmaceutically acceptable salt thereof, wherein R1 is —CH3.
EE9. The compound of any of embodiments EE1-EE7 or a pharmaceutically acceptable salt thereof, wherein R1 is —CH2CH3.
EE10. The compound of any of embodiments EE1-EE6 or a pharmaceutically acceptable salt thereof, wherein R1 is a halogen.
EE11. The compound of any of embodiments EE1-EE6 or a pharmaceutically acceptable salt thereof, wherein R1 is fluoro.
EE12. The compound of any of embodiments EE1-EE11 or a pharmaceutically acceptable salt thereof, wherein R2 is selected from the group consisting of —CH3, —CH2CH3, and —CD3.
EE13. The compound of any of embodiments EE1-EE12 or a pharmaceutically acceptable salt thereof, wherein R2 is —CH3.
EE14. The compound of any of embodiments EE1-EE12 or a pharmaceutically acceptable salt thereof, wherein R2 is —CH2CH3.
EE15. The compound of any of embodiments EE1-EE12 or a pharmaceutically acceptable salt thereof, wherein R2 is —CD3.
EE16. The compound of any of embodiments EE1-EE15 or a pharmaceutically acceptable salt thereof, wherein R3 is a halogen.
EE17. The compound of any of embodiments EE1-EE15 or a pharmaceutically acceptable salt thereof, wherein R3 is chloro.
EE18. The compound of any of embodiments EE1-EE17 or a pharmaceutically acceptable salt thereof, wherein R4 is selected from the group consisting of —CH3, —CH2CH3, —OCH3, —OCH2CH3, —CHF2, —CF3, —CF2CH3, —O—C3 cycloalkyl, O-cyclopropane, —OCH2F, —OCHF2, —OCF3, and —OCD3.
EE19. The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R4 is —CH3.
EE20. The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R4 is —CH2CH3.
EE21. The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R4 is —OCH3.
EE22. The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R4 is —OCH2CH3.
EE23. The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R4 is —CHF2.
EE24. The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R4 is —CF3.
EE25. The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R4 is —CF2CH3.
EE26. The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R4 is —O—C3 cycloalkyl.
EE27. The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R4 is O-cyclopropane.
EE28. The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R4 is —OCH2F.
EE29. The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R4 is —OCHF2.
EE30. The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R4 is —OCF3.
EE31. The compound of any of embodiments EE1-EE18 or a pharmaceutically acceptable salt thereof, wherein R4 is —OCD3.
EE32. The compound of any of embodiments EE1-EE31 or a pharmaceutically acceptable salt thereof, wherein n is 2.
EE33. The compound of any of embodiments EE1-EE31 or a pharmaceutically acceptable salt thereof, wherein n is 1.
EE34. The compound of any of embodiments EE1-EE31 or a pharmaceutically acceptable salt thereof, wherein n is 0.
EE35. The compound of any of embodiments EE1-EE34 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the list consisting of:
Figure US11958865-20240416-C00098
Figure US11958865-20240416-C00099
Figure US11958865-20240416-C00100
Figure US11958865-20240416-C00101
Figure US11958865-20240416-C00102
Figure US11958865-20240416-C00103
or a pharmaceutically acceptable salt thereof.
EE36. The compound of any of embodiments EE1-EE34 or a pharmaceutically salt thereof, wherein the compound is selected from the list consisting of:
8-Chloro-2-(2-methoxypyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-ethoxypyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-3-methyl-2-(2-methyl pyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-ethylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-3-ethyl-2-(2-methoxypyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(5-fluoro-2-methoxypyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-methoxy-4-methylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-3-ethyl-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2,6-dimethylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(5-fluoro-2-methylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2,5-dimethylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-methoxy-5-methylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-methoxy-6-methylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-(1,1-difluoroethyl)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(5-fluoro-2,6-dimethylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-cyclopropoxypyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-3-methyl-2-(2-(trifluoromethyl)pyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-(fluoromethoxy)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-(difluoromethoxy)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-3-methyl-2-(2-(trifluoromethoxy)pyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(3-methoxypyridazin-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(4-methoxy-2-methylpyrimidin-5-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(5-fluoro-2-(methoxy-d3)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-(methoxy-d3)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2,6-dimethylpyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-3-(methyl-d3)-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2,5-dimethylpyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(2-methoxypyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine;
8-Chloro-2-(5-fluoro-2-methoxypyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; and
8-Chloro-2-(5-fluoro-2-methylpyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
EE37. The compound of embodiments EE1-EE36 or a pharmaceutically acceptable salt thereof for use in therapy.
EE38. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof of the previous embodiments EE1-EE36 and one or more pharmaceutically acceptable carriers or diluents.
EE39. The compound according to any one of embodiments EE1-EE36, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or disorder in the central nervous system selected from Lewy body dementia, multiple system atrophy, and Parkinson's disease.
EE40. The compound according to embodiment EE39, or a pharmaceutically acceptable salt thereof, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease, Parkinson's disease in patients carrying a G2019S mutation in LRRK2, or Parkinson's disease in patients carrying one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G.
EE41. The compound according to embodiment EE39, or a pharmaceutically acceptable salt thereof, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying one or more mutated forms of LRRK2 selected from G2019S, 12020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, and Y2189C.
EE42. The compound according to embodiment EE39, or a pharmaceutically acceptable salt thereof, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying a G2019S mutation in LRRK2.
EE43. The compound according to embodiment EE39, or a pharmaceutically acceptable salt thereof, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G.
EE44. The compound according to any one of embodiments EE1-EE36, or a pharmaceutically acceptable salt thereof, for use in a method for the treatment of a disease or disorder characterized by increased LRRK2 kinase activity or by expression of one or more mutated forms of LRRK2 selected from G2019S, 12020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, and Y2189C or a LRRK2 non-coding variant alone or in combination selected from rs76904798-T and Rs1491942-G.
EE45. Use of a compound according to any one of embodiments EE1-EE36, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or disorder in the central nervous system selected from Lewy body dementia, multiple system atrophy or Parkinson's disease.
EE46. Use of a compound according to any one of embodiments EE1-EE36, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of Parkinson's disease.
EE47. A method for the treatment of a disease or disorder in the central nervous system selected from Lewy body dementia, multiple system atrophy or Parkinson's disease comprising the administration of a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, according to any one of embodiments EE1-EE36 to a patient in need thereof.
EE47. The compound according to any one of embodiments EE1-EE36 or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or disorder characterized by increased LRRK2 kinase activity or by expression of one or more mutated forms of LRRK2 selected from G2019S, 12020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, and Y2189C or a LRRK2 non-coding variant alone or in combination selected from rs76904798-T and Rs1491942-G.
In the following additional specific embodiments of the invention are disclosed.
The first additional embodiment is denoted I1, the second embodiment is denoted I2 and so forth.
I1. A compound of formula I, or a pharmaceutically acceptable salt thereof, wherein:
Figure US11958865-20240416-C00104
    • R1 is independently selected from the group consisting of a C1-C3 alkyl, a C1-C3 haloalkyl, and a halogen;
    • R2 is selected from a C1-C3 alkyl or an isotopically labelled C1-C3 alkyl;
    • R3 is selected from the group consisting of a halogen, a cyano, and a C1-C3 haloalkyl;
    • R4 is selected from the group consisting of a C1-C3 alkyl, a O—C1-C3 haloalkyl, a O—C1-C3 alkyl,
    • and a C1-C3 haloalkyl;
    • n is 0, 1 or 2.
I2. The compound according to embodiment I1, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula Ia, wherein:
Figure US11958865-20240416-C00105
    • R1 is selected from the group consisting of a C1-C3 alkyl, a C1-C3 haloalkyl, and a halogen;
    • R2 is selected from a C1-C3 alkyl or an isotopically labelled C1-C3 alkyl;
    • R3 is a halogen;
    • R4 is selected from the group consisting of a C1-C3 alkyl, a O—C1-C3 haloalkyl, a O—C1-C3 alkyl,
    • and a C1-C3 haloalkyl;
      • n is 0 or 1.
I3. The compound according to any one of embodiments I1-I2, or a pharmaceutically acceptable salt thereof, wherein R1 is a C1-C3 alkyl.
I4. The compound according to any one of embodiments I1-I3, or a pharmaceutically acceptable salt thereof, wherein R1 is —CH3.
I5. The compound according to any one of embodiments I1-I4, or a pharmaceutically acceptable salt thereof, wherein R1 is fluoro.
I6. The compound according to any one of embodiments I1-I5, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from the group consisting of —CH3, —CH2CH3, and —CD3.
I7. The compound according to any one of embodiments I1-I6, or a pharmaceutically acceptable salt thereof, wherein R3 is chloro.
I8. The compound according to any one of embodiments I1-I7, or a pharmaceutically acceptable salt thereof, wherein R4 is selected from the group consisting of —CH3, —CH2CH3, —OCH3, and —OCH2CH3.
I9. The compound according to any one of embodiments I1-I8, or a pharmaceutically acceptable salt thereof, wherein n is 1.
I10. The compound according to any one of embodiments I1-I7, or a pharmaceutically acceptable salt thereof, wherein n is 0.
I11. The compound according to embodiment I1, wherein the compound is selected from the list consisting of:
Figure US11958865-20240416-C00106
Figure US11958865-20240416-C00107
or a pharmaceutically acceptable salt thereof.
I12. A pharmaceutical composition comprising a compound according to any one of the previous embodiments I1 to II11 and one or more pharmaceutically acceptable carriers.
I13. A compound, or a pharmaceutically acceptable salt thereof according to any one of embodiments I1 to II11 for use in therapy.
I14. A compound according to any one of embodiments I1 to I11, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease in the central nervous system, such as synucleinopathy selected from Lewy body dementia, multiple system atrophy, or Parkinson's disease.
I15. The compound according to embodiments I14, or a pharmaceutically acceptable salt thereof, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying a G2019S mutation in LRRK2.
I16. A compound according to any one of embodiments I1 to I11, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or disorder characterized by increased LRRK2 kinase activity or by expression of one or more mutated forms of LRRK2 selected from G2019S, 12020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, and Y2189C or a LRRK2 non-coding variant alone or in combination selected from rs76904798-T and Rs1491942-G.
I17. Use of a compound according to any one of embodiments I1 to I11, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or disorder in the central nervous system, such as synucleinopathy selected from Lewy body dementia, multiple system atrophy, or Parkinson's disease.
I18. The use according to embodiment I17 wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease or Parkinson's disease in patients carrying a G2019S mutation in LRRK2, or Parkinson's disease in patients carrying one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G.
I19. A method for the treatment of a disease or disorder in the central nervous system selected from Lewy body dementia, multiple system atrophy or Parkinson's disease comprising the administration of a therapeutically effective amount of the compound according to any one of embodiments I1 to I11, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
I20. The method according to embodiment I19 wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease, Parkinson's disease in patients carrying a G2019S mutation in LRRK2, or Parkinson's disease in patients carrying one or more LRRK2 non-coding variants alone selected from rs76904798-T and Rs1491942-G.
Experimental Section
Preparation of the Compounds of the Invention
Figure US11958865-20240416-C00108
The compounds of formula I, formula IIa or formula Ia may be prepared by methods described below, together with synthetic methods known in the art of organic chemistry, or modifications that are familiar to those of ordinary skill in the art. For example, the methods describe the use of selective protecting groups during the synthesis of the compounds of the invention. One skilled in the art would be able to select the appropriate protecting group for a particular reaction. Methods for protection and deprotection of such groups are well known in the art and may be found in Watts and Green et al., Protective Groups in Organic Synthesis, 2006, 4th Edition, Wiley Interscience, New York. The starting materials used herein are available commercially or may be prepared by routine methods known in the art, such as those method described in standard reference books such as “Compendium of Organic Synthetic Methods, Vol. I-XII” (published by Wiley Interscience). Preferred methods include, but are not limited to, those described below. The schemes are representative of methods useful in synthesizing the compounds of the present invention. They are not to constrain the scope of the invention in any way.
Figure US11958865-20240416-C00109
In brief, compounds of formula I can be prepared according to scheme 1. The compounds of formula I can for example be prepared through a one pot reduction-cyclization procedure by reducing an intermediate of type II with iron and ammonium chloride in a suitable solvent e.g. a mixture of ethanol and water followed by cyclization as described for Example 2.
Figure US11958865-20240416-C00110
A nitropyrazole intermediate of type II can be prepared according to scheme 2 starting from an alcohol such as IV. An intermediate of type IV can be reacted with a pyrazolopyrimidine such as III under Mitsunobu-type conditions employing for example diisopropyl azodicarboxylate and triphenylphosphine in a solvent such as tetrahydrofuran to afford an intermediate of type II. Intermediates of type V (wherein Pg1 is for example TBS) can be converted into an alchohol intermediate of type IV using for example a fluoride source such as tetrabutylammonium fluoride in an appropriate solvent for example tetrahydrofuran. A pyrazole intermediate of type V can be prepared through the coupling of an intermediate of type VII with a pyridine intermediate of type VI (wherein M is for example B(OH)2. The coupling is exemplified by a Chan-Lam type coupling. The reaction can be performed by reacting an intermediate of type VII with a boronic acid intermediate VI in which M═B(OH)2 in the presence of a copper salt such as copper(II) acetate, a base for example pyridine, a drying agent such as 4 Å molecular sieves under an oxygen atmosphere and a suitable solvent such as 1,2-dichloroethane.
The general synthetic sequence in scheme 2 is for example described in the synthesis of intermediate 3,6-dichloro-1-(3-((5-methyl-1-(2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine.
Figure US11958865-20240416-C00111
An intermediate of type VII (wherein Pg1 is for example TBS) can be prepared according to scheme 3. Intermediates of type VII (wherein Pg1 is for example TBS) can be prepared from an alcohol intermediate of type VIII using for example tert-butyldimethylsilyl chloride in the presence of a base such as imidazole and a catalyst such as 4-dimethylaminopyridine in an appropriate solvent such as dichloromethane. An alcohol intermediate such as VIII can be prepared from a nitropyazole such as IX (wherein Pg2 is for example, 2-tetrahydropyranyl) by treatment with an acid such as aqueous hydrochloric acid in a suitable solvent for example methanol.
Alcohol intermediates of type IX can be prepared by reacting a chloro intermediate XI with propane-1,3-diol X in the presence of a base for example cesium fluoride in a solvent such as N,N-dimethylacetamide.
Chloro intermediates such as XI (wherein Pg2 is for example, 2-tetrahydropyranyl) can be prepared from a nitropyrazole intermediate XII (wherein Pg2 is for example, 2-tetrahydropyranyl) using a strong base for example lithium bis(trimethylsilyl)amide, and an electrophile for example hexachloroethane in a suitable solvent such as tetrahydrofuran.
A nitropyrazole intermediate of type XII (wherein Pg2 is for example, 2-tetrahydropyranyl) can be prepared from a pyrazole such as XIII employing 3,4-dihydro-2H-pyran in the presence of an acid for example para-toluenesulfonic acid monohydrate in an appropriate solvent for example tetrahydrofuran.
The general synthetic sequence in scheme 3 is for example described in the synthesis of intermediate 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole.
Figure US11958865-20240416-C00112
Alternatively, compounds of formula I can be prepared from a compound of formula XIV according to scheme 4. The compounds of formula I can be prepared by employing e.g. a copper-mediated coupling between an intermediate of type XIV and an intermediate of type VI (wherein M is for example B(OH)2). The coupling is exemplified by but not limited to a Chan-Lam type coupling. The reaction can be performed by reacting an intermediate of type XIV with a boronic acid intermediate VI in which M═B(OH)2 in the presence of a copper salt such as copper(II) acetate, a base for example pyridine, a drying agent such as 4 Å molecular sieves under an oxygen atmosphere and a suitable solvent such as 1,2-dichloroethane as described for Example 1.
Figure US11958865-20240416-C00113
An intermediate such as XIV can be prepared according to scheme 5. The intermediates of type XIV can for example be prepared through a one pot procedure by reducing an intermediate of type XV (wherein Pg2 is for example, 2-tetrahydropyranyl) with iron and ammonium chloride in a suitable solvent e.g. a mixture of ethanol and water.
Nitropyrazole intermediates like XV can be prepared by reaction a pyrazolopyrimidine like III with an alcohol such as IX (wherein Pg2 is for example, 2-tetrahydropyranyl) employing Mitsunobu-like reaction conditions for example diisopropyl azodicarboxylate and triphenylphosphine in a solvent such as tetrahydrofuran.
The general synthetic sequence in scheme 5 is for example described in the synthesis of intermediate 8-chloro-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine.
Figure US11958865-20240416-C00114
Compounds of formula IIa can be prepared according to scheme 6. The compounds of formula IIa can for example be prepared through a one pot reduction-cyclization procedure by reducing an intermediate of type XVI with iron and ammonium chloride in a suitable solvent e.g. a mixture of ethanol and water followed by cyclization as described for in Example 21.
Figure US11958865-20240416-C00115
A nitropyrazole intermediate of type XVI can be prepared through a 3-step sequence according to scheme 7 starting from a nitropyrazole such as VII.
A pyrazole intermediate of type XVIII (wherein Pg1 is for example TBS) can be prepared through the coupling of an intermediate of type VII (wherein Pg1 is for example TBS) with an intermediate of type XIX (wherein M is for example B(OH)2. The coupling is exemplified by a Chan-Lam type coupling. The reaction can be performed by reacting an intermediate of type VII (wherein Pg1 is for example TBS) with a boronic acid intermediate XIX in which M═B(OH)2 in the presence of a copper salt such as copper(II) triflate, a base for example N,N,N′,N′-tetramethylethylenediamine under an oxygen atmosphere and a suitable solvent such as acetonitrile and dichloromethane. Alternatively, a pyrazole intermediate of type VII can be reacted with an intermediate of type XX (wherein Hal is e.g., CI) to afford an intermediate such as XVIII in the presence of a base e.g., potassium carbonate and an appropriate solvent like acetonitrile.
Intermediates of type XVIII (wherein Pg1 is for example TBS) can be converted into an alchohol intermediate of type XVII using for example a fluoride source such as tetrabutylammonium fluoride an appropriate solvent for example tetrahydrofuran.
An alcohol of intermediate such as XVII can be reacted with a pyrazolopyrimidine such as III under Mitsunobu-type conditions employing for example diisopropyl azodicarboxylate and triphenylphosphine in a solvent such as tetrahydrofuran to afford an intermediate of type XVI.
The general synthetic sequence in scheme 7 is for example described in the synthesis of the intermediates 3,6-dichloro-1-(3-((1-(3-methoxypyridazin-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine and 3,6-dichloro-1-(3-((1-(4-methoxy-2-methylpyrimidin-5-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine.
Figure US11958865-20240416-C00116
Alternatively, compounds of formula IIa can be prepared according to scheme 7 through a 4-step sequence starting from a nitropyrazole intermediate of type XXV.
Nitropyrazole intermediates such as XXIV can for example be synthesized through reaction of a pyrazolopyrimidine such as IV and an alcohol like XXV employing Mitsunobu-like reaction conditions. The Mitsunobu-like coupling can for example be conducted using e.g., triphenylphosphine and diisopropyl azodicarboxylate in a suitable solvent like tetrahydrofuran.
Intermediates of type XXIII can be synthesized from a nitropyrazole intermediate such as XXIV employing a one-pot reduction and cyclization procedure. The reduction and subsequent cyclization can be performed using for example iron in the presence of ammonium chloride in a suitable solvent such as a mixture of ethanol and water.
A bromo intermediate such as XXI can be prepared from a pyrazole like XXIII using a brominating agent for example 2,4,4,6-tetrabromocyclohexa-2,5-dien-1-one in a suitable solvent such as tetrahydrofuran.
A bromo intermediate of type XXI can be reacted with an organometallic species such as XXII (wherein M is for example Bpin, B(OH)2, Sn(n-Bu)3 or SnMe3, Zn, ZnBr or ZnCI). The coupling is exemplified by but not limited to a Negishi-type cross-coupling. The reaction can be performed by reacting an intermediate of type XXI with an organozinc species such as (CD3)2Zn in the presence of a catalyst like bis[tris(tert-butyl)phosphine]palladium, a base such as lithium bis(trimethylsilyl)amide in an appropriate solvent such as tetrahydrofuran to provide a compounds of formula IIa (wherein R2═CD3) as described for Example 25.
Figure US11958865-20240416-C00117
A method to prepare an intermediate of type XXV is depicted in scheme 9. A nitropyrazole intermediate of type XXXI (wherein Pg3 is for example, 2-tetrahydropyranyl) can be prepared from a pyrazole of type XXXII using e.g., 3,4-dihydro-2H-pyran in the presence of an acid for example para-toluenesulfonic acid monohydrate in an appropriate solvent such as tetrahydrofuran.
Chloro intermediates such as XXX (wherein Pg3 is for example, 2-tetrahydropyranyl) can be prepared from a nitropyrazole intermediate XXXI (wherein Pg3 is for example, 2-tetrahydropyranyl) using a strong base for example lithium bis(trimethylsilyl)amide, and an electrophile for example hexachloroethane in a suitable solvent such as tetrahydrofuran.
Alcohol intermediates of type XXIX (wherein Pg3 is for example, 2-tetrahydropyranyl) can be prepared by reacting a chloro intermediate XXX with a diol of type X in the presence of a base for example cesium fluoride in a solvent such as N,N-dimethylacetamide.
An intermediate of type XXIX (wherein Pg3 is for example, 2-tetrahydropyranyl) can be converted into a pyrazole such as XXVIII by treatment with an acid such as aqueous hydrochloric acid in a suitable solvent for example methanol.
Intermediates of type XXVII (wherein Pg2 is e.g., TBS) can be synthesized from an alcohol such as XXVIII using for example tert-butyldimethylsilyl chloride in the presence of a base such as imidazole and a catalyst such as 4-dimethylaminopyridine in an appropriate solvent such as dichloromethane.
Nitropyrazole intermediates of type XXVI (wherein Pg3 is e.g., TBS) can synthesized from pyrazole intermediates such as XXVII and an intermediate of type XIX (wherein M is for example B(OH)2). The coupling is exemplified by a Chan-Lam type coupling. The reaction can be performed by reacting an intermediate of type XXVII (wherein Pg2 is for example TBS) with a boronic acid intermediate XIX in which M═B(OH)2 in the presence of a copper salt such as copper(II) acetate, a base for example pyridine, and a drying agent such as 4 Å molecular sieves under an oxygen atmosphere in a suitable solvent such 1,2-dichloroethane.
Finally, alcohol intermediates of type XXV can be prepared from a nitro pyrazole intermediate of type XXVI (wherein Pg2 is e.g., TBS) using tetra-n-butyl ammonium fluoride in a suitable solvent such as tetrahydrofuran. The synthetic schemes 8 and 9 is for example detailed in the synthesis of 3-bromo-8-chloro-2-(2,6-dimethylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine.
Abbreviations
Abbreviations used in the experimental may include, but are not limited to the following:
Boc: tert-butyloxycarbonyl; Bpin: pinacol boronate; BRIJ-35: polyoxyethylene (23) lauryl ether; C: Celsius; CPME: cyclopentyl methyl ether; c-Pr: cyclopropyl; DBAD: di-tert-butyl azodicarboxylate; DCM: dichloromethane; DIAD: diisopropyl azodicarboxylate; DIPEA: N,N-diisopropylethylamine; DMA: N,N-dimethylacetamide; DMF: N,N-dimethylformamide; DMSO: dimethylsulfoxide; DTBPF: 1,1-bis(di-tert-butylphosphino)ferrocene; DTT: dithiothreitol; EGTA: ethylene glycol-bis(β-aminoethyl ether)-N,N,N,N′-tetraacetic acid; Et: ethyl; EtOAc: ethyl acetate; g: gram; h: hour(s); HMDS: hexamethyldisilazane; L: liter; LDA: lithium diisopropylamide; M: molar; Me: methyl; mg: milligram; mL: milliliter; mmol: millimole; Ms: methanesulfonyl; n-Bu: n-butyl; NFSI: N-fluorobenzenesulfonimide; NMR: nuclear magnetic resonance; Ph: phenyl; Pin: pinacol; PG: protecting group; SFC: supercritical fluid chromatography; TBS: tert-butyl(dimethyl)silyl; TBAF. Tetra-n-butylammonium fluoride; TEA: triethylamine; THF: tetrahydrofuran; THP: tetrahydropyran; TMEDA: N,N,N′,N′-tetramethylethylenediamine; TMS: trimethylsilyl; Tris: trisaminomethane; Ts: toluenesulfonyl.
Chemical Names
The chemical names for the Examples of the invention were generated using ChemDraw, version 20.0.0.41 by PerkinElmer Informatics, Inc.
Analytical Methods
LC-MS Methods
Method A: LC-MS were run on Agilent Prime-6125B UPLC-MS consisting of Agilent Prime including column manager, binary solvent manager, sample organizer, PDA detector (operating at 254 nm), ELS detector, and 6125B equipped with APPI-source operating in positive ion mode.
LC-conditions: The column was Agilent Poroshell 120 EC-C18 1.9 μm; 3.0×30 mm operating at 50° C. with 1.5 mL/min of a binary gradient consisting of water+0.037% trifluoroacetic acid (A) and acetonitrile+0.018% trifluoroacetic acid(B). The retention times (tR) are expressed in minutes based on UV-trace at 254 nm.
    • Gradient: 0.00 min 5% B
      • 1.20 min 80% B
      • 2.5 min 95% B
      • 2.51 min 5% B
      • 3.00 min 5% B
    • Total run time: 3.0 min
Method B: LC-MS were run on Agilent LC1200-MS6150 UPLC-MS consisting of Agilent LC1200 including column manager, binary solvent manager, sample organizer, PDA detector (operating at 220&254 nm), ELS detector, and MS6150 equipped with APPI-source operating in positive ion mode. LC-conditions: The column was MERCK, RP-18 e 25×3.0 mm operating at 50° C. with 1.5 mL/min of a binary gradient consisting of water+0.037% trifluoroacetic acid (A) and acetonitrile+0.018% trifluoroacetic acid(B). The retention times (tR) are expressed in minutes based on UV-trace at 220&254 nm.
    • Gradient: 0.00 min 5% B
      • 0.7 min 95% B
      • 1.1 min 95% B
      • 1.11 min 5% B
      • 1.5 min 5% B
    • Total run time: 1.5 min
Method C: LC-MS were run on Agilent LC1200-MS6110 UPLC-MS consisting of Agilent LC1200 including column manager, binary solvent manager, sample organizer, PDA detector (operating at 220&254 nm), ELS detector, and MS6110 equipped with APPI-source operating in positive ion mode. LC-conditions: The column was Xbridge Shield, RP-18 e 50×2.1 mm operating at 30° C. with 1 mL/min of a binary gradient consisting of water(4 L)+NH3—H2O(0.8 mL) (A) and acetonitrile (B). The retention times (tR) are expressed in minutes based on UV-trace at 220&254 nm.
    • Gradient: 0.00 min 10% B
      • 2 min 80% B
      • 2.48 min 80% B
      • 2.5 min 10% B
      • 3 min 10% B
    • Total run time: 3 min
Method D:LC-MS were run on Waters Aquity UPLC-MS consisting of Waters Aquity including column manager, binary solvent manager, sample organizer, PDA detector (operating at 254 nm), ELS detector, and TQD-MS equipped with ESI-source operating in positive ion mode. LC-conditions: The column was Acquity UPLC BEH C18 1.7 μm; 2.1×50 mm operating at 60° C. with 1.2 ml/min of a binary gradient consisting of water+0.05% trifluoroacetic acid (A) and acetonitrile+5% water+0.03% trifluoroacetic acid. The retention times (tR) are expressed in minutes based on UV-trace at 254 nm.
    • Gradient: 0.00 min 10% B
      • 1.00 min 100% B
      • 1.01 min 10% B
      • 1.15 min 10% B
    • Total run time: 1.15 min
Method E:LC-MS were run on Waters Aquity UPLC-MS consisting of Waters Aquity including column manager, binary solvent manager, sample organizer, PDA detector (operating at 254 nm), ELS detector, and TQD-MS equipped with ESI-source operating in positive ion mode. LC-conditions: The column was Acquity UPLC HSS T3 1.8 μm; 2.1×50 mm operating at 60° C. with 1.2 ml/min of a binary gradient consisting of water+0.05% trifluoroacetic acid (A) and acetonitrile+5% water+0.035% trifluoroacetic acid. The retention times (tR) are expressed in minutes based on UV-trace at 254 nm.
    • Gradient: 0.00 min 2% B
      • 1.00 min 100% B
      • 1.01 min 2% B
      • 1.15 min 2% B
    • Total run time: 1.15 min
Method F: LC-MS were run on Agilent Prime-6125B UPLC-MS consisting of Agilent Prime including column manager, binary solvent manager, sample organizer, PDA detector (operating at 254 nm), ELS detector, and MS6125B equipped with APPI-source operating in positive ion mode. LC-conditions: The column was Agilent Poroshell 120 HPH-C18 1.9 μm 3.0×30 mm operating at 30° C. with 1.5 mL/min of a binary gradient consisting of water+0.05% NH3—H2O (A) and acetonitrile (B). The retention times (tR) are expressed in minutes based on UV-trace at 254 nm.
    • Gradient: 0.00 min 5% B
      • 1.2 min 80% B
      • 2.5 min 95% B
      • 2.51 min 5% B
      • 3.0 min 5% B
    • Total run time: 3.0 min
      NMR
1H NMR spectra were recorded at 600 MHz on a Bruker 600-Avance-III spectrometer, at 400 MHz on Bruker Avance AV-III-400 or Varian MR400 spectrometers. Chemical shift values are expressed in ppm-values relative to tetramethylsilane. The following abbreviations or their combinations are used for multiplicity of NMR signals: br=broad, d=doublet, m=multiplet, q=quartet, quint=quintet, s=singlet and t=triplet.
Preparation of Reagents
Reagent: Bis(methyl-d3)zinc in THF-dibutyl ether-Toluene

CD3I→Mg→CD3MgI→ZnBr2→Zn(CD3)2
To a mixture of magnesium turnings (3.51 g, 145 mmol) and di-(n-butyl) ether (39.0 mL) was added DIBAL-H in toluene (1.00 mL, 1.00 molar, 1.00 mmol) at room temperature. The mixture was stirred for 15 min then iodomethane-d3 (0.62 mL, 10 mmol) was added. The mixture was then heated to 40° C. and stirred for 15 minutes. Then additional iodomethane-d3 (5.6 mL, 90 mmol) was added dropwise over a period of 30 minutes. The mixture was further stirred at 40° C. for 1.5 h. The mixture was cooled, and an aliquot was subjected to iodometric titration (I2 in 2-MeTHF; slow addition of Grignard reagent) to determine the concentration=1.38 M.
To dried zinc(II) bromide (2.20 g, 9.77 mmol) under N2 was added THF (4.40 mL). This was stirred for 10 min. Then di-(n-butyl) ether (4.40 mL) was slowly added to form a white suspension. Then CD3MgI (1.38 M in n-Bu2O) (14.2 mL, 1.38 M, 19.6 mmol) was added slowly over a period of 5 minutes at ˜5° C. (ice-water cooling) to form a white suspension. The mixture was stirred for 30 minutes at room temperature. Then toluene (5.52 mL) was added, and the suspension was stirred for 15 min. The mixture was filtered under an inert atmosphere, and the filtrate was used in the subsequent reaction. Iodometric titration (I2 in 2-MeTHF) to determine the concentration=0.71 M.
Reagent: (Methyl-d3)boronic acid
Figure US11958865-20240416-C00118
To a solution of trimethyl borate (3.68 g, 35.4 mmol) in THF (40 mL) was added iodo(trideuteriomethyl)magnesium (20 mL, 20 mmol, 1 M in diethyl ether) in a dropwise manner at −65° C. and the reaction was stirred at −65° C. for 2 hours. The reaction mixture was quenched with 1M aqueous HCl (10 mL) and the mixture was allowed to warm to 15° C. The mixture was diluted with brine (30 mL) and extracted with Et2O (150 mL). The organic layer was washed with brine (30 mL×3), dried over Na2SO4, and concentrated under reduced pressure to afford (methyl-d3)boronic acid (2.6 g, purity ˜40 w % containing THF) of sufficient purity for the subsequent step.
Alternatively, (Methyl-d3)boronic acid can be prepared in the following manner:
To a solution of trimethyl borate (6 g, 58 mmol) in THF (60 mL) was added (methyl-d3)magnesium iodide (16.2 mL, 32 mmol, 2 M in n-Bu2O) in a dropwise manner at −65° C. The mixture was stirred at −65° C. for 2 h. The mixture was quenched with 1M aqueous HCl (17 mL) and allowed to warm to 15° C. The mixture was diluted with brine (30 mL) and extracted with Et2O (60 mL×7). The combined organic layers were washed with brine (30 mL×2) and dried over Na2SO4 and concentrated under reduced pressure to give (methyl-d3)boronic acid (9.8 g, purity ˜15 w % containing THF and n-Bu2O).
Preparation of Intermediates
Intermediate: 3,6-Dichloro-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00119
Three reactions were run in parallel: To a solution of 6-chloro-1H-pyrazolo[3,4-d]pyrimidine (8 g, 51.8 mmol) in MeCN (240 mL) was added 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione (7.14 g, 36.23 mmol). The mixture was stirred at 85° C. for 24 h. The reaction mixture was concentrated under reduced pressure. The residues from the three reactions were combined and purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→80:20) to afford 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (4.3 g) of sufficient purity for the subsequent step. 1H NMR (DMSO-d6, 400 MHz) δ 14.55 (br s, 1H), 9.29 (s, 1H).
Intermediate: 5-(3-((tert-Butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole
Figure US11958865-20240416-C00120
To a solution of 3-methyl-4-nitro-1H-pyrazole (12 g, 94.4 mmol) in THF (140 mL) was added TsOH-H2O (898 mg, 4.7 mmol) and stirred at 20° C. for 30 minutes. 3,4-Dihydro-2H-pyran (10.2 g, 121 mmol) was added at 0° C. The mixture was stirred at 20° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→80:20) to afford 3-methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (12 g) of sufficient purity for the subsequent step.
To a solution of 3-methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (12 g, 56.8 mmol) in THF (100 mL) was added LiHMDS (1 M in THF, 62.5 mL) at −65° C. and stirred at −65° C. for 30 minutes. Perchloroethane (14.80 g, 62.49 mmol) dissolved in THF (50 mL) was added and the mixture was stirred at −65° C. for 60 minutes and then allowed to warm to 20° C. for 10 minutes. The mixture was quenched with saturated aqueous NH4Cl (200 mL) at 0° C. and then allowed to warm to 20° C. for 20 minutes and extracted with EtOAc (150 mL×3). The combined organic layers were washed with brine (80 mL) and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→90:10) to afford 5-chloro-3-methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (7.9 g) of sufficient purity for the subsequent step.
To a solution of 5-chloro-3-methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (19 g, 77.3 mmol) in DMA (150 mL) was added CsF (41.1 g, 271 mmol) and propane-1,3-diol (29.43 g, 386.7 mmol). The mixture was stirred at 50° C. for 16 h. The mixture was diluted with water (200 mL) and extracted with EtOAc (100 mL×3). The combined organic layers were washed with brine (100 mL×3). The organic layers were concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→69:31) to afford 3-((3-methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)oxy)propan-1-ol (13.7 g) of sufficient purity for the subsequent step.
To a solution of 3-((3-methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)oxy)propan-1-ol (4 g, 14 mmol) in MeOH (20 mL) was added HCl (12 M, 14.0 mL). The mixture was stirred at 20° C. for 16 h and then heated to 60° C. for 2 h. The mixture was concentrated and pH adjusted to 10 with 4M aqueous NaOH. The resulting mixture were concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→20:80) to afford 3-((3-methyl-4-nitro-1H-pyrazol-5-yl)oxy)propan-1-ol (2.7 g) of sufficient purity for the subsequent step. 1H NMR (DMSO-d6, 400 MHz) δ 12.94 (br s, 1H), 4.55 (t, J=4.8 Hz, 1H), 4.28 (t, J=6.4 Hz, 2H), 3.60-3.49 (m, 2H), 2.47 (s, 3H), 1.92-1.82 (m, 2H).
To a solution of 3-((3-methyl-4-nitro-1H-pyrazol-5-yl)oxy)propan-1-ol (2.7 g, 13 mmol) in DCM (30 mL) was added imidazole (1.46 g, 21.5 mmol), TBSCI (4.05 g, 26.8 mmol), and DMAP (820 mg, 6.71 mmol). The mixture was stirred at 20° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→79:21) to afford 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (3.7 g) of sufficient purity for the subsequent step. 1H NMR (CD3OD, 400 MHz) δ 4.40 (t, J=6.4 Hz, 2H), 3.84 (t, J=6.0 Hz, 2H), 2.61 (s, 3H), 2.03 (t, J=6.0 Hz, 2H), 0.89 (s, 9H), 0.05 (s, 6H).
Intermediate: 5-(3-((tert-Butyldimethylsilyl)oxy)propoxy)-3-ethyl-4-nitro-1H-pyrazole
Figure US11958865-20240416-C00121
To a solution of 3-ethyl-4-nitro-1H-pyrazole (12.5 g, 88.6 mmol) in THF (150 mL) was added TsOH-H2O (843 mg, 4.43 mmol). The mixture was stirred at 25° C. for 15 minutes. 3,4-Dihydro-2H-pyran (9.54 g, 113 mmol) was added while stirring at 0° C. The mixture was stirred at 25° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→90:10) to afford 3-ethyl-4-nitro-1-tetrahydropyran-2-yl-pyrazole (19 g) of sufficient purity for the subsequent step. 1H NMR (CDCl3, 400M Hz) 68.33 (s, 1H), 5.34-5.30 (m, 1H), 4.13-4.06 (m, 1H), 3.76-3.66 (m, 1H), 2.98 (q, J=7.6 Hz, 2H), 2.19-2.09 (m, 1H), 2.02-1.96 (m, 1H), 1.77-1.63 (m, 4H), 1.28 (t, J=7.6 Hz, 3H).
To a solution of 3-ethyl-4-nitro-1-tetrahydropyran-2-yl-pyrazole (19 g, 84 mmol) in THF (80 mL) was added LiHMDS (1 M in THF, 92.8 mL) at −65° C. and the reaction was stirred at −65° C. for 30 minutes. 1,1,1,2,2,2-hexachloroethane (22 g, 93 mmol) dissolved in THF (60 mL) was added and the mixture was stirred at −65° C. for 2 h and then allowed to warm to 20° C. for 10 minutes. The mixture was quenched with saturated aqueous NH4Cl solution (200 mL) at 0° C. and then allowed to warm to 20° C. for 20 min and extracted with EtOAc (200 mL×3). The combined organic layers were washed with brine (80 mL×3) and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→95:5) to afford 5-chloro-3-ethyl-4-nitro-1-tetrahydropyran-2-yl-pyrazole (17 g) of sufficient purity for the subsequent step. 1H NMR (CDCl3, 400 MHz) δ 5.52 (dd, J=2.8, 10.0 Hz, 1H), 4.13-4.03 (m, 1H), 3.76-3.64 (m, 1H), 2.98(q, J=7.2 Hz, 2H), 2.51-2.36 (m, 1H), 2.22-2.10 (m, 1H), 1.95-1.85 (m, 1H), 1.81-1.60 (m, 3H), 1.29 (t, J=7.2 Hz, 3H).
To a solution of 5-chloro-3-ethyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (12 g, 46.2 mmol) and propane-1,3-diol (17.6 g, 231 mmol) in DMA (150 mL) was added CsF (21.1 g, 139 mmol). The mixture was stirred at 50° C. for 16 h. The mixture was diluted with water (200 mL) and extracted with EtOAc (150 mL×4). The combined organic layers were washed with brine (100 mL×4) and then concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→60:40) to afford 3-((3-ethyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)oxy)propan-1-ol (14 g) of sufficient purity for the subsequent step.
To a solution of 3-((3-ethyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)oxy)propan-1-ol (14 g, 47 mmol) in MeOH (140 mL) was added concentrated aqueous HCl (24 mL). The mixture was stirred at 60° C. for 3 h. To the mixture was added NaOH and pH adjusted to 8 while stirring at 0° C. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→10:90) to afford 3-((3-ethyl-4-nitro-1H-pyrazol-5-yl)oxy)propan-1-ol (8.5 g) of sufficient purity for the subsequent step. 1H NMR (DMSO-d6, 400 MHz) δ 12.95 (br s, 1H), 4.54 (br, 1H), 4.29 (t, J=6.8 Hz, 2H), 3.54 (t, J=6.0 Hz, 2H), 2.89 (q, J=7.6 Hz, 2H), 1.92-1.83 (m, 2H), 1.20 (t, J=7.6 Hz, 3H).
To a solution of 3-((3-ethyl-4-nitro-1H-pyrazol-5-yl)oxy)propan-1-ol (8.5 g, 40 mmol) in DCM (70 mL) was added DMAP (1.45 g, 11.9 mmol), imidazole (4.30 g, 63.2 mmol), and TBSCI (11.9 g, 80.0 mmol). The mixture was stirred at 25° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→70:30) to afford 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-ethyl-4-nitro-1H-pyrazole (8.5 g) of sufficient purity for the subsequent step. 1H NMR (CDCl3, 400 MHz) δ 4.40 (t, J=6.4 Hz, 2H), 3.83 (t, J=6.0 Hz, 2H), 3.04 (q, J=7.6 Hz, 2H), 2.09-1.99 (m, 2H), 1.33 (t, J=7.6 Hz, 3H), 0.88 (s, 9H), 0.05 (s, 6H).
Intermediate: 8-Chloro-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00122
A mixture of 3-((3-methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)oxy)propan-1-ol (2.00 g, 7.01 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (1.32 g, 7.01 mmol), PPh3 (2.76 g, 10.5 mmol), and DIAD (2.13 g, 10.5 mmol) in THF (20 mL) was stirred at 15° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→70:30). The crude product was dissolved in a mixture of EtOAc 40 mL and petroleum ether 20 mL at 50° C. for 20 minutes. The mixture was allowed to cool to 20° C., filtered, and the filter cake was dried to afford 3,6-dichloro-1-(3-((3-methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (2.3 g) of sufficient purity for the subsequent step. 1H NMR (CDCl3, 400M Hz) δ 9.01 (s, 1H), 5.43 (dd, J=2.8, 10.4 Hz, 1H), 4.70 (t, J=6.8 Hz, 2H), 4.59-4.46 (m, 1H), 4.44-4.34 (m, 1H), 4.08-4.00 (m, 1H), 3.74-3.60 (m, 1H), 2.57-2.47 (m, 5H), 2.43-2.31 (m, 1H), 2.17-2.06 (m, 1H), 1.93-1.79 (m, 1H), 1.78-1.67 (m, 2H), 1.27 (d, J=6.4 Hz, 1H).
To a solution of 3,6-dichloro-1-(3-((3-methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (2.3 g, 5.0 mmol) in EtOH (300 mL) was added Fe (1.41 g, 25.2 mmol) and then a solution of NH4Cl (1.35 g, 25.2 mmol) in H2O (20 mL). The mixture was stirred at 80° C. for 32 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc:DCM:MeOH 100:0:0:0→0:100:0:0→0:0:100:0→0:0:90:10) to afford 8-chloro-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]-triazacycloundecine (500 mg) of sufficient purity for the subsequent step. 1H NMR (DMSO-d, 400 MHz) δ 11.68 (br s, 1H), 9.33 (s, 1H), 8.77 (s, 1H), 4.44-4.24 (m, 4H), 2.18 (s, 3H), 1.82-1.72 (m, 2H). LC-MS (method A) (m/z)=306.1 (MH)+tR=1.19 minutes.
Intermediate: 3,6-Dichloro-1-(3-((1-(2-ethoxypyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00123
To a solution of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (600 mg, 1.90 mmol) and (2-ethoxy-3-pyridyl)boronic acid (635 mg, 3.80 mmol) in DCE (20 mL) was added Cu(OAc)2 (518 mg, 2.85 mmol), pyridine (602 mg, 7.61 mmol) and 4 Å MS (600 mg). The mixture was stirred under an O2-atmosphere at 50° C. for 16 h. Additional (2-ethoxy-3-pyridyl)boronic acid (300 mg, 1.78 mmol) was added. The reaction mixture was stirred for another 16 h. The reaction mixture was filtered. The filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→80:20) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-ethoxypyridine (742 mg) of sufficient purity for the subsequent step. 1H NMR (CDCl3, 400 MHz) δ 8.30 (dd, J=2.0, 4.8 Hz, 1H), 7.70 (dd, J=2.0, 8.0 Hz, 1H), 7.06 (dd, J=4.8, 7.6 Hz, 1H), 4.53-4.39 (m, 4H), 3.85 (t, J=6.0 Hz, 2H), 2.48 (s, 3H), 2.14-2.00 (m, 2H), 1.36 (t, J=7.2 Hz, 3H), 0.92 (s, 9H), 0.06 (s, 6H).
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-ethoxypyridine (735 mg, 1.68 mmol) in THF (10 mL) was added TBAF (1 M in THF, 2.5 mL). The mixture was stirred at 20° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→30:70) to afford 3-((1-(2-ethoxypyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (474 mg) of sufficient purity for the subsequent step. 1H NMR (CDCl3, 400M Hz) δ 8.30 (dd, J=2.0, 4.8 Hz, 1H), 7.68 (dd, J=2.0, 7.6 Hz, 1H), 7.06 (dd, J=4.8, 7.6 Hz, 1H), 4.53 (t, J=6.0 Hz, 2H), 4.46 (q, J=6.8 Hz, 2H), 3.86 (t, J=5.6 Hz, 2H), 2.47 (s, 3H), 2.14-2.06 (m, 2H), 1.36 (t, J=6.8 Hz, 3H).
To a solution of 3-((1-(2-ethoxypyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (250 mg, 0.78 mmol) and 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (147 mg, 0.776 mmol) in THF (15 mL) was added PPh3 (610 mg, 2.33 mmol) followed by DIAD (471 mg, 2.33 mmol) at 5° C. The resulting mixture was stirred at 20° C. for 16 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→55:45) to afford 3,6-dichloro-1-(3-((1-(2-ethoxypyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (163 mg) of sufficient purity for the subsequent step. 1H NMR (CDCl3, 400 MHz) δ 8.97 (s, 1H), 8.30 (dd, J=2.0, 4.8 Hz, 1H), 7.67 (dd, J=2.0, 7.6 Hz, 1H), 7.14-6.96 (m, 1H), 4.69 (t, J=6.4 Hz, 2H), 4.52-4.42 (m, 2H), 4.38 (t, J=5.6 Hz, 2H), 2.55-2.49 (m, 2H), 2.47 (s, 3H), 1.36 (t, J=7.2 Hz, 3H).
Intermediate: 3,6-Dichloro-1-(3-((5-methyl-1-(2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00124
To a solution of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (400 mg, 1.27 mmol) and (2-methyl-3-pyridyl)boronic acid (521 mg, 3.80 mmol) in DCE (20 mL) was added Cu(OAc)2 (345 mg, 1.90 mmol), pyridine (401 mg, 5.07 mmol) and 4 Å MS (400 mg). The mixture was stirred under an O2-atmosphere at 50° C. for 16 h. Additional (2-methyl-3-pyridyl) boronic acid (260 mg, 1.88 mmol) was added. The reaction mixture was stirred for another 16 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→55:45) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-methylpyridine (430 mg) of sufficient purity for the subsequent step. 1H NMR (CDCl3, 400 MHz) δ 8.70 (dd, J=1.2, 4.8 Hz, 1H), 7.60 (dd, J=1.2, 8.0 Hz, 1H), 7.36 (dd, J=4.8, 8.0 Hz, 1H), 4.44 (t, J=6.0 Hz, 2H), 3.85 (t, J=6.0 Hz, 2H), 2.46 (s, 3H), 2.39 (s, 3H), 2.01-2.12 (m, 2H), 0.89 (s, 9H), 0.08 (s, 6H).
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-methylpyridine (425 mg, 1.05 mmol) in THF (10 mL) was added TBAF (1 M in THF, 1.57 mL). The resulting mixture was stirred at 20° C. for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc (10 v % MeOH) 50:50→0:100) to afford 3-((5-methyl-1-(2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (279 mg) of sufficient purity for the subsequent step. 1H NMR (CDCl3, 400 MHz) δ 8.71 (d, J=4.0 Hz, 1H), 7.60 (d, J=6.8 Hz, 1H), 7.36 (dd, J=4.8, 7.6 Hz, 1H), 4.53 (t, J=5.6 Hz, 2H), 3.89 (t, J=5.6 Hz, 2H), 2.46 (s, 3H), 2.39 (s, 3H), 2.15-2.07 (m, 2H).
To a solution of 3-((5-methyl-1-(2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (274 mg, 0.937 mmol) and 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (177 mg, 0.937 mmol) in THF (20 mL) was added PPh3 (738 mg, 2.81 mmol) followed by DIAD (569 mg, 2.81 mmol) at 5° C. The resulting mixture was stirred at 20° C. for 16 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced presure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc (10 v % MeOH) 100:0→35:65) to afford a residue that was washed with MeOH (5 mL) and filtered. The filter cake was isolated to afford 3,6-dichloro-1-(3-((5-methyl-1-(2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (188 mg) of sufficient purity for the subsequent step. 1H NMR (CDCl3, 400 MHz) δ 8.97 (s, 1H), 8.69 (dd, J=1.2, 4.8 Hz, 1H), 7.57 (d, J=8.0 Hz, 1H), 7.35 (dd, J=4.8, 8.0 Hz, 1H), 4.70 (t, J=6.0 Hz, 2H), 4.36 (t, J=6.0 Hz, 2H), 2.51-2.46 (m, 2H), 2.45 (s, 3H), 2.35 (s, 3H).
Intermediate: 3,6-Dichloro-1-(3-((1-(2-ethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00125
To a solution of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (400 mg, 1.27 mmol) and (2-ethyl-3-pyridyl)boronic acid (383 mg, 2.54 mmol) in DCE (16 mL) was added Cu(OAc)2 (345 mg, 1.90 mmol), pyridine (401 mg, 5.07 mmol) and 4 Å MS (400 mg). The mixture was stirred under an O2-atmosphere at 50° C. for 16 h. Additional (2-ethyl-3-pyridyl) boronic acid (190 mg, 1.23 mmol) was added. The reaction mixture was stirred for another 16 h at 50° C. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→35:65) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-ethylpyridine (300 mg) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-ethylpyridine (295 mg, 0.70 mmol) in THF (8 mL) was added TBAF (1 M in THF, 1.05 mL). The mixture was stirred at 20° C. for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc (10 v % MeOH) 80:20→30:70) to afford 3-((1-(2-ethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (136 mg) of sufficient purity for the subsequent step. 1H NMR (CDCl3400 MHz) δ 8.76 (dd, J=1.2, 4.8 Hz, 1H), 7.57 (dd, J=1.6, 8.0 Hz, 1H), 7.35 (dd, J=4.8, 7.6 Hz, 1H), 4.52 (t, J=5.6 Hz, 2H), 3.89 (t, J=5.6 Hz, 2H), 2.62 (q, J=7.2 Hz, 2H), 2.17-2.07 (m, 2H), 1.26 (t, J=7.2 Hz, 3H).
To a solution of 3-((1-(2-ethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (136 mg, 0.44 mmol) and 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (84 mg, 0.44 mmol) in THF (10 mL) was added PPh3 (349 mg, 1.33 mmol) followed by DIAD (269 mg, 1.33 mmol) at 5° C. The resulting mixture was stirred at 20° C. for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc (10 v % MeOH) 100:0→30:70) and the residue was further purified by preparative HPLC (Instrument: Gilson GX-215 Liquid Handler, SHIMADZU LC-20AP, SHIMADZU SPD-20A, column: Welch Xtimate C18 150×30 mm×5 μm, mobile phase A: water (NH3H2O+NH4HCO3), mobile phase B: MeCN, gradient: B from 47% to 77% in 8 min then hold at 100% for 2 min, flow rate (mL/min): 30, column temperature: 30° C., wavelength: 220 nm 254 nm) give afford 3,6-dichloro-1-(3-((1-(2-ethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (40 mg) of sufficient purity for the subsequent step. 1H NMR (CDCl3, 400 MHz) δ 8.97 (s, 1H), 8.74 (dd, J=1.6, 4.8 Hz, 1H), 7.55 (dd, J=1.6, 7.6 Hz, 1H), 7.34 (dd, J=4.8, 7.6 Hz, 1H), 4.70 (t, J=6.4 Hz, 2H), 4.36 (t, J=5.6 Hz, 2H), 2.61-2.47 (m, 4H), 2.44 (s, 3H), 1.23 (t, J=6.8 Hz, 3H).
Intermediate: 3,6-Dichloro-1-(3-((5-ethyl-1-(2-methoxypyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00126
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-ethyl-4-nitro-1H-pyrazole (600 mg, 1.82 mmol), (2-methoxy-3-pyridyl)boronic acid (557 mg, 3.64 mmol), Cu(OAc)2 (496 mg, 2.73 mmol), pyidine (576 mg, 7.28 mmol), and 4 Å MS (600 mg) in DCE (20 mL) was heated for 16 h at 50° C. under an O2-atmosphere (15 psi). The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→50:50) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-ethyl-4-nitro-1H-pyrazol-1-yl)-2-methoxypyridine (430 mg) of sufficient purity for the subsequent step. LC-MS (Method B) (m/z)=437.2 (MH)+tR=1.12 minutes.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-ethyl-4-nitro-1H-pyrazol-1-yl)-2-methoxypyridine (400 mg, 0.92 mmol) in THF (2 mL) was added TBAF (1 M in THF, 1.37 mL). The mixture was stirred at 25° C. for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→50:50) to afford 3-((5-ethyl-1-(2-methoxypyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (220 mg) of sufficient purity for the subsequent step. 1H NMR (CDCl3, 400 MHz) δ 8.34 (dd, J=1.6, 4.8 Hz, 1H), 7.65 (dd, J=1.6, 7.6 Hz, 1H), 7.08 (dd, J=4.8, 7.5 Hz, 1H), 4.52 (t, J=6.0 Hz, 2H), 3.98 (s, 3H), 3.86 (t, J=5.6 Hz, 2H), 2.91-2.61 (m, 2H), 2.14-2.07 (m, 2H), 1.15 (t, J=7.6 Hz, 3H).
To a solution of 3-((5-ethyl-1-(2-methoxypyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (200 mg, 0.62 mmol) and 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (120 mg, 0.64 mmol) in THF (10 mL) was added PPh3 (500 mg, 1.91 mmol) and DIAD (400 mg, 1.98 mmol). The mixture was stirred at 25° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→30:70) to afford 3,6-dichloro-1-(3-((5-ethyl-1-(2-methoxypyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (250 mg) of sufficient purity for the subsequent step.
Intermediate: 3,6-Dichloro-1-(3-((1-(5-fluoro-2-methoxypyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00127
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (800 mg, 2.54 mmol), (5-fluoro-2-methoxypyridin-3-yl)boronic acid (520 mg, 3.04 mmol), pyridine (802 mg, 10.1 mmol), Cu(OAc)2 (691 mg, 3.80 mmol), and 4 Å MS (800 mg) in DCE (30 mL) was degassed and purged with O2×3 and then the mixture was stirred at 50° C. for 15 h under an O2-atmosphere. Additional (5-fluoro-2-methoxypyridin-3-yl)boronic acid (450 mg, 2.63 mmol) was added to the mixture and the reaction was stirred at 50° C. for another 15 h under an O2-atmosphere. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→90:10) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-5-fluoro-2-methoxypyridine (420 mg) of sufficient purity for the subsequent step. 1H NMR (CDCl3, 400 MHz) δ8.20 (d, J=2.8 Hz, 1H), 7.54 (dd, J=2.8, 7.2 Hz, 1H), 4.42 (t, J=6.4 Hz, 2H), 3.98 (s, 3H), 3.83 (t, J=6.0 Hz, 2H), 2.48 (s, 3H), 2.08-2.03 (m, 2H), 0.88 (s, 9H), 0.05 (s, 6H).
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-5-fluoro-2-methoxypyridine (410 mg, 0.93 mmol) in THF (10 mL) was added TBAF (1 M in THF, 1.40 mL). The mixture was stirred at 20° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→50:50) to afford 3-((1-(5-fluoro-2-methoxypyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol(270 mg). LC-MS (Method B) (m/z)=327.1 (MH)+tR=0.78 minutes.
DIAD (483 mg, 2.39 mmol) was added to a solution of 3-((1-(5-fluoro-2-methoxypyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (260 mg, 0.80 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (151 mg, 0.80 mmol), and PPh3 (627 mg, 2.39 mmol) in THF (20 mL) at 0° C. The mixture was stirred at 20° C. for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→80:20) to afford 3,6-dichloro-1-(3-((1-(5-fluoro-2-methoxypyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (600 mg) of sufficient purity for the subsequent step. LC-MS (Method B) (m/z)=497.0 (MH)+tR=0.96 minutes.
Intermediate: 3,6-Dichloro-1-(3-((1-(2-methoxy-4-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00128
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (800 mg, 2.54 mmol), (2-methoxy-4-methylpyridin-3-yl)boronic acid (508 mg, 3.04 mmol), Cu(OAc)2 (691 mg, 3.80 mmol), pyridine (802 mg, 10.1 mmol), and 4 Å MS (800 mg) in DCE (40 mL) was degassed and purged with O2×3, and then the mixture was stirred at 50° C. for 32 h under an O2-atmosphere. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 95:5→70:30) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-methoxy-4-methylpyridine (340 mg) of sufficient purity for the subsequent step. LC-MS (Method B) (m/z)=437.2 (MH)+tR=1.11 minutes.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-methoxy-4-methylpyridine (340 mg, 0.78 mmol) in THF (6 mL) was added TBAF (1.17 mL, 1M in THF) at 0° C. and the reaction was stirred at 30° C. for 2 h. The mixture was concentrated under reduced presure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 95:5→50:50) to afford 3-((1-(2-methoxy-4-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (200 mg) of sufficient purity for the subsequent step. 1H NMR (CDCl3, 400 MHz) δ 8.17 (d, J=5.2 Hz, 1H), 6.92 (d, J=5.2 Hz, 1H), 4.51 (t, J=5.6 Hz, 2H), 3.95 (s, 3H), 3.86 (t, J=5.6 Hz, 2H), 2.39 (s, 3H), 2.14 (s, 3H), 2.13-2.06 (m, 2H).
To a solution of 3-((1-(2-methoxy-4-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (200 mg, 0.62 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (117 mg, 0.62 mmol), and PPh3 (326 mg, 1.24 mmol) in THF (20 mL) was added dropwise DIAD (251 mg, 1.24 mmol) at 0° C. The mixture was stirred at 30° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 20:80→50:50) to afford 3,6-dichloro-1-(3-((1-(2-methoxy-4-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (240 mg) of sufficient purity for the subsequent step. LC-MS (Method B) (m/z)=493.0 (MH)+tR=0.94 minutes.
Intermediate: 3,6-Dichloro-1-(3-((5-ethyl-1-(2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00129
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-ethyl-4-nitro-1H-pyrazole (750 mg, 2.28 mmol), (2-methylpyridin-3-yl)boronic acid (468 mg, 3.41 mmol), Cu(OAc)2 (620 mg, 3.41 mmol), pyridine (720 mg, 9.11 mmol), and 4 Å MS (750 mg) in DCE (20 mL) was degassed and purged with O2×3 and then the mixture was stirred at 50° C. for 15 h under an O2-atmospher. Additional (2-methylpyridin-3-yl)boronic acid (470 mg, 3.41 mmol) was added to the mixture and the reaction was stirred at 50° C. for another 15 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→70:30) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-ethyl-4-nitro-1H-pyrazol-1-yl)-2-methylpyridine (1 g) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-ethyl-4-nitro-1H-pyrazol-1-yl)-2-methylpyridine (1 g, 2.38 mmol) in THF (10 mL) was added TBAF (1 M in THF, 3.6 mL). The mixture was stirred at 20° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→70:30) to afford 3-((5-ethyl-1-(2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (330 mg) of sufficient purity for the subsequent step.
A solution of DIAD (634 mg, 3.13 mmol) was added to a solution of 3-((5-ethyl-1-(2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (320 mg, 1.04 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (197 mg, 1.04 mmol), and PPh3 (822 mg, 3.13 mmol) in THF (15 mL) at 0° C. The mixture was stirred at 20° C. for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→60:40) to afford 3,6-dichloro-1-(3-((5-ethyl-1-(2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (700 mg) of sufficient purity for the subsequent step.
Intermediate: 3,6-Dichloro-1-(3-((1-(2,6-dimethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00130
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (800 mg, 2.54 mmol), (2,6-dimethylpyridin-3-yl)boronic acid (459 mg, 3.04 mmol), Cu(OAc)2 (691 mg, 3.80 mmol), pyridine (802 mg, 10.14 mmol), and 4 Å MS (800 mg) in DCE (40 mL) was degassed and purged with O2×3, and then the mixture was stirred at 50° C. for 32 h under an O2-atmosphere. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 95:5→20:80) followed by preparative HPLC ((Instrument: Gilson GX-281 Liquid Handler, Gilson 322 Pump, Gilson 156 UV Detector column: Xtimate C18 150×40 mm×10 μm, mobile mhase A: water (NH3H2O+NH4HCO3), mobile phase B: MeCN, gradient: B from 60% to 90% in 8 minutes then hold at 100% for 3 minutes, flow rate (mL/min): 55, column temperature: 30° C., wavelength: 220 nm & 254 nm) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2,6-dimethylpyridine (180 mg) of sufficient purity for the subsequent step. LC-MS (Method C) (m/z)=421.2 (MH)+tR=2.41 minutes.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2,6-dimethylpyridine (170 mg, 0.40 mmol) in THF (6 mL) was added TBAF (606 μL, 1M in THF) at 0° C. and the reaction was stirred at 30° C. for 2 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 95:5→30:70) to afford 3-((1-(2,6-dimethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (120 mg) of sufficient purity for the subsequent step.
To a solution of 3-((1-(2,6-dimethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (120 mg, 0.39 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (74 mg, 0.39 mmol), and PPh3 (206 mg, 0.78 mmol) in THF (8 mL) was added dropwise DIAD (158 mg, 0.78 mmol) at 0° C. The mixture was stirred at 30° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 80:20→30:70) to afford 3,6-dichloro-1-(3-((1-(2,6-dimethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (220 mg) of sufficient purity for the subsequent step. LC-MS (Method C) (m/z)=477.1 (MH)+tR=1.91 minutes.
Intermediate: 3,6-Dichloro-1-(3-((1-(5-fluoro-2-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00131
To a solution of 3-bromo-5-fluoro-2-methylpyridine (1.5 g, 7.9 mmol) and triisopropyl borate (2.38 g, 12.6 mmol) in THF (23 mL) was added n-BuLi (4.7 mL, 12 mmol, 2.5 M in hexane) at −65° C. After stirring at −65° C. for 1 h, the mixture was stirred at 0° C. for an additional 1 h. H2O (30 mL) and EtOAc (30 mL) were added to the reaction and the mixture was stirred at 25° C. for 30 minutes. The mixture was neutralized with 1.0 M aqueous HCl and extracted with EtOAc (4×30 mL). The organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure to afford (5-fluoro-2-methylpyridin-3-yl)boronic acid (1.14 g) of sufficient purity for the subsequent step.
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (900 mg, 2.40 mmol), (5-fluoro-2-methylpyridin-3-yl)boronic acid (1.11 g, 7.19 mmol), pyridine (758 mg, 9.59 mmol), Cu(OAc)2 (653 mg, 3.59 mmol) and 4 Å MS (900 mg) in DCE (30 mL) was degassed and purged with N2×3, and then the mixture was stirred at 50° C. for 36 h under an O2-atmosphere. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→85:15) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-5-fluoro-2-methylpyridine (225 mg) of sufficient purity for the subsequent step. 1H NMR (CDCl3, 400 MHz) δ 8.59 (d, J=2.8 Hz, 1H), 7.38 (dd, J=2.4, 7.2 Hz, 1H), 4.42 (t, J=6.4 Hz, 2H), 3.83 (t, J=6.0 Hz, 2H), 2.47 (s, 3H), 2.35 (s, 3H), 2.15-2.03 (m, 2H), 0.88 (s, 9H), 0.05 (s, 6H).
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-5-fluoro-2-methylpyridine (290 mg, 0.68 mmol) in THF (6 mL) was added TBAF (1 M in THF, 1.02 mL) at 0° C. and the reaction mixture was stirred at 25° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→40:60) to afford 3-((1-(5-fluoro-2-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (187 mg) of sufficient purity for the subsequent step. LC-MS (Method B) (m/z)=311.1 (MH)+tR=0.72 minutes.
To a solution of 3-((1-(5-fluoro-2-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (160 mg, 0.51 mmol) in THF (16 mL) was added 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (117 mg, 0.619 mmol), PPh3 (406 mg, 1.55 mmol), and DIAD (313 mg, 1.55 mmol) at 0° C. The mixture was stirred at 25° C. for 12 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→45:55) to afford 3,6-dichloro-1-(3-((1-(5-fluoro-2-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (200 mg) of sufficient purity for the subsequent step. LC-MS (Method B) (m/z)=481.0 (MH)+tR=0.92 minutes.
Intermediate: 3,6-Dichloro-1-(3-((1-(2,5-dimethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00132
n-BuLi (13 mL, 33 mmol, 2.5 M in hexane) was added in a dropwise manner to 3-bromo-2,5-dimethyl-pyridine (3 g, 16 mmol) and triisopropyl borate (6.07 g, 32.3 mmol) in THF (50 mL) at −78° C. The mixture was stirred at −78° C. for 3 h. The mixture was quenched with aqueous NH4Cl (20 mL) and then extracted with EtOAc (20 mL×4). The combined organic layers were concentrated under reduced pressure to afford (2,5-dimethyl-3-pyridyl)boronic acid (2 g) of sufficient purity for the subsequent step.
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (800 mg, 2.54 mmol), (2,5-dimethyl-3-pyridyl)boronic acid (500 mg, 3.31 mmol), Cu(OAc)2 (691 mg, 3.80 mmol), pyridine (803 mg, 10.1 mmol) and 4 Å MS (800 mg) in DCE (20 mL) was degassed and purged with O2×3, and then stirred at 50° C. for 16 h under an O2-atmosphere. Additional (2,5-dimethyl-3-pyridyl)boronic acid (300 mg, 1.99 mmol) was added and the reaction was stirred at 50° C. for another 6 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→75:25) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2,5-dimethylpyridine (900 mg) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2,5-dimethylpyridine (900 mg, 2.14 mmol) in THF (20 mL) was added TBAF (3.2 mL, 3.2 mmol, 1 M in THF). The mixture was stirred at 25° C. for 2 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→10:90) to afford 3-((1-(2,5-dimethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (550 mg) of sufficient purity for the subsequent step.
A mixture of 3-((1-(2,5-dimethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (300 mg, 0.98 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (185 mg, 0.98 mmol), PPh3 (780 mg, 2.97 mmol), and DIAD (600 mg, 2.97 mmol) in THF (25 mL) was stirred at 25° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→30:70) to afford 3,6-dichloro-1-(3-((1-(2,5-dimethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (570 mg) of sufficient purity for the subsequent step.
Intermediate: 3,6-Dichloro-1-(3-((1-(2-methoxy-5-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00133
A mixture of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (500 mg, 1.59 mmol), (2-methoxy-5-methylpyridin-3-yl)boronic acid (318 mg, 1.90 mmol), pyridine (502 mg, 6.35 mmol), 4 Å MS (500 mg), and Cu(OAc)2 (432 mg, 2.38 mmol) in DCE (20 mL) was degassed and purged with O2×3 and then stirred at 50° C. for 15 h under an O2-atmosphere. Additional (2-methoxy-5-methylpyridin-3-yl)boronic acid (318 mg, 1.90 mmol) was added to the mixture and reaction was stirred at 50° C. for another 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→10:90) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-methoxy-5-methylpyridine (410 mg) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-methoxy-5-methylpyridine (410 mg, 0.939 mmol) in THF (10 mL) was added TBAF (1.41 mL, 1.41 mmol, 1 M in THF). The mixture was stirred at 20° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→50:50) to afford 3-((1-(2-methoxy-5-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (220 mg) of sufficient purity for the subsequent step.
A solution of DIAD (396 mg, 1.96 mmol) was added to a solution of 3-((1-(2-methoxy-5-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (210 mg, 0.612 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (124 mg, 0.656 mmol), and PPh3 (513 mg, 1.96 mmol) in THF (10 mL) at 0° C. The mixture was stirred at 20° C. for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→80:20) to afford 3,6-dichloro-1-(3-((1-(2-methoxy-5-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (500 mg) of sufficient purity for the subsequent step.
Intermediate: 3,6-Dichloro-1-(3-((1-(2-methoxy-6-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00134
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (800 mg, 2.54 mmol), (2-methoxy-6-methylpyridin-3-yl)boronic acid (847 mg, 5.07 mmol), 4 Å MS (800 mg), pyridine (802 mg, 10.1 mmol), and Cu(OAc)2 (691 mg, 3.80 mmol) in DCE (25 mL) was heated for 16 h at 50° C. under an O2-atmosphere. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→85:15) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-methoxy-6-methylpyridine (860 mg) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-methoxy-6-methylpyridine (850 mg, 1.95 mmol) in THF (9 mL) was added TBAF (2.92 mL, 2.92 mmol, 1 M in THF) and stirred at 25° C. for 1.5 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→40:60) to afford 3-((1-(2-methoxy-6-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (620 mg) of sufficient purity for the subsequent step.
To a solution of 3-((1-(2-methoxy-6-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (600 mg, 1.86 mmol) in THF (50 mL) was added 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (422 mg, 2.23 mmol), PPh3 (1.46 g, 5.58 mmol), and DIAD (1.13 g, 5.58 mmol) at 0° C. The mixture was stirred at 25° C. for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→85:15) to afford 3,6-dichloro-1-(3-((1-(2-methoxy-6-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (1.3 g) of sufficient purity for the subsequent step.
Intermediate: 3,6-Dichloro-1-(3-((1-(2-(1,1-difluoroethyl)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00135
To a solution of 3-bromo-2-(1,1-difluoroethyl)pyridine (3.3 g, 15 mmol) and triisopropyl borate (8.39 g, 44.6 mmol) in THF (50 mL) was added dropwise n-BuLi (8.3 mL, 21 mmol, 2.5 M in hexane) at −78° C. The reaction mixture was stirred at −78° C. for 2 h. The reaction mixture was quenched with saturated aqueous NH4Cl (50 mL) and extracted with EtOAc (100 mL×3). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure to afford (2-(1,1-difluoroethyl)pyridin-3-yl)boronic acid (2.5 g) of sufficient purity for the subsequent step.
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (1.0 g, 3.2 mmol), (2-(1,1-difluoroethyl)pyridin-3-yl)boronic acid (900 mg, 4.81 mmol), Cu(OAc)2 (864 mg, 4.76 mmol), pyridine (1.00 g, 12.7 mmol) and 4 Å MS (1 g) in DCE (20 mL) was degassed and purged with O2×3 and then stirred at 60° C. for 15 h under an O2-atmosphere. Additional [2-(1,1-difluoroethyl)-3-pyridyl]boronic acid (900 mg, 4.81 mmol) was added to the mixture and the reaction was stirred at 60° C. for another 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→60:40) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-(1,1-difluoroethyl)pyridine (1.2 g) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-(1,1-difluoroethyl)pyridine (1.2 g, 2.63 mmol) in THF (20 mL) was added TBAF (1 M in THF, 3.9 mL). The mixture was stirred at 20° C. for 17 hours. The reaction mixture was concentrated. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100) to afford 3-((1-(2-(1,1-difluoroethyl)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (260 mg) of sufficient purity for the subsequent step.
DIAD (443 mg, 2.19 mmol) was added to a solution of 3-((1-(2-(1,1-difluoroethyl)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (250 mg, 0.730 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (139 mg, 0.735 mmol), and PPh3 (575 mg, 2.19 mmol) in THF (10 mL) at 0° C. The mixture was stirred at 20° C. for 1 h and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→50:50) to afford 3,6-dichloro-1-(3-((1-(2-(1,1-difluoroethyl)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (370 mg) of sufficient purity for the subsequent step.
Intermediate: 3,6-Dichloro-1-(3-((1-(5-fluoro-2,6-dimethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00136
To 2-bromo-5-fluoropyridin-3-amine (5 g, 26 mmol) in MeCN (200 ml) was added NBS (4.66 g, 26.2 mmol) in a portionwise manner at 0° C. The mixture was stirred at 0° C. for 3 h. The mixture was concentrated under reduced pressure, diluted with water (50 mL), and extracted with ethyl acetate (50 mL×3). The combined organic layers were dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→90:10) to afford 2,6-dibromo-5-fluoropyridin-3-amine (7.71 g) of sufficient purity for the subsequent step.
2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (16.3 g, 129 mmol) was added to a stirred suspension of 2,6-dibromo-5-fluoropyridin-3-amine (13.0 g, 51.8 mmol), K3PO4 (22.0 g, 104 mmol), and XPhos Pd G3 (4.38 g, 5.18 mmol) in 1,4-dioxane (450 mL). The mixture was stirred at 95° C. for 12 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→30:70) to afford 5-fluoro-2,6-dimethylpyridin-3-amine (5.26 g) of sufficient purity for the subsequent step.
To a solution of 5-fluoro-2,6-dimethylpyridin-3-amine (5.26 g, 37.5 mmol) and CuBr2 (10.1 g, 45.0 mmol) in CHBr3 (100 mL) was added tert-butyl nitrite (4.64 g, 45.0 mmol) in a dropwise manner at 20° C. The solution was stirred at 20° C. for 12 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→90:10) to afford 3-bromo-5-fluoro-2,6-dimethylpyridine (3.8 g) of sufficient purity for the subsequent step.
To a mixture of 3-bromo-5-fluoro-2,6-dimethylpyridine (4.57 g, 22.4 mmol), triisopropyl borate (5.05 g, 26.9 mmol) in THF (115 mL) was added n-BuLi (10.8 mL, 27 mmol, 2.5 M in hexane) in a dropwise manner at −65° C. Upon complete addition the mixture was stirred at −65° C. for another 2 h. The reaction mixture was quenched with saturated aqueous NH4Cl (20 mL) and water (20 mL) and extracted with EtOAc (5×30 mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure to afford (5-fluoro-2,6-dimethylpyridin-3-yl)boronic acid (2.44 g) of sufficient purity for the subsequent step.
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (1.1 g, 3.5 mmol), (5-fluoro-2,6-dimethylpyridin-3-yl)boronic acid (2.36 g, 14.0 mmol), Cu(OAc)2 (950 mg, 5.23 mmol), pyridine (1.10 g, 14.0 mmol) and 4 Å MS (1.1 g) in DCE (25 mL) was heated for 16 h at 50° C. under an O2-atmosphere. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→85:15) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-5-fluoro-2,6-dimethylpyridine (1.15 g) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-5-fluoro-2,6-dimethylpyridine (1.15 g, 2.62 mmol) in THF (10 mL) was added TBAF (3.9 mL, 3.9 mmol, 1 M in THF) and stirred at 20° C. for 2 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→40:60) to afford 3-((1-(5-fluoro-2,6-dimethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (700 mg) of sufficient purity for the subsequent step.
To a solution 3-((1-(5-fluoro-2,6-dimethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (350 mg, 1.08 mmol) in THF (35 mL) was added 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (224 mg, 1.19 mmol), PPh3 (849 mg, 3.24 mmol), and DEAD (564 mg, 3.24 mmol) at 0° C. The mixture was stirred at 20° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→70:30) to afford 3,6-dichloro-1-(3-((1-(5-fluoro-2,6-dimethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (710 mg) of sufficient purity for the subsequent step.
Intermediate: 3,6-Dichloro-1-(3-((1-(2-cyclopropoxypyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00137
To a solution of 3-bromo-2-fluoropyridine (5.0 g, 28 mmol) in DMF (60 mL) was added Cs2CO3 (13.89 g, 42.62 mmol) and cyclopropanol (4.95 g, 85.23 mmol). The mixture was stirred at 20° C. for 15 h. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (100 mL×3). The combined organic layers were washed with brine (100 mL×3), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→98:2) to afford 3-bromo-2-cyclopropoxypyridine (3.2 g) of sufficient purity for the subsequent step.
To a solution of 3-bromo-2-cyclopropoxypyridine (3 g, 14 mmol) and triisopropyl borate (7.91 g, 42.0 mmol) in THF (50 mL) was added n-BuLi (8.41 mL, 21 mmol, 2.5 M in hexane) in a dropwise manner at −78° C. The reaction mixture was stirred at −78° C. for 1.5 h. The reaction mixture was quenched with saturated aqueous NH4Cl (20 mL) and extracted with EtOAc (50 mL×3). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure to afford (2-cyclopropoxypyridin-3-yl)boronic acid (2.2 g) of sufficient purity for the subsequent step.
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (1.0 g, 3.2 mmol), (2-cyclopropoxypyridin-3-yl)boronic acid (1.13 g, 6.31 mmol), Cu(OAc)2 (864 mg, 4.76 mmol), pyridine (1.00 g, 12.7 mmol), and 4 Å MS (1 g) in DCE (20 mL) was degassed and purged with O2×3 and then stirred at 60° C. for 15 h under an O2-atmosphere. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→80:20) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-cyclopropoxypyridine (600 mg) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-cyclopropoxypyridine (600 mg, 1.34 mmol) in THF (20 mL) was added TBAF (2 mL, 2 mmol, 1 M in THF). The mixture was stirred at 20° C. for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100) to afford 3-((1-(2-cyclopropoxypyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (410 mg) of sufficient purity for the subsequent step.
DIAD (726 mg, 3.59 mmol) was added to a solution of 3-((1-(2-cyclopropoxypyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (400 mg, 1.20 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (228 mg, 1.21 mmol), and PPh3 (942 mg, 3.59 mmol) in THF (10 mL) at 0° C. The mixture was stirred at 20° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→70:30) to afford 3,6-dichloro-1-(3-((1-(2-cyclopropoxypyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (420 mg) of sufficient purity for the subsequent step.
Intermediate: 3,6-Dichloro-1-(3-((5-methyl-4-nitro-1-(2-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00138
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (1.00 g, 3.17 mmol), (2-(trifluoromethyl)pyridin-3-yl)boronic acid (726 mg, 3.80 mmol), Cu(OAc)2 (864 mg, 4.76 mmol), pyridine (1.00 g, 12.7 mmol) and 4 Å MS (1 g) in DCE (40 mL) was degassed and purged with O2×3 and stirred at 80° C. for 16 h under an O2-atmosphere. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 83:17→67:33) followed by preparative HPLC (Instrument: Gilson GX-281 Liquid Handler, Gilson 322 Pump, Gilson 156 UV Detector, Column: Xtimate C18 150×40 mm×10 μm, Mobile Phase A: water (NH3H2O+NH4HCO3), Mobile phase B: MeCN, Gradient: B from 60% to 90% in 8 min then hold at 100% for 3 min, Flow Rate (mL/min): 55, Column temperature: 30° C., Wavelength: 220 nm, 254 nm) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-(trifluoromethyl)pyridine (50 mg) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-(trifluoromethyl)pyridine (100 mg, 0.22 mmol) in THF (8 mL) was added TBAF (0.326 mL, 0.22 mmol, 1M in THF) at 0° C. and the reaction was stirred at 30° C. for 2 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 95:5→30:70) to afford 3-((5-methyl-4-nitro-1-(2-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (70 mg) of sufficient purity for the subsequent step.
To a solution of 3-((5-methyl-4-nitro-1-(2-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (65 mg, 0.19 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (43 mg, 0.23 mmol), and PPh3 (246 mg, 0.94 mmol) in THF (5 mL) was added DIAD (190 mg, 0.94 mmol) in a dropwise manner at 0° C. The mixture was stirred at 25° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→70:30) to afford 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(2-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (250 mg) of sufficient purity for the subsequent step.
Intermediate: 3,6-Dichloro-1-(3-((1-(2-(fluoromethoxy)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00139
A mixture of 3-bromopyridin-2-ol (13 g, 751 mmol), fluoromethyl 4-methylbenzenesulfonate (30.52 g, 149.4 mmol), and K2CO3 (20.65 g, 149.4 mmol) in DMF (170 mL) was degassed and purged with N2×3 and then stirred at 50° C. for 12 h. The reaction mixture was diluted with water (120 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were washed with brine (3×100 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→95:5) to afford 3-bromo-2-(fluoromethoxy)pyridine (7 g) of sufficient purity for the subsequent step.
To a solution of 3-bromo-2-(fluoromethoxy)pyridine (7.0 g, 34 mmol) and triisopropyl borate (12.78 g, 67.96 mmol) in THF (100 mL) was added n-BuLi (20.4 mL, 51 mmol, 2.5 M in hexane) at −65° C. The mixture was stirred at −65° C. for 1.5 h followed by 1.5 h stirring at 0° C. The reaction mixture was quenched with saturated aqueous NH4Cl (100 mL) and extracted with EtOAc (6×100 mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure to afford (2-(fluoromethoxy)pyridin-3-yl)boronic acid (5.4 g) of sufficient purity for the subsequent step.
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (1.0 g, 3.2 mmol), (2-(fluoromethoxy)pyridin-3-yl)boronic acid (1.19 g, 6.97 mmol), pyridine (1.00 g, 12.7 mmol), Cu(OAc)2 (864 mg, 4.76 mmol), and 4 Å MS (1 g) in DCE (15 mL) was heated for 16 h at 50° C. under an O2-atmosphere. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→80:20) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-(fluoromethoxy)pyridine (120 mg) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-(fluoromethoxy)pyridine (500 mg, 1.13 mmol) in THF (5 mL) was added TBAF (1.7 mL, 1.7 mmol 1 M in THF) and stirred at 20° C. for 2 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→40:60) to afford 3-((1-(2-(fluoromethoxy)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (250 mg) of sufficient purity for the subsequent step.
To a solution of 3-((1-(2-(fluoromethoxy)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (340 mg, 1.04 mmol) in THF (25 mL) was added 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (197 mg, 1.04 mmol), PPh3 (820 mg, 3.13 mmol), and DIAD (632 mg, 3.13 mmol) at 0° C. The mixture was stirred at 20° C. for 0.5 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→60:40) to afford 3,6-dichloro-1-(3-((1-(2-(fluoromethoxy)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (385 mg) of sufficient purity for the subsequent step.
Intermediate: 3,6-Dichloro-1-(3-((1-(2-(difluoromethoxy)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00140
To a solution of 3-bromopyridin-2-ol (5.0 g, 29 mmol) in MeCN (140 mL) was added 2,2-difluoro-2-(fluorosulfonyl)acetic acid (6.14 g, 34.5 mmol) and Na2SO4 (4.49 g, 31.6 mmol). The mixture was stirred at 15° C. for 16 h. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→95:5) to afford 3-bromo-2-(difluoromethoxy)pyridine (5.7 g) of sufficient purity for the subsequent step.
To a solution of 3-bromo-2-(difluoromethoxy)pyridine (6.6 g, 29 mmol) and triisopropyl borate (11.08 g, 58.93 mmol) in THF (100 mL) was added n-BuLi (17.7 mL, 44 mmol, 2.5 M in hexane) at −65° C. and stirred at −65° C. for 4.5 h. The reaction mixture was quenched with saturated aqueous NH4Cl (40 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→80:20) to afford (2-(difluoromethoxy)pyridin-3-yl)boronic acid (4 g) of sufficient purity for the subsequent step.
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (1.0 g, 3.2 mmol), (2-(difluoromethoxy)pyridin-3-yl)boronic acid (1.20 g, 6.34 mmol), pyridine (1.00 g, 12.7 mmol), Cu(OAc)2 (864 mg, 4.76 mmol) and 4 Å MS (1 g) in DCE (15 mL) was heated for 16 h at 60° C. under an O2-atmosphere. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→75:25) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-(difluoromethoxy)pyridine (160 mg) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-(difluoromethoxy)pyridine (320 mg, 0.698 mmol) in THF (8 mL) was added TBAF (1.1 mL, 1.1 mmol, 1 M in THF) and stirred at 20° C. for 2 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100) to afford 3-((1-(2-(difluoromethoxy)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (170 mg) of sufficient purity for the subsequent step.
To a solution of 3-((1-(2-(difluoromethoxy)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (160 mg, 0.465 mmol) in THF (16 mL) was added 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (88 mg, 0.47 mmol), PPh3 (366 mg, 1.40 mmol), and DIAD (282 mg, 1.39 mmol) at 0° C. The mixture was stirred at 20° C. for 0.5 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→60:40) to afford 3,6-dichloro-1-(3-((1-(2-(difluoromethoxy)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (200 mg) of sufficient purity for the subsequent step.
Intermediate: 3,6-Dichloro-1-(3-((5-methyl-4-nitro-1-(2-(trifluoromethoxy)pyridin-3-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00141
A mixture of 3-bromopyridin-2-ol (24.78 g, 142.40 mmol), 1-(trifluoromethyl)-1λ3-benzo[d][1,2]iodaoxol-3(1H)-one (15 g, 47 mmol) in CH3NO2(342 g, 5.61 mol) was degassed and purged with N2×3, and then stirred at 100° C. for 16 h. The mixture was diluted with water (300 mL) and extracted with DCM (2×300 mL). The organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0) to afford 3-bromo-2-(trifluoromethoxy)pyridine (5.6 g) of sufficient purity for the subsequent step.
To a solution of 3-bromo-2-(trifluoromethoxy)pyridine (6.0 g, 25 mmol) and triisopropyl borate (7.46 g, 39.7 mmol) in THF (100 mL) was added n-BuLi (14.9 mL, 37 mmol, 2.5 M in hexane) at −65° C. and stirred at −65° C. for 3 h. The reaction mixture was quenched with saturated aqueous NH4Cl (100 mL) and extracted with EtOAc (6×60 mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→75:25) to afford (2-(trifluoromethoxy)pyridin-3-yl)boronic acid (2.5 g) of sufficient purity for the subsequent step.
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (1.0 g, 3.2 mmol), (2-(trifluoromethoxy)pyridin-3-yl)boronic acid (655 mg, 3.17 mmol), Cu(OAc)2 (864 mg, 4.76 mmol), pyridine (1.00 g, 12.7 mmol) and 4 Å MS (1 g) in DCE (100 mL) was heated for 16 h at 60° C. under an O2-atmosphere. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→80:20) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-(trifluoromethoxy)pyridine (55 mg) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-(trifluoromethoxy)pyridine (220 mg, 0.462 mmol) in THF (5 mL) was added TBAF (0.692 mL, 0.69 mmol, 1 M in THF) and stirred at 20° C. for 3 h. The reaction mixture was concentrated under reduced pressure The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→30:70) to afford 3-((5-methyl-4-nitro-1-(2-(trifluoromethoxy)pyridin-3-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (130 mg) of sufficient purity for the subsequent step.
To a solution of 3-((5-methyl-4-nitro-1-(2-(trifluoromethoxy)pyridin-3-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (110 mg, 0.304 mmol) in toluene (11 mL) was added 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (57 mg, 0.30 mmol), PPh3 (239 mg, 0.911 mmol), and DIAD (184 mg, 0.911 mmol) at 0° C. The mixture was stirred at 60° C. for 0.4 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→60:40) to afford 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(2-(trifluoromethoxy)pyridin-3-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (90 mg) of sufficient purity for the subsequent step.
Intermediate: 3,6-Dichloro-1-(3-((1-(3-methoxypyridazin-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00142
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (1.0 g, 3.2 mmol), 3,4-dichloropyridazine (472 mg, 3.17 mmol), K2CO3 (789 mg, 5.71 mmol) in MeCN (50 mL) was degassed and purged with N2×3 and then stirred at 60° C. for 48 h. The reaction mixture diluted with water (20 mL) and extracted with EtOAc (3×40 mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→70:30) to afford 4-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-3-chloropyridazine (400 mg) of sufficient purity for the subsequent step.
To a solution of 4-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-3-chloropyridazine (140 mg, 0.327 mmol) in MeOH (5 mL) was added NaOMe (118 mg, 0.654 mmol, 30 w % in MeOH) at 0° C. The mixture was stirred at 25° C. for 1 h. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure to afford 4-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-3-methoxypyridazine (120 mg) of sufficient purity for the subsequent step.
To a solution of 4-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-3-methoxypyridazine (100 mg, 0.236 mmol) in THF (5 mL) was added TBAF (0.354 mL, 0.35 mmol, 1 M in THF) and stirred at 25° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100) to afford 3-((1-(3-methoxypyridazin-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (45 mg) of sufficient purity for the subsequent step.
To a solution of 3-((1-(3-methoxypyridazin-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (110 mg, 0.356 mmol) in THF (10 mL) was added 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (81 mg, 0.43 mmol), PPh3 (280 mg, 1.07 mmol), and DIAD (216 mg, 1.07 mmol) at 0° C. The mixture was stirred at 25° C. for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→10:90) to afford 3,6-dichloro-1-(3-((1-(3-methoxypyridazin-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (165 mg) of sufficient purity for the subsequent step.
Intermediate: 3,6-Dichloro-1-(3-((1-(4-methoxy-2-methylpyrimidin-5-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00143
To a solution of 5-bromo-4-chloro-2-methyl-pyrimidine (3.0 g, 14 mmol) in MeOH (50 mL) was added NaOMe (43.5 mL, 44 mmol, 1 M in MeOH) at 0° C. The mixture was stirred at 0° C. for 1 h. The mixture was diluted with water (30 mL) and extracted with EtOAc (50 mL×3). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to afford 5-bromo-4-methoxy-2-methyl-pyrimidine (2.9 g) of sufficient purity for the subsequent step.
To a solution of 5-bromo-4-methoxy-2-methyl-pyrimidine (3.4 g, 17 mmol) and triisopropyl borate (6.30 g, 33.5 mmol) in THF (40 mL) was added n-BuLi (8.0 mL, 20 mmol, 2.5 M in hexane) at −65° C. The mixture was stirred at −65° C. for 2 h and allowed to warm to 20° C. and stirred at 20° C. for 16 h. The reaction was quenched by addition of aqueous HCl (10 mL, 1 M) and pH adjusted to 6 using 1M aqueous HCl. The mixture was extracted with EtOAc (50 mL×8) and the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to afford (4-methoxy-2-methyl-pyrimidin-5-yl)boronic acid (2.03 g) of sufficient purity for the subsequent step.
A mixture of (4-methoxy-2-methyl-pyrimidin-5-yl)boronic acid (906 mg, 5.39 mmol), 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (1.0 g, 3.2 mmol), TMEDA (1.11 g, 9.51 mmol), and Cu(OTf)2 (3.44 g, 9.51 mmol) in MeCN (9 mL) and DCM (6 mL) was degassed and purged with O2×3 and then stirred at 20° C. for 16 h under an O2-atmosphere. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→80:20) followed by preparative HPLC (Instrument: Gilson GX-281 Liquid Handler, Gilson 322 Pump, Gilson 156 UV Detector; Column: Xtimate C18 150×40 mm×10 μm; Mobile Phase A: water (0.05% NH3H2O+10 mM NH4HCO3); Mobile phase B: MeCN; Gradient: B from 70% to 100% in 8 min then hold at 100% for 3 min; Flow Rate (mL/min): 55; Column temperature: ° C.; Wavelength: 220 nm 254 nmbasic condition) to afford 5-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-4-methoxy-2-methylpyrimidine (460 mg) of sufficient purity for the subsequent step.
To a solution of 5-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-4-methoxy-2-methylpyrimidine (460 mg, 1.05 mmol) in THF (10 mL) was added TBAF (1.6 mL, 1.6 mmol, 1 M in THF). The mixture was stirred at 20° C. for 2 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100) to afford 3-((1-(4-methoxy-2-methylpyrimidin-5-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (330 mg) of sufficient purity for the subsequent step.
A mixture of 3-((1-(4-methoxy-2-methylpyrimidin-5-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (330 mg, 1.02 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (193 mg, 1.02 mmol), PPh3 (900 mg, 3.43 mmol), and DIAD (730 mg, 3.61 mmol) in THF (10 mL) was stirred at 15° C. for 2 h. The mixture was concentrated unduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→60:40) to afford 3,6-dichloro-1-(3-((1-(4-methoxy-2-methylpyrimidin-5-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (900 mg) of sufficient purity for the subsequent step.
Intermediate: 3,6-Dichloro-1-(3-((1-(5-fluoro-2-(methoxy-d3)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00144
To a solution of 3-bromo-5-fluoro-pyridin-2-ol (10 g, 52 mmol) in toluene (150 mL) was added Ag2CO3 (10.05 g, 36.46 mmol) and trideuterio(iodo)methane (9.0 g, 62 mmol) at 5° C. The mixture was stirred at 25° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→95:5) to afford 3-bromo-5-fluoro-2-(trideuteriomethoxy)pyridine (7.6 g) of sufficient purity for the subsequent step.
n-BuLi (8.61 mL, 22 mmol, 2.5 M in hexane) was slowly added to a solution of 3-bromo-5-fluoro-2-(trideuteriomethoxy)pyridine (3.0 g, 14 mmol) and triisopropyl borate (6.82 g, 36.3 mmol) in THF (30 mL) at −65° C. The mixture was stirred at −65° C. for 2 h and then allowed to warm to 25° C. and stirred for 14 h. The mixture was adjusted to pH 6 with aqueous HCl (1 M) and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→70:30) to afford (5-fluoro-2-(methoxy-d3)pyridin-3-yl)boronic acid (2 g) of sufficient purity for the subsequent step.
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (2.0 g, 6.3 mmol), (5-fluoro-2-(methoxy-d3)pyridin-3-yl)boronic acid (1.32 g, 7.61 mmol), Cu(OAc)2, (1.73 g, 9.51 mmol), pyridine (2.01 g, 25.4 mmol), and 4 Å MS (2 g) in DCE (40 mL) was degassed and purged with O2×3. The mixture was stirred at 50° C. for 16 h under an O2-atmosphere. Additional (5-fluoro-2-(methoxy-d3)pyridin-3-yl)boronic acid (600 mg, 3.45 mmol) was added and the mixture was stirred at 50° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→80:20) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-5-fluoro-2-(methoxy-d3)pyridine (900 mg) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-5-fluoro-2-(methoxy-d3)pyridine (800 mg, 1.80 mmol) in THF (10 mL) was added TBAF (2.7 mL, 2.7 mmol, 1 M in THF). The mixture was stirred at 25° C. for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→30:70) to afford 3-((1-(5-fluoro-2-(methoxy-d3)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (500 mg) of sufficient purity for the subsequent step.
To a mixture of 3-((1-(5-fluoro-2-(methoxy-d3)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (300 mg, 0.900 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (172 mg, 0.910 mmol), PPh3 (717 mg, 2.73 mmol) in THF (20 mL) was added DIAD (553 mg, 2.73 mmol) at 0° C. The mixture was stirred at 25° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→80:20) to afford 3,6-dichloro-1-(3-((1-(5-fluoro-2-(methoxy-d3)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (380 mg) of sufficient purity for the subsequent step.
Intermediate: 3,6-Dichloro-1-(3-((1-(2-(methoxy-d3)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine
Figure US11958865-20240416-C00145
To a solution of 3-bromopyridin-2-ol (5.0 g, 29 mmol) in CHCl3 (50 mL) was added Ag2CO3 (15.85 g, 57.47 mmol) and trideuterio(iodo)methane (8.33 g, 57.5 mmol). The mixture was stirred at 20° C. for 15 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→95:5) to afford 3-bromo-2-(methoxy-d3)pyridine (3.85 g) of sufficient purity for the subsequent step.
To a solution of 3-bromo-2-(methoxy-d3)pyridine (4.2 g, 22 mmol) in THF (40 mL) was added n-BuLi (9.67 mL, 24 mmol, 2.5 M, in hexane) in a dropewise manner at −78° C. The reaction mixture was stirred at −78° C. for 30 minutes, then triisopropyl borate (8.27 g, 44.0 mmol) was added and the mixture was stirred 20° C. for 14.5 h. The reaction mixture was quenched with saturated aqueous NH4Cl (20 mL) and extracted with EtOAc (50 mL×3). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure to afford (2-(methoxy-d3)pyridin-3-yl)boronic acid (2 g) of sufficient purity for the subsequent step.
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-3-methyl-4-nitro-1H-pyrazole (600 mg, 1.90 mmol), (2-(methoxy-d3)pyridin-3-yl)boronic acid (890 mg, 5.71 mmol), Cu(OAc)2 (518 mg, 2.85 mmol), pyridine (602 mg, 7.61 mmol) and 4 Å MS (600 mg) in DCE (20 mL) was degassed and purged with O2×3. The mixture was stirred at 50° C. for 15 h under an O2-atmosphere, Additional (2-(methoxy-d3)pyridin-3-yl)boronic acid (890 mg, 5.71 mmol) was added to the mixture and the reaction was stirred at 50° C. for another 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→70:30) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-(methoxy-d3)pyridine (700 mg) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)-2-(methoxy-d3)pyridine (690 mg, 1.62 mmol) in THF (10 mL) was added TBAF (2.4 mL, 2.4 mmol, 1 M in THF). The mixture was stirred at 20° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→40:60) to afford 3-((1-(2-(methoxy-d3)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (380 mg) of sufficient purity for the subsequent step.
A solution of DIAD (721 mg, 3.57 mmol) was added to a solution of 3-((1-(2-(methoxy-d3)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (370 mg, 1.19 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (225 mg, 1.19 mmol), and PPh3 (935 mg, 3.57 mmol) in THF (20 mL) at 0° C. The mixture was stirred at 20° C. for 13 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→70:30) to afford 3,6-dichloro-1-(3-((1-(2-(methoxy-d3)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (310 mg) of sufficient purity for the subsequent step.
Intermediate: 3-Bromo-8-chloro-2-(2,6-dimethylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00146
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazole (1.0 g, 3.2 mmol), (2,6-dimethyl-3-pyridyl)boronic acid (1.0 g, 6.6 mmol), Cu(OAc)2 (904 mg, 4.98 mmol), pyridine (1.05 g, 13.27 mmol), and 4 Å MS (1 g) in DCE (60 mL) was degassed and purged with oxygen×3. The mixture was stirred at 60° C. for 16 h under an O2-atmosphere. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→40:60) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazol-1-yl)-2,6-dimethylpyridine (1.3 g) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazol-1-yl)-2,6-dimethylpyridine (1.5 g, 3.7 mmol) in THF (20 mL) was added TBAF (5.5 mL, 5.5 mmol, 1 M in THF) and the mixture was stirred at 25° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc (10 v % MeOH) 100:0→50:50) to afford 3-((1-(2,6-dimethylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (0.71 g) of sufficient purity for the subsequent step.
To a mixture of 3-((1-(2,6-dimethylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (0.64 g, 2.19 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (414 mg, 2.19 mmol), and PPh3 (1.72 g, 6.57 mmol) in THF (40 mL) was added DIAD (1.33 g, 6.57 mmol) at 0° C. The mixture was stirred at 25° C. for 5 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc (10 v % MeOH and 10 v % DCM) 100:0→70:30) to afford 3,6-dichloro-1-(3-((1-(2,6-dimethylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (0.8 g) of sufficient purity for the subsequent step.
To a mixture of 3,6-dichloro-1-(3-((1-(2,6-dimethylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (0.70 g, 1.5 mmol) and NH4Cl (404 mg, 7.55 mmol) in a mixture of EtOH (70 mL) and H2O (7 mL) was added Fe (422 mg, 7.55 mmol) at 20° C. The mixture was stirred at 80° C. for 16 h. Additional NH4Cl (400 mg) was added and the mixture was stirred at 80° C. for another 7 h. The mixture was filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc (10 v % DCM) 100:0→50:50) to afford 8-chloro-2-(2,6-dimethylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (0.55 g) of sufficient purity for the subsequent step.
A solution of 2,4,4,6-tetrabromocyclohexa-2,5-dien-1-one (0.38 g, 0.94 mmol) in THF (2 mL) was added dropwise to a solution of 8-chloro-2-(2,6-dimethylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (0.31 g, 0.78 mmol) in THF (60 mL) at 20° C. The mixture was stirred for 2 h at 20° C. Additional 2,4,4,6-tetrabromocyclohexa-2,5-dien-1-one (0.38 g, 0.84 mmol) in THF (2 mL) was added to the mixture and stirred for 15 h at 20° C. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc (10 v % MeOH) 100:0→50:50) followed by preparative SFC (Instrument: Berger, MULTIGRAM-II, Column: DAICEL CHIRALPAK AD 250×30 mm I.D. 10 μm, Mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=40/60, Flow Rate: 80 mL/min, Column Temperature: 38° C., Nozzle Pressure: 100 bar (10 MPa), Nozzle Temperature: 60° C., Evaporator Temperature: 20° C., Trimmer Temperature: 25° C., Wavelength: 220 nm) to afford 3-bromo-8-chloro-2-(2,6-dimethylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (0.17 g) of sufficient purity for the subsequent step.
Intermediate: 3-Bromo-8-chloro-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00147
A mixture of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazole (8.0 g, 27 mmol), (2-methyl-3-pyridyl)boronic acid (4.36 g, 31.9 mmol), pyridine (8.40 g, 106 mmol), Cu(OAc)2 (7.23 g, 39.9 mmol), and 4 Å MS (8 g) in DCE (200 mL) was degassed and purged with O2×3, and then stirred at 50° C. for 15 h under an O2-atmosphere. Additional (2-methyl-3-pyridyl)boronic acid (4.36 g, 3.19 mmol) was added to the mixture and the mixture was stirred at 50° C. for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→90:10) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazol-1-yl)-2-methylpyridine (8.6 g) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazol-1-yl)-2-methylpyridine (8.6 g, 22 mmol) in THF (100 mL) was added TBAF (32.9 mL, 33 mmol, 1 M in THF). The mixture was stirred at 20° C. for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100) to afford 3-((1-(2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (5.3 g) of sufficient purity for the subsequent step.
A solution of DIAD (6.54 g, 32.3 mmol) was added to a solution of 3-((1-(2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (3.0 g, 11 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (2.04 g, 10.8 mmol), and PPh3 (8.48 g, 32.3 mmol) in THF (200 mL) at 0° C. The mixture was stirred at 20° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→20:80) to afford 3,6-dichloro-1-(3-((1-(2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (12 g) of sufficient purity for the subsequent step. All the above material was dissolved in EtOH (300 mL) and H2O (30 mL). Fe (7.46 g, 134 mmol) and NH4Cl (7.20 g, 134 mmol) were added. The mixture was stirred at 80° C. for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100) and triturated with MeOH (20 mL) to afford 8-chloro-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (1.5 g) of sufficient purity for the subsequent step.
A solution of NBS (391 mg, 2.19 mmol) in THF (10 mL) was added dropwise to a solution of 8-chloro-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (700 mg, 1.83 mmol) in THF (100 mL) at 20° C. The mixture was stirred at 20° C. for 15 h. Additional NBS (160 mg, 0.899 mmol) was added to the mixture and the mixture was stirred at 20° C. for 3 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100) to afford 3-bromo-8-chloro-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (320 mg) of sufficient purity for the subsequent step.
Intermediate: 3-Bromo-8-chloro-2-(2,5-dimethylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00148
A mixture of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazole (2.0 g, 6.6 mmol), (2,5-dimethylpyridin-3-yl)boronic acid (1.20 g, 7.96 mmol), Cu(OAc)2 (1.81 g, 9.95 mmol), pyridine (2.10 g, 26.5 mmol), and 4 Å MS (2 g) in DCE (100 mL) was degassed and purged with O2×3 and stirred at 50° C. for 16 h under an O2-atmosphere. To the mixture was added (2,5-dimethylpyridin-3-yl)boronic acid (1 g) and stirred at 50° C. for another 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→85:15) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazol-1-yl)-2,5-dimethylpyridine (2.5 g) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazol-1-yl)-2,5-dimethylpyridine (2.5 g, 6.2 mmol) in THF (30 mL) was added TBAF (9.2 mL, 9.2 mmol, 1 M in THF). The mixture was stirred at 20° C. for 2 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100) to afford 3-((1-(2,5-dimethylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (1.6 g) of sufficient purity for the subsequent step.
A mixture of 3-((1-(2,5-dimethylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (1.6 g, 5.5 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (1.03 g, 5.47 mmol), PPh3 (2.87 g, 10.95 mmol), and DIAD (2.21 g, 10.95 mmol) in THF (50 mL) was degassed and purged with N2×3 and stirred at 20° C. for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→50:50) to afford 3,6-dichloro-1-(3-((1-(2,5-dimethylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (4.5 g) of sufficient purity for the subsequent step.
To a solution of 3,6-dichloro-1-(3-((1-(2,5-dimethylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (4 g, 8.6 mmol) in EtOH (300 mL) was added Fe (2.41 g, 43.2 mmol) and a solution of NH4Cl (2.31 g, 43.2 mmol) in H2O (10 mL). The mixture was stirred at 80° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100) to afford 8-chloro-2-(2,5-dimethylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (850 mg) of sufficient purity for the subsequent step.
To a solution of 8-chloro-2-(2,5-dimethylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (450 mg, 1.13 mmol) in THF (15 mL) was added a solution of 2,4,4,6-tetrabromocyclohexa-2,5-dien-1-one (563 mg, 1.37 mmol) in THF (5 mL). The mixture was stirred at 20° C. for 16 hours. Additional 2,4,4,6-tetrabromocyclohexa-2,5-dien-1-one (270 mg, 0.659 mmol) in THF (1 mL) was added and the reaction was stirred at 20° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100) to afford 3-bromo-8-chloro-2-(2,5-dimethylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (220 mg) of sufficient purity for the subsequent step.
Intermediate: 3-Bromo-8-chloro-2-(2-methoxypyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00149
A mixture of 5-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazole (5.0 g, 17 mmol), (2-methoxy-3-pyridyl)boronic acid (3.04 g, 19.9 mmol), Cu(OAc)2 (4.52 g, 24.9 mmol), pyridine (5.25 g, 66.4 mmol) and 4 Å MS (5 g) in DCE (100 mL) was degassed and purged with O2×3 and stirred at 50° C. for 16 h under an O2-atmosphere. To the mixture was added (2-methoxy-3-pyridyl)boronic acid(2 g) and stirred at 50° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→85:15) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazol-1-yl)-2-methoxypyridine (5.4 g) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazol-1-yl)-2-methoxypyridine (5.4 g, 13 mmol) in THF (40 mL) was added TBAF (19.8 mL, 20 mmol, 1 M in THF). The mixture was stirred at 25° C. for 2 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→50:50) to afford 3-((1-(2-methoxypyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (3.6 g) of sufficient purity for the subsequent step.
A mixture of 3-[1-(2-methoxy-3-pyridyl)-4-nitro-pyrazol-3-yl]oxypropan-1-ol (3.6 g, 12 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (2.31 g, 12.2 mmol), PPh3 (9.63 g, 36.7 mmol), and DIAD(7.42 g, 36.7 mmol) in THF (100 mL) was stirred at 25° C. for 3 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→70:30) to afford 3,6-dichloro-1-(3-((1-(2-methoxypyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine of sufficient purity for the subsequent step.
To a solution of 3,6-dichloro-1-(3-((1-(2-methoxypyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (2.4 g, 5.2 mmol) and Fe (1.44 g, 25.8 mmol) in EtOH (400 mL) was added a solution of NH4Cl (1.38 g, 25.8 mmol) in H2O (100 mL). The mixture was stirred at 80° C. for 16 h. Additional NH4Cl (1.4 g, 26 mmol) was added and the mixture was stirred at 80° C. for another 16 h. A final portion of NH4Cl (0.3 g, 6 mmol) was added and the mixture was stirred at 80° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100) to afford 8-chloro-2-(2-methoxypyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (240 mg) of sufficient purity for the subsequent step.
To a solution of 8-chloro-2-(2-methoxypyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (330 mg, 0.83 mmol) in THF (34 mL) was added NBS (177 mg, 0.99 mmol). The mixture was stirred at 20° C. for 16 h. A solution of NBS (90 mg, 0.51 mmol) in THF (1 mL) was added, the mixture was stirred at 20° C. for another 16 h. Finally, a solution of NBS (60 mg, 0.33 mmol) in THF (0.5 mL) was added and the mixture was stirred at 20° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→40:60) to afford 3-bromo-8-chloro-2-(2-methoxypyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (150 mg) of sufficient purity for the subsequent step.
Intermediate: 3-Bromo-8-chloro-2-(5-fluoro-2-methoxypyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00150
A mixture of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazole (3.0 g, 10 mmol), (5-fluoro-2-methoxy-3-pyridyl)boronic acid (1.7 g, 10 mmol), Cu(OAc)2 (2.71 g, 14.9 mmol), pyridine (3.15 g, 39.8 mmol), and 4 Å MS (3 g) in DCE (60 mL) was degassed and purged with oxygen×3 and stirred at 50° C. for 16 h under an O2-atmosphere. Additional (5-fluoro-2-methoxy-3-pyridyl)boronic acid (1.7 g) was added to the mixture and the reaction was stirred at 50° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→70:30) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazol-1-yl)-5-fluoro-2-methoxypyridine (2.8 g) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazol-1-yl)-5-fluoro-2-methoxypyridine (4.7 g, 11 mmol) in THF (50 mL) was added TBAF (16.5 mL, 17 mmol, 1 M in THF) and stirred at 25° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc (10 v % MeOH) 100:0→50:50) to afford 3-((1-(5-fluoro-2-methoxypyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (3.3 g) of sufficient purity for the subsequent step.
To a mixture of 3-((1-(5-fluoro-2-methoxypyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (1.65 g, 5.28 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (1 g, 5.28 mmol), and PPh3 (4.16 g, 15.9 mmol) in THF (200 mL) was added DIAD (3.21 g, 15.9 mmol) at 0° C. The mixture was stirred at 25° C. for 15 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc (10 v % MeOH, 10 v % DCM) 100:0→70:30) to afford 3,6-dichloro-1-(3-((1-(5-fluoro-2-methoxypyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (3 g) of sufficient purity for the subsequent step.
To a mixture of 3,6-dichloro-1-(3-((1-(5-fluoro-2-methoxypyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (1.2 g, 2.5 mmol) and NH4Cl (598 mg, 11.2 mmol) in a mixture of EtOH (120 mL) and H2O (12 mL) was added Fe (624 mg, 11.2 mmol) at 20° C. The mixture was stirred at 80° C. for 16 h. Additional NH4Cl (600 mg, 11.2 mmol) was added to the mixture and the reaction was stirred at 80° C. for another 16 h. The mixture was filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc (10 v % DCM) 100:0→50:50) to afford 8-chloro-2-(5-fluoro-2-methoxypyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (0.7 g) of sufficient purity for the subsequent step.
A solution of NBS (164 mg, 0.92 mmol) in CHCl3 (5 mL) was added dropwise to a solution of 8-chloro-2-(5-fluoro-2-methoxypyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (0.32 g, 0.77 mmol) in CHCl3 (35 mL) at 25° C. The mixture was stirred for 16 h at 25° C. Additional NBS (100 mg, 0.562 mmol) in CHCl3 (2 mL) was added in a dropwise manner and the mixture was stirred at 25° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc (10 v % MeOH, 10 v % DCM) 100:0→80:20) followed by SFC (Instrument: Thar SFC Prep 80, Column: DAICEL CHIRALCEL OD-H 250×30 mm I.D. 5 μm, Mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=70/30, Flow Rate: 80 mL/min, Column Temperature: 38° C., Nozzle Pressure: 100 bar (10 MPa), Nozzle Temperature: 60° C., Evaporator Temperature: 20° C., Trimmer Temperature: 25° C., Wavelength: 220 nm) to afford 3-bromo-8-chloro-2-(5-fluoro-2-methoxypyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (0.3 g) of sufficient purity for the subsequent step.
Intermediate: 3-Bromo-8-chloro-2-(5-fluoro-2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00151
A mixture of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazole (6.0 g, 20 mmol), (5-fluoro-2-methylpyridin-3-yl)boronic acid (3.39 g, 21.9 mmol), Cu(OAc)2 (5.42 g, 29.9 mmol), pyridine (6.30 g, 79.6 mmol) and 4 Å MS (6 g) in DCE (60 mL) was degassed and purged with O2×3 and the mixture was stirred at 50° C. for 16 h under an O2-atmosphere. Additional (5-fluoro-2-methylpyridin-3-yl)boronic acid (1.0 g, 6.5 mmol) was added and the mixture was stirred at 50° C. for another 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→80:20) to afford 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazol-1-yl)-2-methoxypyridine (5.8 g) of sufficient purity for the subsequent step.
To a solution of 3-(3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazol-1-yl)-2-methoxypyridine (5.8 g, 14 mmol) in THF (60 mL) was added TBAF (21.2 mL, 21 mmol, 1 M in THF). The mixture was stirred at 20° C. for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→70:30) to afford 3-[1-(5-fluoro-2-methyl-3-pyridyl)-4-nitro-pyrazol-3-yl]oxypropan-1-ol (3.05 g) of sufficient purity for the subsequent step.
To a mixture of 3-[1-(5-fluoro-2-methyl-3-pyridyl)-4-nitro-pyrazol-3-yl]oxypropan-1-ol (2.9 g, 10 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (1.85 g, 9.79 mmol), and PPh3 (7.70 g, 29.4 mmol) in THF (160 mL) was added DIAD (5.94 g, 29.4 mmol). The mixture was stirred at 20° C. for 0.5 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→70:30) to afford 3,6-dichloro-1-(3-((1-(5-fluoro-2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (3.7 g) of sufficient purity for the subsequent step.
To a solution of 3,6-dichloro-1-(3-((1-(5-fluoro-2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (2.7 g, 5.8 mmol) in EtOH (300 mL) and H2O (30 mL) was added Fe (1.61 g, 28.9 mmol) and NH4Cl (1.85 g, 34.7 mmol). The mixture was stirred at 80° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→30:70) and triturated with EtOAc to afford 8-chloro-2-(5-fluoro-2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (750 mg) of sufficient purity for the subsequent step.
To a solution of 8-chloro-2-(5-fluoro-2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (670 mg, 1.67 mmol) in CHCl3 (100 mL) was added a solution of NBS (328 mg, 1.84 mmol) in CHCl3 (50 mL) dropwise at 20° C. over 20 minutes. The mixture was stirred at 20° C. for 16 hours. Additional NBS (150 mg, 0.843 mmol) in CHCl3 (20 mL) was added and the mixture was stirred at 20° C. for 2 h. A final solution of NBS (50 mg, 0.28 mmol) in CHCl3 (5 mL) was added and the reaction was stirred at 20° C. for 1 hour. The mixture was washed with water (30 mL×2) and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→70:30) and triturated with EtOAc to afford 3-bromo-8-chloro-2-(5-fluoro-2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (420 mg) of sufficient purity for the subsequent step.
Compounds of the Invention
Example 1: 8-Chloro-2-(2-methoxypyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00152
Two reactions were run in parallel at the same scale and under similar conditions: A mixture of 8-chloro-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (250 mg, 0.82 mmol), (2-methoxy-3-pyridyl)boronic acid (188 mg, 1.23 mmol), Cu(OAc)2 (225 mg, 1.24 mmol), pyridine (259 mg, 3.27 mmol) and 4 Å MS (250 mg) in DCE (6 mL) was degassed and purged with O2 three times, and then the mixture was stirred at 65° C. for 16 h under an O2-atmosphere (15 Psi). The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100). The residue from the two reactions were combined and further purified by preparative SFC purification (instrument: Thar SFC Prep 80, column: DAICEL CHIRALCEL OJ (250×30 mm), particle size 10 μm, mobile phase: CO2/EtOH (0.1% NH3—H2O, v %)=65/35, flow rate 70 mL/min, column temperature: 38° C., nozzle pressure: 100 bar (10 MPa), nozzle Temperature: 60° C., evaporator temperature: 20° C., trimmer temperature: 25° C.) to afford the title compound (70 mg). 1H NMR (CDCl3, 400 MHz) δ 8.70 (s, 1H), 8.24 (dd, J=1.6, 5.6 Hz, 1H), 7.71 (dd, J=2.0, 7.6 Hz, 1H), 7.04 (dd, J=4.8, 7.2 Hz, 1H), 6.69 (br s, 1H), 4.58-4.52 (m, 2H), 4.51-4.47 (m, 2H), 4.00 (s, 3H), 2.18 (s, 3H), 2.08-1.79 (m, 2H). LC-MS (Method A) (m/z)=413.1 (MH)+tR=1.49 minutes.
Example 2: 8-Chloro-2-(2-ethoxypyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00153
To a solution of 3,6-dichloro-1-(3-((1-(2-ethoxypyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (160 mg, 0.32 mmol) in EtOH (16 mL) and H2O (4 mL) was added Fe (91 mg, 1.62 mmol) and NH4Cl (87 mg, 1.62 mmol). The resulting mixture was stirred at 80° C. for 16 h. The mixture was filtered and concentrated. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→40:60) to afford the title compound (58 mg). 1H NMR (DMSO-d6, 400 MHz) δ 9.55 (s, 1H), 8.83 (s, 1H), 8.26 (d, J=3.6 Hz, 1H), 7.79 (d, J=7.2 Hz, 1H), 7.29-7.06 (m, 1H), 4.50-4.24 (m, 6H), 2.12 (s, 3H), 1.97-1.64 (m, 2H), 1.31 (t, J=6.8 Hz, 3H). LC-MS (Method A) (m/z)=427.2 (MH)+tR=1.55 minutes.
Example 3: 8-Chloro-3-methyl-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00154
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((5-methyl-1-(2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (188 mg, 0.41 mmol), Fe (113 mg, 2.03 mmol), and NH4Cl (109 mg, 2.03 mmol) in EtOH (20 mL) and H2O (5 mL) at 80° C. for 16 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc (10 v % MeOH) 100:0→15:85), and preparative SFC (Instrument: PREPSFC150Mgm, Column: DAICEL CHIRALPAK AD 250×30 mm, particle size 10 μm, mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=40/60, flow rate: 120 mL/min, column temperature: 38° C., nozzle pressure: 100 bar (10 MPa), nozzle temperature: 60° C., evaporator temperature: 20° C., trimmer temperature: 25° C., Wavelength: 220 nm) to afford the title compound (90 mg). 1H NMR (CDCl3, 400 MHz) δ 9.61 (s, 1H), 8.84 (s, 1H), 8.57 (dd, J=1.2, 4.8 Hz, 1H), 7.80 (dd, J=1.6, 8.0 Hz, 1H), 7.41 (dd, J=4.8, 8.0 Hz, 1H), 4.39-4.34 (m, 4H), 2.28 (s, 3H), 2.10 (s, 3H), 2.00-1.63 (m, 2H). LC-MS (Method A) (m/z)=397.1 (MH)+tR 1.21 minutes.
Example 4: 8-Chloro-2-(2-ethylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00155
The compound was prepared in a manner similar to Example 2 using of 3,6-dichloro-1-(3-((1-(2-ethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (40 mg, 0.84 mmol), Fe (23 mg, 0.42 mmol), and NH4Cl (22 mg, 0.41 mmol) in EtOH (8 mL) and H2O (2 mL) at 80° C. for 16 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc (10 v % MeOH) 90:10→35:65), and preparative SFC (Instrument: Thar SFC Prep 80, column: DAICEL CHIRALPAK AD 250×30 mm, particle size 10 μm, mobile phase: supercritical CO2/IPA (0.1% NH3·H2O, v %)=60/40, flow rate: 80 mL/min, column temperature: 38° C., nozzle pressure: 100 bar (10 MPa), nozzle temperature: 60° C., evaporator temperature: 20° C., trimmer temperature: 25° C., wavelength: 220 nm) to afford the title compound (15 mg). 1H NMR (CDCl3, 400 MHz,) δ 8.71 (s, 1H), 8.67 (dd, J=1.2, 4.8 Hz, 1H), 7.60 (dd, J=1.2, 8.0 Hz, 1H), 7.31-7.28 (m, 1H), 6.73 (br s, 1H), 4.55-4.46 (m, 4H), 2.68 (q, J=7.6 Hz, 2H), 2.14 (s, 3H), 2.04-1.92 (m, 2H), 1.26 (t, J=7.6 Hz, 3H). LC-MS (Method A) (m/z)=411.1 (MH)+tR=1.32 minutes.
Example 5: 8-Chloro-3-ethyl-2-(2-methoxypyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00156
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((5-ethyl-1-(2-methoxypyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (240 mg, 0.48 mmol), Fe (144 mg, 2.58 mmol), and NH4Cl (144 mg, 2.69 mmol) in EtOH (20 mL) and H2O (5 mL) at 80° C. for 16 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100), and preparative SFC (instrument: Thar SFC Prep 80, column: DAICEL CHIRALCEL OD-H 250×30 mm, particle size 5 μm, mobile phase: CO2/EtOH (0.1% NH3—H2O, v %)=70/30, flow rate 80 mL/min, column temperature: 38° C., nozzle pressure: 100 bar (10 MPa), nozzle Temperature: 60° C., evaporator temperature: 20° C., trimmer temperature: 25° C., wavelength: 220 nm) to afford the title compound (42 mg). 1H NMR (CDCl3, 400 MHz) δ 8.70 (s, 1H), 8.25 (dd, J=1.6, 4.8 Hz, 1H), 7.69 (dd, J=1.6, 7.6 Hz, 1H), 7.03 (dd, J=4.2, 7.6 Hz, 1H), 6.82 (br s, 1H), 4.57-4.41 (m, 4H), 3.98 (s, 3H), 2.57 (q, J=7.6 Hz, 2H), 2.07-1.86 (m, 2H), 1.12 (t, J=7.6 Hz, 3H). LC-MS (Method A)) (m/z)=427.2 (MH)+tR=1.53 minutes.
Example 6: 8-Chloro-2-(5-fluoro-2-methoxypyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00157
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(5-fluoro-2-methoxypyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (580 mg, 1.17 mmol), Fe (348 mg, 6.23 mmol), and NH4Cl (348 mg, 6.51 mmol) in EtOH (30 mL) and H2O (3 mL) at 80° C. for 13 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→60:40), and preparative SFC (Instrument: Thar SFC Prep 80, column: DAICEL CHIRALPAK AD 250×30 mm, particle size 10 μm, mobile phase: supercritical CO2/IPA (0.1% NH3·H2O, v %)=75/25, flow rate: 100 mL/min, column temperature: 38° C., nozzle pressure: 100 bar (10 MPa), nozzle temperature: 60° C., evaporator temperature: 20° C., trimmer temperature: 25° C.; wavelength: 220 nm) to afford the title compound (120 mg). 1H NMR (CDCl3, 400 MHz) δ8.70 (s, 1H), 8.10 (d, J=2.8 Hz, 1H), 7.55 (dd, J=2.8, 7.6 Hz, 1H), 6.88 (br s, 1H), 4.57-4.45 (m, 4H), 3.98 (s, 3H), 2.21 (s, 3H), 2.04-1.87 (m, 2H). LC-MS (Method A) (m/z)=431.1 (MH)+tR=1.59 minutes.
Example 7: 8-Chloro-2-(2-methoxy-4-methylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00158
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(2-methoxy-4-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (240 mg, 0.49 mmol), Fe (136 mg, 2.43 mmol), and NH4Cl (130 mg, 2.43 mmol) in EtOH (10 mL) and H2O (1.5 mL) at 80° C. for 16 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 80:20→50:50), and preparative SFC ((Instrument: SFC-80Q, column: DAICEL CHIRALCEL OD-H (250 mm×30 mm), particle size, 5 μm, mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=75/25, rate: 80 mL/min, column temperature: 38° C., nozzle pressure: 100 bar (10 MPa), nozzle temperature: 60° C., evaporator temperature: 20° C., trimmer temperature: 25° C., wavelength: 220 nm) to afford the title compound (50 mg). 1H NMR (CDCl3, 400 MHz,) δ 8.70 (s, 1H), 8.10 (d, J=5.2 Hz, 1H), 6.88 (d, J=5.2 Hz, 1H), 6.75 (br s, 1H), 4.63-4.39 (m, 4H), 3.94 (s, 3H), 2.16 (s, 3H), 2.08 (s, 3H), 2.06-1.86 (m, 2H). LC-MS (Method A) (m/z)=427.2 (MH)+tR=1.51 minutes.
Example 8: 8-Chloro-3-ethyl-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00159
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((5-ethyl-1-(2-methylpyridin-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (680 mg, 1.42 mmol), Fe (408 mg, 7.31 mmol), and NH4Cl (408 mg, 7.63 mmol) in EtOH (40 mL) and H2O (4 mL) at 80° C. for 15 h. After stirring for 15 h, additional Fe (408 mg, 7.31 mmol) and NH4Cl (408 mg, 7.63 mmol) were added and the reaction was stirred at 80° C. for 20 h, followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100), and preparative SFC (instrument: Thar SFC Prep 80, column: DAICEL CHIRALCEL OD-H 250×30 mm, particle size 5 μm, mobile phase: CO2/EtOH (0.1% NH3—H2O, v %)=75/25, flow rate 70 mL/min, column temperature: 38° C., nozzle pressure: 100 bar (10 MPa), nozzle Temperature: 60° C., evaporator temperature: 20° C., trimmer temperature: 25° C., wavelength: 220 nm) to afford the title compound (100 mg). 1H NMR (400 MHz, CDCl3) δ 8.71 (s, 1H), 8.62 (dd, J=1.6, 4.8 Hz, 1H), 7.63 (dd, J=1.6, 8.0 Hz, 1H), 7.30 (dd, J=4.8, 8.0 Hz, 1H), 6.71 (br s, 1H), 4.56-4.45 (m, 4H), 2.55 (q, J=7.6 Hz, 2H), 2.41 (s, 3H), 2.05-1.90 (m, 2H), 1.09 (t, J=7.6 Hz, 3H). LC-MS (Method A) (m/z)=411.1 (MH)+tR=1.33 minutes.
Example 9: 8-Chloro-2-(2,6-dimethylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00160
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(2,6-dimethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (220 mg, 0.46 mmol), Fe (129 mg, 2.30 mmol), and NH4Cl (123 mg, 2.30 mmol) in EtOH (10 mL) and H2O (1.5 mL) at 80° C. for 16 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 83:17→0:100), and preparative SFC (Instrument: Thar SFC Prep 80, column: DAICEL CHIRALCEL OJ (250 mm×30 mm), particle size 10 μm, mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=75/25, rate: 70 mL/min, column temperature: 38° C., nozzle pressure: 100 bar (10 MPa), nozzle temperature: 60° C., evaporator temperature: 20° C., trimmer temperature: 25° C., wavelength: 220 nm) to afford the title compound (45 mg). 1H NMR (CDCl3, 400 MHz) δ8.70 (s, 1H), 7.50 (d, J=8.0 Hz, 1H), 7.14 (d, J=8.0 Hz, 1H), 6.70 (br s, 1H), 4.55-4.45 (m, 4H), 2.63 (s, 3H), 2.38 (s, 3H), 2.13 (s, 3H), 2.02-1.93 (m, 2H). LC-MS (Method A) (m/z)=411.2 (MH)+tR=1.20 minutes.
Example 10: 8-Chloro-2-(5-fluoro-2-methylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00161
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(5-fluoro-2-methyl pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[[3,4-d]pyrimidine (180 mg, 0.37 mmol), Fe (104 mg, 1.87 mmol), and NH4Cl (100 mg, 1.87 mmol) in EtOH (18 mL) and H2O (1.8 mL) at 80° C. for 16 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 0:100→45:55), and preparative SFC ((Instrument: SFC-80Q, column: DAICEL CHIRALPAK AD (250 mm×30 mm), particle size 10 μm, mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=50/50, flow rate: 80 mL/min, column temperature: 38° C., nozzle pressure: 100 bar (10 MPa), nozzle temperature: 60° C., evaporator temperature: 20° C., trimmer temperature: 25° C., wavelength: 220 nm) to afford the title compound (60 mg). 1H NMR (DSMO-d6, 400 MHz) δ 9.63 (s. 1H), 8.83 (s, 1H), 8.62 (d,J=2.4 Hz, 1H), 7.95 (dd, J=2.8, 8.8 Hz, 1H), 4.45-4.35 (m, 4H) 2.27 (s, 3H), 2.13 (s, 3H), 1.87 (m, 2H). LC-MS (Method A)(m/z)=415.1(MH)+tR=1.47 minutes.
Example 11: 8-Chloro-2-(2,5-dimethylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00162
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(2,5-dimethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-[3,4-d]pyrimidine (500 m, 1.05 mg mm ol), Fe (300, 5.37 mmol), and NH4Cl (300 mg, 5.61 mmol) in EtOH (50 mL) and H2O (5 mL) at 80° C. for 16 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100), and preparative SFC (Instrument: Thar SFC Prep 80, Column: DAICEL CHIRALCEL OD-H (250 mm×30 mm×5 μm), Mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=70/30, Flow Rate: 70 mL/min, Column temperature: 38° C., Nozzle pressure: 100 bar (10 MPa), Nozzle temperature: 60° C., Evaporator temperature: 20° C., Trimmer temperature: 25° C., Wavelength: 220 nm) to afford the title compound (70 mg). 1H NMR (CDCl3, 400 MHz) δ 8.70 (s, 1H), 8.44 (s, 1H), 7.44 (s, 1H), 6.75 (br s, 1H), 4.56-4.44 (m, 4H), 2.38 (s, 3H), 2.36 (s, 3H), 2.14 (s, 3H), 2.04-1.94 (m, 2H). LC-MS (Method A) (m/z)=411.2 (MH)+tR 1.23 minutes.
Example 12: 8-Chloro-2-(2-methoxy-5-methylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00163
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(2-methoxy-5-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (500 mg, 1.01 mmol), Fe (283 mg, 5.07 mmol), and NH4Cl (272 mg, 5.09 mmol) in EtOH (30 mL) and H2O (3 mL) at 80° C. for 15 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→50:50), and preparative SFC (Instrument: SFC150AP, Column: DAICEL CHIRALPAK AD 250×30 mm, 10 μm, Mobile phase: supercritical CO2/ETOH (0.1% NH3·H2O, v %)=50/50, Flow Rate: 110 mL/min, Column Temperature: 38° C., Nozzle Pressure: 100 bar (10 MPa), Nozzle Temperature: 60° C., Evaporator Temperature: 20° C., Trimmer Temperature: 25° C., Wavelength: 220 nm) to afford the title compound (95 mg). 1H NMR (DMSO-d6, 400 MHz) δ 9.53 (s, 1H), 8.82 (s, 1H), 8.10 (d, J=1.2 Hz, 1H), 7.65 (d, J=2.0 Hz, 1H), 4.45-4.24 (m, 4H), 3.88 (s, 3H), 2.29 (s, 3H), 2.09 (s, 3H), 1.97-1.60 (m, 2H). LC-MS (Method A) (m/z)=427.2 (MH)+tR=1.55 minutes.
Example 13: 8-Chloro-2-(2-methoxy-6-methylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00164
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(2-methoxy-6-methylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (1.25 g, 2.53 mmol), Fe (708 mg, 12.7 mmol), and NH4Cl (678 mg, 12.7 mmol) in EtOH (100 mL) and H2O (10 mL) at 80° C. for 12 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→50:50), and preparative SFC (Instrument: Berger MultiGram II, Column: DAICEL CHIRALCEL OD (250 mm×30 mm, 10 μm), Mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=75/25, Flow Rate: 100 mL/min, Column temperature: 38° C., Nozzle pressure: 100 bar (10 MPa), Nozzle temperature: 60° C., Evaporator temperature: 20° C., Trimmer temperature: 25° C., Wavelength: 220 nm) to afford the title compound (160 mg). 1H NMR (CDCl3, 400 MHz) δ 8.69 (s, 1H), 7.56 (d, J=7.6 Hz, 1H), 6.85 (d, J=7.2 Hz, 1H), 6.80 (br s, 1H), 4.57-4.43 (m, 4H), 3.97 (s, 3H), 2.52 (s, 3H), 2.16 (s, 3H), 1.99-1.83 (m, 2H). LC-MS (Method A) (m/z)=427.2 (MH)+tR=1.60 minutes.
Example 14: 8-Chloro-2-(2-(1,1-difluoroethyl)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00165
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(2-(1,1-difluoroethyl)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (320 mg, 0.623 mmol), Fe (190 mg, 3.40 mmol), and NH4Cl (167 mg, 3.12 mmol) in EtOH (20 mL) and H2O (2 mL) at 80° C. for 15 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→20:80), and preparative SFC (Instrument: Prep SFC 150 Mgm, Column: DAICEL CHIRALCEL OD 250×30 mm, 10 μm, Mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=75/25, Flow Rate: 150 mL/min, Column Temperature: 38° C., Nozzle Pressure: 100 bar (10 MPa), Nozzle Temperature: 60° C., Evaporator Temperature: 20° C., Trimmer Temperature: 25° C., Wavelength: 220 nm) to afford the title compound (110 mg). 1H NMR (DMSO-d6, 400 MHz) δ 9.59 (s, 1H), 8.83 (s, 1H), 8.80 (d, J=4.4 Hz, 1H), 8.00 (d, J=7.6 Hz, 1H), 7.74 (dd, J=4.8, 8.4 Hz, 1H), 4.48-4.24 (m, 4H), 2.08 (s, 3H), 2.00 (t, J=19.2 Hz, 3H), 1.94-1.63 (m, 2H). LC-MS (Method A) (m/z)=447.2 (MH)+tR=1.50 minutes.
Example 15: 8-Chloro-2-(5-fluoro-2,6-dimethylpyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00166
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(5-fluoro-2,6-dimethylpyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (690 mg, 1.40 mmol), Fe (389 mg, 6.97 mmol), and NH4Cl (373 mg, 6.97 mmol) in EtOH (70 mL) and H2O (7 mL) at 80° C. for 16 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→50:50), and preparative SFC (Instrument: Thar SFC Prep 80, Column: DAICEL CHIRALCEL OD-H (250 mm×30 mm, 5 μm), Mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=70/30, Flow Rate: 80 mL/min, Column temperature: 38° C., Nozzle pressure: 100 bar (10 MPa), Nozzle temperature: 60° C., Evaporator temperature: 20° C., Trimmer temperature: 25° C., Wavelength: 220 nm) to afford the title compound (70 mg). 1H NMR (DMSO-d6, 400 MHz) δ 9.61 (s, 1H), 8.83 (s, 1H), 7.84 (d, J=9.6 Hz, 1H), 4.44-4.31 (m, 4H), 2.49-2.47 (m, 3H), 2.21 (s, 3H), 2.11 (s, 3H), 2.01-1.61 (m, 2H). LC-MS (Method A) (m/z)=429.2 (MH)+tR=1.51 minutes.
Example 16: 8-Chloro-2-(2-cyclopropoxypyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00167
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(2-cyclopropoxypyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (410 mg, 0.811 mmol), Fe (246 mg, 4.40 mmol), and NH4Cl (246 mg, 4.60 mmol) in EtOH (20 mL) and H2O (2 mL) at 80° C. for 15 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100), and preparative SFC (Instrument: SFC-80Q, Column: DAICEL CHIRALPAK AD 250×30 mm, 10 μm, Mobile phase: supercritical CO2/ETOH (0.1% NH3·H2O, v %)=50/50, Flow Rate: 80 mL/min, Column Temperature: 38° C., Nozzle Pressure: 100 bar (10 MPa), Nozzle Temperature: 60° C., Evaporator Temperature: 20° C., Trimmer Temperature: 25° C., Wavelength: 220 nm) to afford the title compound (130 mg). 1H NMR (CDCl3, 400 MHz) δ8.69 (s, 1H), 8.29 (dd, J=1.6, 6.4 Hz, 1H), 7.71 (dd, J=2.0, 7.6 Hz, 1H), 7.07 (dd, J=5.2, 7.6 Hz, 1H), 6.95 (br s, 1H), 4.55-4.46 (m, 4H), 4.38-4.32 (m, 1H), 2.15 (s, 3H), 2.03-1.95 (m, 2H), 0.86-0.72 (m, 4H). LC-MS (Method A) (m/z)=439.1 (MH)+tR=1.56 minutes.
Example 17: 8-Chloro-3-methyl-2-(2-(trifluoromethyl)pyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00168
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(2-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (150 mg, 0.290 mmol), Fe (81 mg, 1.45 mmol), and NH4Cl (78 mg, 1.45 mmol) in EtOH (9 mL) and H2O (1.5 mL) at 80° C. for 16 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 83:17→0:100), and preparative SFC (Instrument: Thar SFC Prep 80, Column: DAICEL CHIRALCEL OJ (250 mm×30 mm, 10 μm), Mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=75/25, Rate: 70 mL/min, Column temperature: 38° C., Nozzle pressure: 100 bar (10 MPa), Nozzle temperature: 60° C., Evaporator temperature: 20° C., Trimmer temperature: 25° C., Wavelength: 220 nm) to afford the title compound (15 mg). 1H NMR (CDCl3, 400 MHz) δ8.84 (d, J=3.6 Hz, 1H), 8.71 (s, 1H), 7.85 (d, J=7.2 Hz, 1H), 7.69 (dd, J=8.0, 4.4 Hz, 1H), 6.80 (br s, 1H), 4.56-4.44 (m, 4H), 2.16 (s, 3H), 2.02-1.92 (m, 2H). LC-MS (Method A) (m/z)=451.1 (MH)+tR=1.52 minutes.
Example 18: 8-Chloro-2-(2-(fluoromethoxy)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00169
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(2-(fluoromethoxy)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (370 mg, 0.744 mmol), Fe (208 mg, 3.72 mmol), and NH4Cl (199 mg, 3.72 mmol) in EtOH (35 mL) and H2O (3.5 mL) at 80° C. for 16 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→50:50), and preparative SFC (Instrument: Thar SFC Prep 80, Column: DAICEL CHIRALPAK AD (250 mm×30 mm, 10 μm, Mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=55/45, Flow Rate: 80 mL/min, Column temperature: 38° C., Nozzle pressure: 100 bar (10 MPa), Nozzle temperature: 60° C., Evaporator temperature: 20° C., Trimmer temperature: 25° C., Wavelength: 220 nm) to afford the title compound (70 mg). 1H NMR (DMSO-d6, 400 MHz) δ 9.59 (s, 1H), 8.83 (s, 1H), 8.36 (d, J=4.8 Hz, 1H), 7.96 (d, J=7.6 Hz, 1H), 7.39-7.34 (m, 1H), 6.15 (d, J=52.4 Hz, 2H), 4.39-4.36 (m, 4H), 2.12 (s, 3H), 1.87-1.72 (m, 2H). LC-MS (Method A) (m/z)=431.2 (MH)+tR=1.50 minutes.
Example 19: 8-Chloro-2-(2-(difluoromethoxy)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00170
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(2-(difluoromethoxy)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (190 mg, 0.369 mmol), Fe (103 mg, 1.84 mmol), and NH4Cl (99 mg, 1.8 mmol) in EtOH (20 mL) and H2O (2 mL) at 80° C. for 16 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→35:65), and preparative SFC (Instrument: SFC-80Q, Column: DAICEL CHIRALPAK AD (250 mm×30 mm, 10 μm), Mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=50/50, Flow Rate: 80 mL/min, Column temperature: 38° C., Nozzle pressure: 100 bar (10 MPa), Nozzle temperature: 60° C., Evaporator temperature: 20° C., Trimmer temperature: 25° C., Wavelength: 220 nm) to afford the title compound (55 mg). 1H NMR (DMSO-d6, 400 MHz) δ 9.60 (s, 1H), 8.83 (s, 1H), 8.37 (dd, J=1.6, 4.8 Hz, 1H), 8.05 (dd, J=1.2, 7.6 Hz, 1H), 7.82 (t, J=72.4 Hz, 1H), 7.46 (dd, J=5.2, 8.0 Hz, 1H), 4.39-4.37 (m, 4H), 2.15 (s, 3H), 1.91-1.75 (m, 2H). LC-MS (Method A) (m/z)=449.1 (MH)+tR=1.59 minutes.
Example 20: 8-Chloro-3-methyl-2-(2-(trifluoromethoxy)pyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00171
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(2-(trifluoromethoxy)pyridin-3-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (80 mg, 0.15 mmol), Fe (42 mg, 0.75 mmol), and NH4Cl (40 mg, 0.75 mmol) in EtOH (10 mL) and H2O (1 mL) at 80° C. for 20 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→30:70), and preparative SFC×2 (Instrument: Prep SFC 150 Mgm, Column: DAICEL CHIRALPAK AD (250 mm×30 mm, 10 μm), Mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=70/30, Flow Rate: 150 mL/min, Column temperature: 38° C., Nozzle pressure: 100 bar (10 MPa), Nozzle temperature: 60° C., Evaporator temperature: 20° C., Trimmer temperature: 25° C., Wavelength: 220 nm. SFC method 2: Instrument: Prep SFC 150 Mgm, Column: DAICEL CHIRALPAK OD (250 mm×30 mm, 10 μm), Mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=80/20, Flow Rate: 150 mL/min, Column temperature: 38° C., Nozzle pressure: 100 bar (10 MPa), Nozzle temperature: 60° C., Evaporator temperature: 20° C., Trimmer temperature: 25° C., Wavelength: 220 nm) to afford the title compound (18 mg). 1H NMR (CDCl3, 400 MHz) δ 8.71 (s, 1H), 8.37 (dd, J=1.6, 4.8 Hz, 1H), 7.92 (dd, J=2.0, 8.0 Hz, 1H), 7.39 (dd, J=4.8, 7.6 Hz, 1H), 6.86 (br s, 1H), 4.55-4.48 (m, 4H), 2.24 (s, 3H), 1.99-1.96 (m, 2H). LC-MS (Method A) (m/z)=467.1 (MH)+tR=1.64 minutes.
Example 21: 8-Chloro-2-(3-methoxypyridazin-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00172
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(3-methoxypyridazin-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (140 mg, 0.292 mmol), Fe (81 mg, 1.5 mmol), and NH4Cl (78 mg, 1.5 mmol) in EtOH (14 mL) and H2O (1.4 mL) at 80° C. for 16 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→15:85), and preparative SFC×2 (Instrument: Berger MultiGram II, Column: DAICEL CHIRALCEL AD (250 mm×30 mm, 10 μm), Mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=40/60, Flow Rate: 80 mL/min, Column temperature: 38° C., Nozzle pressure: 100 bar (10 MPa), Nozzle temperature: 60° C., Evaporator temperature: 20° C., Trimmer temperature: 25° C., Wavelength: 220 nm. Instrument: Berger MultiGram II; Column: DAICEL CHIRALCEL AD (250 mm×30 mm, 10 μm), Mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=65/35, Flow Rate: 100 mL/min, Column temperature: 38° C., Nozzle pressure: 100 bar (10 MPa), Nozzle temperature: 60° C., Evaporator temperature: 20° C., Trimmer temperature: 25° C., Wavelength: 220 nm) to afford the title compound (8 mg). 1H NMR (CDCl3, 400 MHz) δ 8.99 (br s, 1H), 8.74 (br s, 1H), 7.53 (br s, 1H), 6.88 (br s, 1H), 4.61-4.38 (m, 4H), 4.25 (s, 3H), 2.28 (s, 3H), 1.99-1.94 (m, 2H). LC-MS (Method A) (m/z)=414.1 (MH)+tR=1.35 minutes.
Example 22: 8-Chloro-2-(4-methoxy-2-methylpyrimidin-5-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00173
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-[3-[1-(4-methoxy-2-methyl-pyrimidin-5-yl)-5-methyl-4-nitro-pyrazol-3-yl]oxypropyl]pyrazolo[3,4-d]pyrimidine (900 mg, 1.82 mmol), Fe (508 mg, 9.10 mmol), and NH4Cl (487 mg, 9.10 mmol) in EtOH (50 mL) and H2O (5 mL) at 80° C. for 16 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100), and preparative SFC (Instrument: SFC-80Q, Column: DAICEL CHIRALPAK AD (250 mm×30 mm, 10 μm), Mobile phase: supercritical CO2/EtOH (0.1% NH3·H2O, v %)=45/55, Flow Rate: 80 mL/min, Column temperature: 38° C., Nozzle pressure: 100 bar (10 MPa), Nozzle temperature: 60° C., Evaporator temperature: 20° C., Trimmer temperature: 25° C., Wavelength: 220 nm) to afford the title compound (90 mg). 1H NMR (DMSO-d6, 400 MHz) δ 9.58 (s, 1H), 8.83 (s, 1H), 8.51 (s, 1H), 4.44-4.29 (m, 4H), 3.98 (s, 3H), 2.62 (s, 3H), 2.10 (s, 3H), 1.97-1.52 (m, 2H). LC-MS (Method A) (m/z)=428.2 (MH)+tR 1.42 minutes.
Example 23: 8-Chloro-2-(5-fluoro-2-(methoxy-d3)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00174
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(5-fluoro-2-(methoxy-d3)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (380 mg, 0.760 mmol), Fe (212 mg, 3.80 mmol), and NH4Cl (203 mg, 3.80 mmol) in EtOH (35 mL) and H2O (5 mL) at 80° C. for 16 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→40:60), and preparative SFC (Instrument: SFC-80Q, Column: DAICEL CHIRALPAK AD (250 mm×30 mm, 10 μm), Mobile phase: supercritical CO2/IPA (0.1% NH3·H2O, v %)=50/50, Flow Rate: 80 mL/min, Column temperature: 38° C., Nozzle pressure: 100 bar (10 MPa), Nozzle temperature: 60° C., Evaporator temperature: 20° C., Trimmer temperature: 25° C., Wavelength: 220 nm) to afford the title compound (60 mg). 1H NMR (CDCl3, 400 MHz) δ 8.70 (s, 1H), 8.10 (d, J=2.8 Hz, 1H), 7.55 (dd, J=2.8, 7.8 Hz, 1H), 6.81 (br s, 1H), 4.61-4.48 (m, 4H), 2.21 (s, 3H), 2.09-1.91 (m, 2H). LC-MS (Method A) (m/z)=434.2 (MH)+tR=1.59 minutes.
Example 24: 8-Chloro-2-(2-(methoxy-d3)pyridin-3-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00175
The compound was prepared in a manner similar to Example 2 using 3,6-dichloro-1-(3-((1-(2-(methoxy-d3)pyridin-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (310 mg, 0.643 mmol), Fe (185 mg, 3.31 mmol), and NH4Cl (185 mg, 3.46 mmol) in EtOH (40 mL) and H2O (4 mL) at 80° C. for 15 h followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→20:80), and preparative SFC (Instrument: SFC-80Q, Column: DAICEL CHIRALPAK AD (250 mm×30 mm, 10 μm), Mobile phase: supercritical CO2/IPA (0.1% NH3·H2O, v %)=50/50, Flow Rate: 80 mL/min, Column temperature: 38° C., Nozzle pressure: 100 bar (10 MPa), Nozzle temperature: 60° C., Evaporator temperature: 20° C., Trimmer temperature: 25° C., Wavelength: 220 nm) to afford the title compound (100 mg). 1H NMR (CDCl3, 400 MHz) δ 8.70 (s, 1H), 8.24 (dd, J=1.6, 4.8 Hz, 1H), 7.71 (dd, J=1.6, 7.6 Hz, 1H), 7.04 (dd, J=4.8, 7.6 Hz, 1H), 6.78 (br s, 1H), 4.58-4.45 (m, 4H), 2.18 (s, 3H), 2.04-1.89 (m, 2H). LC-MS (Method F) (m/z)=416.2 (MH)+ tR=1.45 minutes.
Example 25: 8-Chloro-2-(2,6-dimethylpyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00176
To a mixture of 3-bromo-8-chloro-2-(2,6-dimethylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (50 mg, 0.11 mmol) and bis[tris(tert-butyl)phosphine]palladium (5.4 mg, 0.011 mmol) was added THF (2 mL) at room temperature. Then LiHMDS (0.12 mL, 0.12 mmol, 1 M in THF) was added. The mixture was stirred for 20 minutes followed by addition of bis(methyl-d3)zinc in THF-dibutyl ether-PhMe (0.30 mL, 0.18 mmol, 0.6 M). The reaction mixture was heated at 50° C. for 18 h. The mixture was cooled to room temperature and quenched by addition of saturated aqueous NH4Cl solution (5 mL) and water (5 mL). The mixture was stirred for 15 minutes and extracted with EtOAc. The organic phase was washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: Heptane:EtOAc) to afford the title compound (11 mg). 1H NMR (DMSO-d6, 400 MHz) δ 9.59 (s, 1H), 8.83 (s, 1H), 7.69 (d, J=8.0 Hz, 1H), 7.26 (d, J=8.0 Hz, 1H), 4.30-4.46 (m, 4H), 2.53 (s, 3H), 2.23 (s, 3H), 1.64-2.0 (m, 2H). LC-MS (Method E) (m/z)=414.0 (MH)+tR=0.41 minutes.
Example 26: 8-Chloro-3-(methyl-d3)-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00177
A mixture of 3-bromo-8-chloro-2-(2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (150 mg, 0.325 mmol), trideuteri(methyl-d3)boronic acid (102 mg, 1.62 mmol), K2CO3 (135 mg, 0.975 mmol), and Pd(PPh3)4(38 mg, 0.032 mmol) in 1,4-dioxane (40 mL) and H2O (10 mL) was degassed and purged with N2×3, and then stirred at 90° C. for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→70:30) followed by preparative SFC (Instrument: Prep SFC 150 Mgm, Column: DAICEL CHIRALCEL OD (250 mm×30 mm, 10 μm), Mobile phase: supercritical CO2/EtOH (0.1% NH3—H2O, v %)=75/25; Rate: 60 mL/min, Column temperature: 38° C.; Nozzle pressure: 100 bar (10 MPa), Nozzle temperature: 60° C., Evaporator temperature: 20° C., Trimmer temperature: 25° C., Wavelength: 220 nm) to afford the title compound (30 mg). 1H NMR (DMSO-d6, 400 MHz) δ 9.60 (s, 1H), 8.83 (s, 1H), 8.57 (d, J=3.2 Hz, 1H), 7.80 (dd, J=8.0, 1.6 Hz, 1H), 7.41 (dd, J=8.0, 4.8 Hz, 1H), 4.41-4.31 (m, 4H), 2.28 (s, 3H), 1.95-1.75 (m, 2H). LC-MS (Method F) (m/z)=400.2 (MH)+tR=1.33 minutes.
Example 27: 8-Chloro-2-(2,5-dimethylpyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00178
The compound was prepared in a manner similar to Example 26. 3-Bromo-8-chloro-2-(2,5-dimethylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (200 mg, 0.42 mmol), (methyl-d3)boronic acid (1 g, 2.4 mmol, ˜15 w % containing THF and n-Bu2O), K2CO3 (174 mg, 1.26 mmol), and Pd(PPh3)4(49 mg, 0.042 mmol) in 1,4-dioxane (5 mL) and H2O (1 mL) was stirred at 90° C. for 16 h. Additional (methyl-d3)boronic acid (2.5 g, 6.0 mmol, ˜15 w % containing THF and n-Bu2O) and Pd(PPh3)4(40 mg) were added and the mixture was stirred at 90° C. for 16 h. A final portion of (methyl-d3)boronic acid (2 g, 4.7 mmol, ˜15 w % containing THF and n-Bu2O), K2CO3 (100 mg), and Pd(PPh3)4(40 mg) was added and the mixture was stirred at 90° C. for another 16 h. This was followed by work-up, purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100), and preparative SFC (Instrument: Thar SFC Prep 80, Column: DAICEL CHIRALCEL OJ (250 mm×30 mm, 10 μm), Mobile phase: supercritical CO2/EtOH (0.1% NH3—H2O, v %)=70/30, Rate: 70 mL/min, Column temperature: 38° C., Nozzle pressure: 100 bar (10 MPa), Nozzle temperature: 60° C., Evaporator temperature: 20° C., Trimmer temperature: 25° C., Wavelength: 220 nm) to afford the title compound (15 mg). 1H NMR (CDCl3, 400 MHz) δ 8.71 (s, 1H), 8.46 (s, 1H), 7.51 (s, 1H), 6.83 (s, 1H), 4.59-4.42 (m, 4H), 2.43-2.39 (m, 6H), 2.02-1.89 (m, 2H). LC-MS (Method A) (m/z)=414.2 (MH)+tR=1.25 minutes.
Example 28: 8-Chloro-2-(2-methoxypyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00179
The compound was prepared in a manner similar to Example 26. 3-Bromo-8-chloro-2-(2-methoxypyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (100 mg, 0.21 mmol), (methyl-d3)boronic acid (132 mg, 0.31 mmol, ˜15 w %, containing THF and n-Bu2O), K2CO3 (87 mg, 0.63 mmol), and Pd(PPh3)4(24 mg, 0.02 mmol) in 1,4-dioxane (1 mL) and H2O (0.2 mL) was stirred at 90° C. for 16 h. Additional (methyl-d3)boronic acid (2.0 g, 4.7 mmol, ˜15 w % containing THF and n-Bu2O), Pd(PPh3)4(25 mg) and K2CO3 (50 mg) were added and the mixture was stirred at 90° C. for 16 h. Additional (methyl-d3)boronic acid (3.0 g, 7.2 mmol, ˜15 w %, containing THF and n-Bu2O) and Pd(PPh3)4 (25 mg, 0.02 mmol) were added and the mixture was stirred at 90° C. for another 16 h. A final portion of (methyl-d3)boronic acid (2.0 g, 4.7 mmol, ˜15 w % containing THF and n-Bu2O), K2CO3 (50 mg), and Pd(PPh3)4(25 mg, 0.02 mmol) was added and the mixture was stirred at 90° C. for another 16 h. This was followed by work-up followed and purification by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→20:80), and preparative SFC (Instrument: Prep SFC 150 Mgm, Column: DAICEL CHIRALCEL OD (250 mm×30 mm, 10 μm), Mobile phase: supercritical CO2/EtOH (0.1% NH3—H2O, v %)=70/30; Flow Rate: 150 mL/min; Column temperature: 38° C.; Nozzle pressure: 100 bar (10 MPa); Nozzle temperature: 60° C.; Evaporator temperature: 20° C.; Trimmer temperature: 25° C.; Wavelength: 220 nm) to afford the title compound (24 mg). 1H NMR (DMSO-d6, 400 MHz) δ 9.56 (s, 1H), 8.82 (s, 1H), 8.29 (dd, J=4.8, 1.6 Hz, 1H), 7.81 (dd, J=7.6, 2.0 Hz, 1H), 7.17 (dd, J=7.6, 5.2 Hz, 1H), 4.44-4.29 (m, 4H), 3.92 (s, 3H), 2.07-1.58 (m, 2H). LC-MS (Method A) (m/z)=416.2 (MH)+ tR=1.48 minutes.
Example 29: 8-Chloro-2-(5-fluoro-2-methoxypyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00180
THF (8 mL) was added to 3-bromo-8-chloro-2-(5-fluoro-2-methoxypyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (144 mg, 0.290 mmol), Pd(OAc)2 (7 mg, 0.03 mmol) and 1,1-bis(di-tert-butylphosphino)ferrocene (14 mg, 0.030 mmol). Lithium bis(trimethylsilyl)amide solution (0.330 mL, 0.33 mmol, 1 M in THF) was added dropwise to the solution and stirred for 20 minutes at room temperature, followed by addition of bis(methyl-d3)zinc (1.20 mL, 0.48 mmol, 0.40 M in THF-dibutyl ether-PhMe) and the reaction was then heated to 50° C. and stirred for 2 h. The mixture was filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: Heptane.EtOAc) to afford the title compound (79 mg). 1H NMR (DMSO-d6, 600 MHz,) δ 9.58 (s, 1H), 8.83 (s, 1H), 8.33 (d, J=2.9 Hz, 1H), 7.94 (dd, J=8.2, 2.9 Hz, 1H), 4.44-4.29 (m, 4H), 3.92 (s, 3H), 1.82 (m, 2H). LC-MS (Method D) (m/z)=436.1 (MH)+tR=0.67 minutes.
Example 30: 8-Chloro-2-(5-fluoro-2-methylpyridin-3-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine
Figure US11958865-20240416-C00181
The compound was prepared in a manner similar to Example 25 using 3-bromo-8-chloro-2-(5-fluoro-2-methylpyridin-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (381 mg, 0.794 mmol), bis[tris(tert-butyl)phosphine]palladium (40 mg, 0.078 mmol), LiHMDS (0.80 mL, 0.80 mmol, 1 M in THF), and bis(methyl-d3)zinc in (1.82 mL, 1.27 mmol, 0.70 M in THF-dibutyl ether-PhMe) in THF (8.5 mL) at 50° C. for 3 h and additional bis(methyl-d3)zinc (0.3 mL, 0.2 mmol, 0.70 M in THF-dibutyl ether-PhMe) at 50° C. for 2 h followed by work-up, purification by chromatography on silica gel (eluent: Heptane:EtOAc), and preparative SFC (Instrument: Shimadzu Nexera Prep SFC; Column: 2-Ethylpyridine (21.2 mm×150 mm, 5 μm); Mobile phase: supercritical CO2/iPrOH (EtOH)=15%; Flow Rate: 60 mL/min; Column temperature: 40° C.; Nozzle pressure: 100 bar (10 MPa); Nozzle temperature: 60° C.; Evaporator temperature: 20° C.; Trimmer temperature: 25° C.; Wavelength: 254 nm) to afford the title compound (133 mg). 1H NMR (CDCl3, 600 MHz) δ8.71 (s, 1H), 8.50 (d, J=2.8 Hz, 1H), 7.38 (dd, J=8.1, 2.7 Hz, 1H), 6.61 (s, 1H), 4.50 (m, 4H), 2.39 (d, J=1.3 Hz, 3H), 2.00-1.92 (m, 2H). LC-MS (Method E) (m/z)=418.1 (MH)+ tR=0.69 minutes.
Example I—LRRK2 Wild-Type and G2019S Kinase Activity Assay
LRRK2 kinase activity was measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (Fluorescein-ERM LRRKtide obtainable from Life Technologies Corporation) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody (pLRRKtide antibody), obtainable from Life Technologies Corporation) and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.
The LRRK2 kinase was obtained from Invitrogen (Life Technologies Corporation) and comprises residue 970 to 2527 of the full length human wild-type LRRK2 kinase, or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild type. The kinase reactions were performed in a 20 μL volume in 384-well plates. The kinase reaction buffer consisted of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.
In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase in kinase reaction buffer was incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction was initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) was incubated for 3.5 h (for LRRK2 WT) and 3 h (for LRRK2 G2019S) at 30° C., before the reaction was terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 l). The mixture was further incubated for 30 minutes at RT. TR-FRET was measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 s) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 s. The measurement was repeated 30 times for fluorescein and 30 times for terbium emission with a 1000 s time window between repeats. TR-FRET measurements were performed on a Biotek Synergy plate. The TR-FRET signal was calculated as the emission-ratio at 520 nm over 495 nm.
The TR-FRET ratio readout for test compounds was normalized to 0% inhibition corresponding to TR-FRET ratio measured in control wells with no inhibition of the kinase activity and 100% inhibition corresponding to TR-FRET ratio measured in control wells with inhibitor. Test compound potency (IC50) was estimated by nonlinear regression using the sigmoidal dose-response (variable slope) using Xlfit 4 (IDBS, Guildford, Surrey, UK, model 205). Were the IC50 could not be determined the % inhibition at the highest tested concentration is given by equation 1.
Equation (1):
y=(A+((B−A)/(1+((C/x){circumflex over ( )}D))))  (1)
where y is the normalized TR-TRET ratio measurement for a given concentration of test compound, x is the concentration of test compound, A is the estimated efficacy (% inhibition) at infinite compound dilution, and B is the maximal efficacy (% inhibition). C is the IC50 value and D is the Hill slope coefficient. IC50 estimates were obtained from independent experiment and the logarithmic average was calculated.
LRRK2 Wild-Type ADP-Glo Protocol
LRRK2 kinase activity was measured using an ADP-Glo kinase assay from Promega Corporation. The assay is a homogeneous luminescence-based assay that measures ADP formed from a kinase reaction. The ADP is converted into ATP, which is used to generate light in a luciferase reaction. The luminescence generated correlates with kinase activity.
The LRRK2 kinase was obtained from Invitrogen (Life Technologies Corporation) and comprises residue 970 to 2527 of the full length human wild-type LRRK2 kinase. The kinase reactions were performed in a 10 μL volume in 384-well plates. The kinase reaction buffer consisted of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.
In the assay, 0.5 nM LRRK2 WT kinase in kinase reaction buffer was incubated with the test compound (typically at 0 to 2 μM) for 30 minutes before the kinase reaction was initiated by addition of 1.0 mM ATP and 260 μM LRRKtide. The reaction mixture (10 μl total volume) was incubated for 3 hours at room temperature (RT, ca. 25° C.), before the reaction was terminated by addition of 10 μl ADP-Glo reagent. The mixture was further incubated for 60 minutes at RT before addition of 20 μl Kinase detection reagent from the ADP-Glo assay kit. Luminescence signal was measure on a BMG Labtech Pherastar FSX multimode microplate reader. The signal integration time was 0.5 s.
The luminescence readout for test compounds was normalized to 0% inhibition corresponding to luminescence measured in control wells with no inhibition of the kinase activity and 100% inhibition corresponding to luminescence measured in control wells with inhibitor. Test compound potency (Ki,app) was estimated by nonlinear regression using the tight-binding fit model in GeneData Screener (GeneData AG). In cases where the Ki,app could not be determined, the % inhibition at the highest tested concentration is reported. The tight-binding fit model is given by euquation (2).
Equation (2):
S S =S 0−(S inf −S 0)*(([E]+[I]+K i,app−([E]+[1]+K i,app)2−4*[E]*[I])0.5)/(2*[E]))  (2)
Where S0 is the estimated efficacy (% inhibition) at infinite compound dilution, and Sinf is the maximal efficacy (% inhibition), [E] is the enzyme concentration (active enzyme concentration) and [I] is the concentration of test compound. Ki,app is the apparent dissociation constant of the inhibitor. The IC50 can be calculated as given by equation (3).
Equation (3):
IC 50 =K i,app +[E]/2  (3)
IC50 estimates were obtained from independent experiment and the logarithmic average was calculated.
Table 2 below shows the IC50 values in nM obtained as described above for the exemplified compounds, data is based on n≥2 tests.
TABLE 2
LRRK2 wild-type and G2019S kinase activity
LRRK2 LRRK2 LRRK2 WT
Example G2019S WT ADPGlo
Number IC50 (nM) IC50 (nM) IC50 (nM)
1 0.45 1.1 0.46
2 0.35 0.98 0.28
3 1.9 7.6 1.2
4 1.8 7.0 0.82
5 1.4 4.0 0.41
6 0.2 0.53 0.40
7 2.3 6.9 0.78
8 12 35 2.5
9 2.4 6.3 1.0
10 2.7 8.8 1.0
11 0.59 2.0 0.39
12 0.13 0.4 0.63
13 0.22 0.57 0.33
14 4.2 14 1.5
15 1.4 4.0 0.66
16 0.93 2.1 0.57
17 5.5 20 3.1
18 0.49 0.67 0.44
19 0.35 1.1 0.32
20 1.1 3.4 0.48
21 0.24 0.94 0.45
22 0.59 2.1 0.60
23 0.32 0.61 0.34
24 0.35 0.95 0.49
25 1.4 4.8 0.83
26 1.7 4.9 0.96
27 0.65 2.1 0.56
28 0.23 0.76 0.63
29 0.79 2.4 0.53
30 7.7 16 1.4
Example II—Broad Kinase Selectivity
Protein kinase profiling of the inhibitors (Fabian, M. A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336 (2005)) were undertaken at a concentration of 0.010 μM and carried out in Eurofins DiscoverX KINOMEscan scanMAX panel of 403 wild type kinases (primarily of human origin) covering AGC (PKA, PKG, PKC family kinases), CAMK (Calcium/calmodulin-dependent protein kinases), CK1 (Casein kinase 1 kinases), CMGC (CDK, MAPK, GSK3, CLK families), STE (homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases), TK (Tyrosine kinases), TKL (Tyrosine kinase-like kinases), lipid and atypical kinase families.
Selectivity Score or S-score is a quantitative measure of compound selectivity. It was calculated by dividing the number of kinases that a compound binds to by the total number of distinct kinases tested, excluding mutant variants. S=Number of hits/Number of assays. This value can be calculated using % Ctrl as a potency threshold (below) and provides a quantitative method of describing compound selectivity to facilitate comparison of different compounds.
TABLE 3
Kinase selectivity
Selectivity Num- Number of Screening
Com- Score ber Non-Mutant Concentration Selectivity
pound Type of Hits Kinases (nM) Score
Exam- S(35) 12 403 10 0.03
ple 1 S(10) 4 403 10 0.01
S(1)* 2 403 10 0.005
*LRRK2 WT; S(35) = (number of non-mutant kinases with % Ctrl <35)/(number of non-mutant kinases tested); S(10) = (number of non-mutant kinases with % Ctrl <10)/(number of non-mutant kinases tested); S(1) = (number of non-mutant kinases with % Ctrl <1)/(number of non-mutant kinases tested)
Example III—Rat Brain Disposition
Brain disposition was evaluated in male Sprague-Dawley rats (n=3, standard body weight). Briefly, test compound was formulated as a simple suspension (0.5% HPMC in water) then administered by oral gavage (10 mg/kg, 10 mL/kg or 5 mg/kg, 10 mL/kg). At the designated time point (0.5 or 1 h post dose) rats were sacrificed and terminal blood and brain samples taken. Isolated plasma and brain homogenates were extracted by standard protein precipitation in acetonitrile, containing internal standard. Diluted extracts were analyzed by liquid-chromatography coupled with tandem mass spectrometry detection (LC-MS/MS) using a bioanalytical method. Concentrations of test compound in plasma and brain were quantified against matrix matched calibration standards. The total plasma and brain concentration time data are presented in Table 4 alongside the calculated brain Kp (total brain concentration:total plasma concentration ratio).
The fraction of unbound compound in male Sprague-Dawley rat plasma (fuplasma) and brain homogenate (fubrain) were determined by equilibrium dialysis using 96-well HTD-dialysis plates with dialysis membranes (molecular weight cut off 12-14 KDa). One side of the HTD-dialysis plate was loaded with matrix (plasma or brain homogenate) and the other side with buffer (100 mM sodium phosphate buffer, pH 7.4). Test compounds were dissolved in DMSO then spiked (5 μL of 0.2 mM) into blank (995 μL) plasma or diluted brain homogenate (1:4 ratio in phosphate buffer) giving a final nominal concentration 1 μM (≤0.5% DMSO). The matrices were loaded into respective chambers and equilibrated against phosphate buffer for 5 h at 37° C. (in a humidified air incubator with 5% CO2 with shaking). Samples from both chambers (buffer and plasma or brain homogenate) were aliquoted to fresh 96-well polypropylene plates then matrix matched using an equal volume of opposite blank matrix before extraction with cold solvent (3 volumes acetonitrile) containing an appropriate bioanalytical internal standard. After centrifugation (20 min, 3200 g, 4° C.) the supernatants were diluted with appropriate volumes of water and compound concentrations were quantified by LC/MS-MS against matrix matched calibration standards. The fuplasma and fubrain were calculated according to equation 4 below.
Equation ⁢ ( 4 ) Percent ⁢ of ⁢ unbound ⁢ compound = 100 × ( 1 D 1 [ F ] [ T ] - 1 + 1 D ) ( 4 )
Where [F] is the compound concentration on the buffer (receiver) side of the membrane; [T] is the compound concentration on the plasma or brain (donor) side of the membrane; D is the matrix dilution factor which is determined as D=4 for brain matrix and D=1 for plasma matrix in these assays.
TABLE 4
Total concentrations, brain Kp and brain Kp,uu are presented
(mean ± stdev from n = 3 rats)
Total plasma Total brain
Oral Time concentratio concentratio fubrain/
Example dose point n n Brain fuplasma Brain
Number (mg/kg) (h) (ng/ml) (ng/g) Kp (% free) Kp,uu
1 10 1 245 ± 121 620 ± 280 2.6 ± 0.2  4.7/14.7 0.83 ± 0.07
2 10 0.5 32 ± 18 31 ± 11 1.2 ± 0.7 2.7/9.7 0.35 ± 0.18
3 5 0.5 362 ± 38  414 ± 97  1.1 ± 0.1 10.4/22.6 0.52 ± 0.06
5 5 1   4 ± 0.8 7 ± 3 1.9 ± 0.3  5.2/12.3 0.80 ± 0.13
6 5 1 69 ± 7  205 ± 21     3 ± 0.06 3.7/8.9 1.22 ± 0.03
7 5 1 6 ± 2 10 ± 2  1.9 ± 0.3  7.5/21.0 0.68 ± 0.12
8 5 1 297 ± 29  279 ± 10  0.9 ± 0.1  7.5/19.3 0.37 ± 0.03
9 5 1 664 ± 47  906 ± 87  1.4 ± 0.2  7.4/10.2 1.00 ± 0.12
10 5 1 246 ± 61  524 ± 79  2.2 ± 0.3  9.3/22.7 0.89 ± 0.14
11 5 1 586 ± 82  649 ± 99  1.1 ± 0.2  5.3/11.7 0.51 ± 0.07
12 5 1 76 ± 23 146 ± 56  1.9 ± 0.3 3.0/6.7 0.85 ± 0.15
13 5 1 199 ± 52  496 ± 128 2.5 ± 0.1 1.9/7.4 0.74 ± 0.01
14 5 1 283 ± 57  347 ± 53  1.2 ± 0.1  5.8/14.6 0.49 ± 0.04
15 5 1 143 ± 8   254 ± 32  1.8 ± 0.2  5.0/11.0 0.81 ± 0.07
16 5 1 112 ± 18  141 ± 30  1.3 ± 0.2  3.5/13.9 0.32 ± 0.06
18 5 1 122 ± 11  343 ± 54  2.8 ± 0.6  4.7/12.8 1.04 ± 0.21
19 5 1 19 ± 8  48 ± 11 2.8 ± 0.5 2.7/8.6 0.87 ± 0.17
22 5 1 86 ± 8  216 ± 42  2.5 ± 0.4  6.8/16.8 1.02 ± 0.17
The total brain-to-plasma partition coefficient (brain Kp) is given by the ratio of the total brain concentration and total plasma concentration of the compound according to the equation below:
Brain ⁢ K p = total ⁢ brain ⁢ concentration total ⁢ plasma ⁢ concentration
Based on the measured rat fuplasma and fubrain values and the brain Kp the unbound brain-to-plasma partition coefficient (brain Kp,uu for each compound was calculated. The Kp,uu parameter describes the extent of brain penetration for each compound, i.e. the parameter gives a direct quantitative description of how the blood-brain barrier (BBB) handles the compounds regarding passive transport and active influx/efflux. The brain Kp,uu is given by the equation below:
Brain ⁢ ⁢ K p , u ⁢ u = brain ⁢ ⁢ K p × f ⁢ u brain f ⁢ u p ⁢ l ⁢ a ⁢ s ⁢ m ⁢ a
The Compounds reported in Table 4 are classified as being moderately or highly brain penetrant.
Example IV—Hepatocyte Intrinsic Clearance Assay
Test compounds (final concentration 0.05 μM, 0.05% organic) were incubated for 2 h at 37° C., with shaking, in supplemented Leibovitz L-15 media (pH 7.4) containing commercially sourced, pooled donor, cryopreserved hepatocytes (final concentration 1×106 hepatocytes/mL). The CLint reactions (350 μL) were initiated by addition of test compound. Aliquots (25 μL) were taken at 1, 5, 10, 15, 30, 60, 90 and 120 minutes and then protein crashed with ice-cold acetonitrile containing internal standard (150 μL) then centrifuged (1960 g for 20 minutes at 4° C.). Supernatant was diluted (1:4) with deionized water then analyzed by liquid chromatography (LC)-tandem mass spectrometry (MS/MS). The intrinsic clearances (CLint) were calculated from the slope (k) of the linear regressions of percentages of compound remaining in incubation against incubation time, according to equations 5 and 6:
Equation (5):
t 1/2 =In(2)/k  (5)
Equation (6):
CL int(L/h/kg body weight)=Ln(2)×V(L/106 hepatocytes)/t 1/2(h)×hepatocellularity(106 hepatocytes/g liver)×liver weight(g liver/kg body weight)  (6)
    • V=incubation volume=0.001 L/106 hepatocytes, Human hepatocellularity=120×106 hepatocytes/g, Human liver weight=20 g/kg body weight.
TABLE 5
Hepatocyte intrinsic clearance for compounds of the invention
Example
Number CLint (L/h/kg)
1 0.64*
3 0.36*
6 0.86*
7 0.47
9 0.97*
10 0.33*
11 <0.24 **
12 0.48
13 1.88
14 0.47
15 0.72
22 <0.24 ** *
23 0.97*
24 1.06
25 1.19*
29 0.93*
*CLint measured on a single occasion
**Below the assay lower limit of quantification
Based on the hepatocyte CLint values reported in Table 5 the tested compounds are classified as having low rates of metabolism, excepting compound 13 which shows a moderate to high rate of metabolism.
Example V—Hepatic Microsomal Intrinsic Clearance Assay
Compounds (final concentration 1 μM, 1% organic) of the invention were incubated for 1 hour at 37° C., with shaking, in phosphate buffer (pH 7.4) containing commercially sourced pooled liver microsomes (final concentration 0.5 mg/mL). The intrinsic clearance (CLint) reactions were initiated by addition of cofactor solution (final concentration 1 mM NADPH and 1 mM MgCl2, final incubation volume 100 μL). At designated time points (0, 5, 10, 20, 30 and 60 minutes) ice-cold acetonitrile containing internal standard (300 μL) was added to an incubation well to stop the reaction then mixed and centrifuged (3220 g for 20 minutes at 4° C.). Supernatant was diluted (1:4) with deionized water then analyzed by LC-MS/MS. The intrinsic clearances were calculated from the slope (k) of the linear regressions of percentages of compound remaining in incubation against incubation time, according to equations 7 and 8.
Equation (7):
t 1/2 =In(2)k  (7)
Equation (8):
CL int(L/h/kg body weight)=In(2)×V(L/mg)/t 1/2(h)×microsomal protein concentration(mg protein/g liver)×liver weight(g liver/kg body weight)  (8)
    • V=incubation volume=0.002 L/mg (0.5 mg/mL protein concentration)
    • Microsomal protein concentration=45 mg/g liver
    • Rat liver weight=45 g/kg body weight
    • Human liver weight=25 g/kg body weight
TABLE 6
Hepatic microsomal intrinsic clearance for compounds of the invention
Example
Number CLint (L/h/kg)
1 0.58
2 1.25
3 0.43
4 1.43
5 1.39
6 1.26
7 0.97
8 1.01
9 BQL**
10 1.20
11 0.74
12 1.01
13 1.82
14 1.03
15 0.72
16 1.12
17 0.92
18 0.67
19 2.03
20 1.10
21 1.54
22 <0.36**
23 1.43
24 0.75
25 <0.36*
26 0.70
27 0.49
28 0.61
29 1.28
30 0.84
*CLint measured on a single occasion
**below the assay lower limit of quantification, 0.36 L/h/kg
Based on the liver microsomal CLint values reported in Table 6 the tested compounds are classified as having either low or low to moderate rates of metabolism, excepting compounds 13 and 19 which show a moderate to high rate of metabolism.

Claims (19)

The invention claimed is:
1. A compound of formula IIa, or a pharmaceutically acceptable salt thereof, wherein:
Figure US11958865-20240416-C00182
X is CH, CR1 or N;
Y is CH, CR1 or N;
R1 is independently selected from the group consisting of a C1-C3 alkyl, a C1-C3 haloalkyl, and a halogen;
R2 is selected from a C1-C3 alkyl and an isotopically labelled C1-C3 alkyl;
R3 is selected from the group consisting of a halogen, a cyano, and a C1-C3 haloalkyl;
R4 is selected from the group consisting of a C1-C3 alkyl, an isotopically labelled C1-C3 alkyl, a C1-C3 haloalkyl, a O—C1-C3 alkyl, an isotopically labelled O—C1-C3 alkyl, a O—C1-C3 haloalkyl, and a O—C3-C6 cycloalkyl;
n is 0, 1 or 2.
2. The compound of claim 1, or a pharmaceutically salt thereof, wherein X is CH and Y is CH; X is CR1 and Y is CR1; X is CH and Y is CR1; X is CR1 and Y is CH; X is CH and Y is N; X is CR1 and Y is N; X is N and Y is CH; or X is N and Y is CR1.
3. The compound of claim 1, or a pharmaceutically salt thereof, wherein R1 is a C1-C3 alkyl or a halogen.
4. The compound of claim 1, or a pharmaceutically salt thereof, wherein R1 is —CH3; —CH2CH3; or fluoro.
5. The compound of claim 1, or a pharmaceutically salt thereof, wherein R2 is selected from the group consisting of —CH3, —CH2CH3, and —CD3.
6. The compound of claim 1, or a pharmaceutically salt thereof, wherein R3 is chloro.
7. The compound of claim 1, or a pharmaceutically salt thereof, wherein R4 is selected from the group consisting of —CH3, —CH2CH3, —OCH3, —OCH2CH3, —CHF2, —CF3, —CF2CH3, O-cyclopropane, —OCH2F, —OCHF2, —OCF3, and —OCD3.
8. The compound of claim 1, or a pharmaceutically salt thereof, wherein n is 0 or 1.
9. The compound of claim 1, wherein the compound is selected from the list consisting of:
Figure US11958865-20240416-C00183
Figure US11958865-20240416-C00184
Figure US11958865-20240416-C00185
Figure US11958865-20240416-C00186
Figure US11958865-20240416-C00187
Figure US11958865-20240416-C00188
or a pharmaceutically acceptable salt thereof.
10. The compound of claim 1, wherein the compound is
Figure US11958865-20240416-C00189
11. The compound of claim 1, wherein the compound is
Figure US11958865-20240416-C00190
12. The compound of claim 1, wherein the compound is
Figure US11958865-20240416-C00191
13. The compound of claim 1, wherein the compound is
Figure US11958865-20240416-C00192
14. The compound of claim 1, wherein the compound is
Figure US11958865-20240416-C00193
15. The compound of claim 1, wherein the compound is
Figure US11958865-20240416-C00194
or a pharmaceutically acceptable salt thereof.
16. The compound of claim 1, wherein the compound is
Figure US11958865-20240416-C00195
or a pharmaceutically acceptable salt thereof.
17. The compound of claim 1, wherein the compound is
Figure US11958865-20240416-C00196
or a pharmaceutically acceptable salt thereof.
18. The compound of claim 1, wherein the compound is
Figure US11958865-20240416-C00197
or a pharmaceutically acceptable salt thereof.
19. The compound of claim 1, wherein the compound is
Figure US11958865-20240416-C00198
or a pharmaceutically acceptable salt thereof.
US18/467,162 2022-09-15 2023-09-14 Leucine-rich repeat kinase 2 (LRRK2) inhibitors Active US11958865B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/583,002 US20240343741A1 (en) 2022-09-15 2024-02-21 Leucine-rich repeat kinase 2 (lrrk2) inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP22195861 2022-09-15
DK22195861.4 2022-09-15
DK23168862.3 2023-04-20
EP23168862 2023-04-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/583,002 Continuation US20240343741A1 (en) 2022-09-15 2024-02-21 Leucine-rich repeat kinase 2 (lrrk2) inhibitors

Publications (1)

Publication Number Publication Date
US11958865B1 true US11958865B1 (en) 2024-04-16

Family

ID=88060556

Family Applications (2)

Application Number Title Priority Date Filing Date
US18/467,162 Active US11958865B1 (en) 2022-09-15 2023-09-14 Leucine-rich repeat kinase 2 (LRRK2) inhibitors
US18/583,002 Abandoned US20240343741A1 (en) 2022-09-15 2024-02-21 Leucine-rich repeat kinase 2 (lrrk2) inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
US18/583,002 Abandoned US20240343741A1 (en) 2022-09-15 2024-02-21 Leucine-rich repeat kinase 2 (lrrk2) inhibitors

Country Status (4)

Country Link
US (2) US11958865B1 (en)
AR (1) AR130483A1 (en)
TW (1) TW202412777A (en)
WO (1) WO2024056775A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024218296A1 (en) * 2023-04-20 2024-10-24 H. Lundbeck A/S Combination treatments comprising administration of leucine-rich repeat kinase 2 (lrrk2) inhibitors

Citations (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013046019A1 (en) 2011-09-30 2013-04-04 Alcatel Lucent Method of configuring timing advance group and/or value of time alignment timer
US20140005183A1 (en) 2012-06-29 2014-01-02 Pfizer Inc. Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors
WO2014137723A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014137725A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014137728A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134772A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014140235A1 (en) 2013-03-15 2014-09-18 Ipsen Pharma S.A.S. Macrocyclic lrrk2 kinase inhibitors
WO2015007334A1 (en) 2013-07-19 2015-01-22 Hewlett-Packard Development Company, L. P. Color separation
WO2015026683A1 (en) 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
WO2015113451A1 (en) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2015113452A1 (en) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2016036586A1 (en) 2014-09-03 2016-03-10 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2016042089A1 (en) 2014-09-17 2016-03-24 Oncodesign S.A. Macrocyclic lrrk2 kinase inhibitors
WO2016130920A2 (en) 2015-02-13 2016-08-18 Dana-Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
WO2017012576A1 (en) 2015-07-23 2017-01-26 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
WO2017106771A1 (en) 2015-12-16 2017-06-22 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
WO2017218843A1 (en) 2016-06-16 2017-12-21 Denali Therapeutics Inc. Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
WO2018137607A1 (en) 2017-01-25 2018-08-02 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2018137573A1 (en) 2017-01-25 2018-08-02 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2018137593A1 (en) 2017-01-25 2018-08-02 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2018155916A2 (en) 2017-02-22 2018-08-30 재단법인 대구경북첨단의료산업진흥재단 Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease
WO2018217946A1 (en) 2017-05-24 2018-11-29 Denali Therapeutics Inc. Compounds, compositions and methods
WO2019012093A1 (en) 2017-07-14 2019-01-17 Glaxosmithkline Intellectual Property Development Limited Inhibitors of leucine rich repeat kinase 2
WO2019074809A1 (en) 2017-10-11 2019-04-18 Merck Sharp & Dohme Corp. Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2019074810A1 (en) 2017-10-11 2019-04-18 Merck Sharp & Dohme Corp. Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2019112269A1 (en) 2017-12-05 2019-06-13 주식회사 오스코텍 Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor
WO2020106685A1 (en) 2018-11-19 2020-05-28 Dana-Farber Cancer Institute, Inc. Macrocyclic inhibitors of dyrk1a
US20230144725A1 (en) 2021-10-27 2023-05-11 H. Lundbeck A/S Lrrk2 inhibitors
WO2023224894A1 (en) 2022-05-20 2023-11-23 Merck Sharp & Dohme Llc Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2023222005A1 (en) 2022-05-18 2023-11-23 上海翊石医药科技有限公司 Aromatic heterocyclic compound and intermediate, pharmaceutical composition and use thereof

Patent Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013046019A1 (en) 2011-09-30 2013-04-04 Alcatel Lucent Method of configuring timing advance group and/or value of time alignment timer
US20140005183A1 (en) 2012-06-29 2014-01-02 Pfizer Inc. Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors
WO2014137723A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014137725A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014137728A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134772A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014137719A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014140235A1 (en) 2013-03-15 2014-09-18 Ipsen Pharma S.A.S. Macrocyclic lrrk2 kinase inhibitors
US20160031905A1 (en) 2013-03-15 2016-02-04 Ipsen Pharma S.A.S. Macrocyclic LRRK2 Kinase Inhibitors
WO2015007334A1 (en) 2013-07-19 2015-01-22 Hewlett-Packard Development Company, L. P. Color separation
WO2015026683A1 (en) 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
WO2015113451A1 (en) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2015113452A1 (en) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2016036586A1 (en) 2014-09-03 2016-03-10 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2016042089A1 (en) 2014-09-17 2016-03-24 Oncodesign S.A. Macrocyclic lrrk2 kinase inhibitors
US20170240565A1 (en) 2014-09-17 2017-08-24 Oncodesign S.A. Macrocyclic lrrk2 kinase inhibitors
WO2016130920A2 (en) 2015-02-13 2016-08-18 Dana-Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
WO2017012576A1 (en) 2015-07-23 2017-01-26 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
WO2017106771A1 (en) 2015-12-16 2017-06-22 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
WO2017218843A1 (en) 2016-06-16 2017-12-21 Denali Therapeutics Inc. Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
WO2018137607A1 (en) 2017-01-25 2018-08-02 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2018137573A1 (en) 2017-01-25 2018-08-02 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2018137593A1 (en) 2017-01-25 2018-08-02 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2018155916A2 (en) 2017-02-22 2018-08-30 재단법인 대구경북첨단의료산업진흥재단 Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease
WO2018217946A1 (en) 2017-05-24 2018-11-29 Denali Therapeutics Inc. Compounds, compositions and methods
WO2019012093A1 (en) 2017-07-14 2019-01-17 Glaxosmithkline Intellectual Property Development Limited Inhibitors of leucine rich repeat kinase 2
WO2019074809A1 (en) 2017-10-11 2019-04-18 Merck Sharp & Dohme Corp. Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2019074810A1 (en) 2017-10-11 2019-04-18 Merck Sharp & Dohme Corp. Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2019112269A1 (en) 2017-12-05 2019-06-13 주식회사 오스코텍 Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor
WO2020106685A1 (en) 2018-11-19 2020-05-28 Dana-Farber Cancer Institute, Inc. Macrocyclic inhibitors of dyrk1a
US20230144725A1 (en) 2021-10-27 2023-05-11 H. Lundbeck A/S Lrrk2 inhibitors
US11780851B2 (en) 2021-10-27 2023-10-10 H. Lundbeck A/S LRRK2 inhibitors
WO2023222005A1 (en) 2022-05-18 2023-11-23 上海翊石医药科技有限公司 Aromatic heterocyclic compound and intermediate, pharmaceutical composition and use thereof
WO2023224894A1 (en) 2022-05-20 2023-11-23 Merck Sharp & Dohme Llc Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Deng et al., Leucine-rich repeat kinase 2 inhibitors: a patent review (2006-2011). Expert Opin Ther Pat. Dec. 2012;22(12):1415-26. Epub Nov. 6, 2012.
Ding et al., Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors. Bioorg Med Chem Lett. May 15, 2018;28(9):1615-1620. Epub Mar. 19, 2018.
Ding et al., Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present). Expert Opin Ther Pat. Apr. 2020;30(4):275-286. Epub Feb. 18, 2020.
Domingos et al., Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease. Future Med Chem. Aug. 2019;11(15):1953-1977.
Estrada et al., Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. Nov. 26, 2012;55(22):9416-33. Epub Oct. 15, 2012.
Estrada et al., Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. Feb. 13, 2014;57(3):921-36. Epub Jan. 15, 2014.
Galatsis, P. Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016). Expert Opin Ther Pat. Jun. 2017;27(6):667-676. Epub Jan. 31, 2017.
Hatcher et al., Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor. ACS Med Chem Lett. Apr. 7, 2015;6(5):584-9.
Henderson et al., Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem. Jan. 8, 2015;58(1):419-32. Epub Nov. 17, 2014.
Jensen et al., U.S. Appl. No. 18/331,289, filed Jun. 8, 2023. *
Kethiri et al., Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011-2013). Expert Opin Ther Pat. Jul. 2014;24(7):745-57. Epub Jun. 11, 2014.
Scott et al., Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity. J Med Chem. Apr. 13, 2017;60(7):2983-2992. Epub Mar. 16, 2017.

Also Published As

Publication number Publication date
WO2024056775A1 (en) 2024-03-21
US20240343741A1 (en) 2024-10-17
AR130483A1 (en) 2024-12-11
TW202412777A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
US11466016B2 (en) Pharmaceutical compounds
US10039753B2 (en) Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors
US11993612B2 (en) LRRK2 inhibitors
US11427601B1 (en) Inhibitors of KEAP1-Nrf2 protein-protein interaction
US20210380599A1 (en) Quinolino-pyrrolidin-2-one derivative and application thereof
US11312713B2 (en) Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors
US10703751B2 (en) Amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof
US11174248B2 (en) Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
US12030872B2 (en) N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
US10851116B2 (en) Bicyclic amines as novel JAK kinase inhibitors
US11958865B1 (en) Leucine-rich repeat kinase 2 (LRRK2) inhibitors
TW202442652A (en) Leucine-rich repeat kinase 2 (lrrk2) inhibitors
TW202442235A (en) Leucine-rich repeat kinase 2 (lrrk2) inhibitors
TW202442651A (en) Leucine-rich repeat kinase 2 (lrrk2) inhibitors
WO2024218296A1 (en) Combination treatments comprising administration of leucine-rich repeat kinase 2 (lrrk2) inhibitors
US20240132490A1 (en) Inhibitors of protein kinase a
US20230373972A1 (en) Piperazine derivative, preparation method therefor and use thereof
BR112019014191B1 (en) Pharmaceutical compound and composition
HK1258857B (en) Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE